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Inflammation triggers the recruitment and differentiation of inflammatory monocytes into 
microbicidal phagocytes or monocyte-derived dendritic cells (moDCs). It is unclear if 
environmental inflammatory cues control the polarization of monocytes toward each of these fates 
or if specialized monocyte progenitor subsets exist prior to inflammation. Here I show that naïve 
monocytes are heterogeneous and contain an NR4A1- and Flt3L-independent, CCR2-dependent, 
Flt3+CD11c-MHCII+PU.1high subset. This subset acts as a precursor for FcγRII/III+PD-L2+ 
CD209+, GM-CSF-dependent moDCs but is distal from the DC lineage as shown by fate mapping 
experiments using Zbtb46. By contrast, Flt3-CD11c-MHCII-PU.1low monocytes differentiate into 
FcγRII/III+PD-L2-CD209-iNOS+ macrophages upon microbial stimulation. Importantly, 
Sfpi1/Pu.1 haplo-insufficiency genetically distinguishes the precursor activities of monocytes 
toward moDCs or microbicidal macrophages. Indeed, Sfpi1+/- mice have reduced Flt3+CD11c-
MHCII+ monocytes and GM-CSF-dependent FcγRII/III+PD-L2+CD209+ moDCs but generate 
iNOS+ macrophages more efficiently. Therefore, intercellular disparities of PU.1 expression 
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1.1 A historical perspective of immunity 
 
 ‘There is at the end only one genuinely scientific treatment for all diseases, and that is to 
stimulate the phagocytes.’ – The Doctor’s Dilemma.  
George Bernard Shaw’s play was written in 1908, the same year the Nobel prize for 
Medicine was awarded to Ilya Metchnikoff for his discovery of phagocytosis. By the time 
of his discovery, the ‘germ theory of disease’ put forth by Robert Koch and Louis Pasteur 
was well accepted and Jenner’s initial discovery of immunization against small pox 
(1796) had been used as the basis for the development of the first vaccines against rabies 
and anthrax. However, the exact mechanism by which the human body can develop this 
immunity to disease was unclear.  
Metchnikoff attributed the purpose of phagocytosis to the clearance of dying cells, as well 
as the first line of defence against infection. Meanwhile, humoral biologists believed in 
the works of Paul Ehrlich, Von Behring and Kitasato who predicted the presence of 
immune entities (antibodies) in the humora that were elicited by specialized cells within 
the immune system (B and T lymphocytes) (Kaufmann, 2008). It was Paul Ehrlich who 
suggested that this function originates within ‘hematopoietic tissue’ (tissue responsible 
for the ‘making’ of ‘blood components’) and first proposed the concept of self vs non-
self. These concepts were crucial to the discovery by George Snell and Peter Gorer of the 
genetic locus of major histocompatibility complex that determined the acceptance of 
grafts in mice. This in turn, led to the ground-breaking discovery of the interaction 
between the innate cellular immune cells and the specialized adaptive T cell by Peter 
Doherty and Rolf Zinkernagel in 1974. By carrying out an in vitro reaction with 
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lymphocytic choriomeningitis virus (LCMV) infected cells and T cells from other 
infected mice, they noted that the T cells killed only infected cells and those that came 
from a syngeneic donor. This seminal experiment described the MHC restriction of 
antigen presentation (Doherty and Zinkernagel, 1975; Zinkernagel and Doherty, 1974). 
The molecular structure of the MHC constituted immunological ‘self’; the virus-infected 
cells of the same MHC identity constituted ‘altered self’due to virus-induced changes of 
the MHC identity. T cells killed the altered-self cells while the non-infected self and 
infected non-self cells remained untouched by the T cells. This finding complemented 
Bretscher and Cohn’s hypothesis of the need of a non-antigen-specific secondary signal 
to generate self-non-self discrimination. This secondary signal was required to decide 
between paralysis and activation of the T cells (Bretscher and Cohn, 1970). 
Bretscher and Cohn’s proposal was refined with the discovery of CD28 and CD40L co-
stimulatory molecule expression on T cells that bound with cognate ligands on APCs 
(Bernard et al., 2002).  These co-stimulatory molecules like the B7 family of molecules, 
are not present on resting monocytes but are induced upon activation of these cells and 
are present on more terminally differentiated myeloid cell types. Dendritic cells, first 
identified by Ralph Steinman in n 1973, specialize in priming T cells, (Steinman and 
Cohn, 1973; Steinman and Witmer, 1978) especially as they express co-stimulatory B7 
molecules throughout their activation. This was a revolutionary finding on the role of 
phagocytic cells that Elie Matchinikoff had originally described almost 100 years before 
Steinman.  
What remained to be understood then, was how T cells would learn to distinguish between 
non-self/altered self, and self, if they were only ever exposed to self-antigens in the 
thymus prior to their first encounter with non-self. It was Charles Janeway who proposed 
that the immune system recognized ‘infectious self’ through pattern recognition receptors 
(PRRs) on their surface. In 1997, Janeway and Medzhitov discovered the first PRR 
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namely Toll like Receptor (TLR) 4. Ectopic expression of this receptor induced the 
increased expression of pro-inflammatory cytokines and co-stimulatory molecules. Polly 
Matzinger then improved on the principle of Janeway in 1989 by suggesting that immune 
cells recognize danger signals in the form of dying or dead cells and proteins from 
necrotic cells. Indeed, it was found that the same receptors that recognized infectious self, 
recognized heat shock proteins from necrotic cells.  
Thus, the main tenets of cellular immunology and innate and adaptive sensing have 
developed over 150 years. Exploration into the development of the various cell types and 
their role in the context of inflammation continues to intrigue researchers. This thesis will 
explore the origins of the phagocytes that characterise several inflammatory states. 
1.2 The Hematopoietic System  
Hematopoiesis is a complex and orchestrated process that results from the competition 
between master transcriptional regulators that decide on the fate of every hematopoietic 
stem cell (HSC). Progressively, sub-threshold levels of these transcription factors 
‘transcriptionally prime’ a multipotent progenitor cell to express a multi-lineage 
expression pattern. Upon reaching the critical threshold level, transcriptional regulators 
like PU.1 interact with secondary regulators (factors that either co-operate or antagonise) 
to specify a lineage (Burda et al., 2010). Adult hematopoiesis originates from HSCs that 
differentiate into into non-self-renewing cells that may become committed to a specific 
cell lineage. These precursor cells include common myeloid progenitors (CMPs)  (Akashi 
et al., 2000) and common lymphoid progenitors (CLPs) (Kondo et al., 1997). Although, 
the current understanding of hematopoietic development is more plastic than origically 
thought  cells such as the CMP and CLP represent transitioning stages that are capable of 
amplification but not self-renewal and that differentiate into more specialized cell 
populations of  granulocytes and precursors of monocytes, erythrocytes and lymphoid 
cells s (Kondo et al., 1997) (Notta et al., 2015).  
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There are specific phenotypic markers that help define pluripotent, multipotent and fully 
committed cells within the hematopoietic system. HSCs in murine and human bone 
marrow are contained entirely within a fraction of cells positive for the stem cell growth 
factor receptor (SCF-R) or cKit (CD117) (Sánchez et al., 1996). These cKit+ populations 
are highly cycling and generate colonies of differentiated cells in vitro depending on the 
cytokines and growth factors available and the stage of commitment of the HSC. 
Differentiated cell populations express lineage-specific markers. In this thesis, I have 
focussed on the ontogeny of the mononuclear phagocytes namely dendritic cells (DCs), 
monocytes and macrophages. 
1.3 The mononuclear phagocyte system 
The mononuclear phagocyte system (MPS) is a collective term that includes phagocytic 
innate immune cells like macrophages, classical dendritic cells and their precursors. Each 
of these differentiated cell types are divided into sub-populations based on surface marker 
expression, function and anatomical location. While they may originate from a common 
branch of hematopoiesis, each cell type has been found to have unique progenitors 
(Akashi et al., 2000).  The current section of this thesis will elaborate on the ontogeny of 
each of these cell populations, the transcription factors and growth factors that influence 
their development, as well as the specialized phenotype and function of each cell 
population that distinguishes them as members of the MPS. 
1.3.1 Dendritic cells  
‘Classical’ or ‘conventional’ dendritic cells (cDCs) exhibit a stellate morphology 
(Steinman and Cohn, 1973) and rely on the growth factor fetal liver kinase-2 (flk-2/Flt3L) 
for their development (Karsunky et al., 2003; Waskow et al., 2008). cDCs are considered 
immature (expressing low levels of co-stimulatory molecules like CD80, CD86) before 
they are stimulated by non-self signals. Immature cDCs are very efficient at antigen 
capture via  receptor-mediated uptake such as through the mannose receptor 
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(Mr1/CD206) in peripheral tissues while mature cDCs downregulate antigen uptake, 
upregulate their expression of co-stimulatory molecules, and increase antigen 
presentation to T cells (Caux et al., 1997; Mellman et al., 1998). Dendritic cells are 
divided into 2 sub-sets – cDC1 (XCR1+CD8α+) and cDC2 (CD11b+CD8a-), the 
development and function of which is dependent on unique progenitor populations and 
the transcription factors that dictate their fate. Both cDC1 and cDC2 are required for the 
immune system to receive environmental signals within the tissue and convey these to T 
cells. cDC1 cells specialize in the cross-presentation and the stimulation of a Th1 
response to viruses or cytosolic bacteria such as Listeria monocytogenes, Salmonella 
typhi and Toxoplasma gondii (Hildner et al., 2008; Mashayekhi et al., 2011; Torti et al., 
2011). cDC2s present antigen via MHCII to CD4+T cells and can stimulate a Th2 or Th17 
response to infections with pathogens such as Citrobacter rodentium (Satpathy et al., 
2013). 
1.3.1.1 Ontogeny of cDCs 
Dendritic cells were established as a unique population of immune cells distinct from 
macrophages, lymphocytes and granulocytes with the seminal publication by Steinman 
and Cohn (Steinman and Cohn, 1973). Several studies have gone on to prove the 
independence of dendritic cells from other lineages with the most recent fate-mapping 
and bar-coding studies of hematopoietic progenitors (Naik et al., 2013; Schraml et al., 
2013) 
The earliest progenitor shown to be able to distinctly give rise to cDCs are the monocyte-
DC progenitors (MDPs) (Auffray et al., 2009). Adoptive transfer of reporter-labelled 
MDPs into the spleen of WT recipient mice results in the production of cDC1s and cDC2s 
(Varol et al., 2007). The cDC2s include CD4+CD11b+ and CD4-CD11b+ cDCs. Dendritic 
cells rely on their expression of the receptor tyrosine kinase Flt3 which binds with its 
ligand Flt3L - a growth factor required for the homeostatic development of the common 
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dendritic cell precursors (CDPs) and all DC-lineage committed cells (McKenna et al., 
2000; Waskow et al., 2008). CDPs give rise to pre-cDCs which have a lower proliferative 
capacity and are committed to the generation of cDCs, not plasmacytoid DCs (pDCs) (Liu 
et al., 2007). pDCs originate from a separate progenitor population identified within the 
Lin-ckitint/loCD115-Flt3+ population that expresses high-levels of the transcription factor 
E2-2 (Onai et al., 2013) (Figure 1-1).  
Until 2015, it was thought that pre-cDCs were homogeneously Lin-Flt3+SIRPαintMHCII-
CD11c+ (Liu et al., 2007) and equally capable of giving rise to cDC1s and cDC2s. 
However, Grajales-Reyes et al and Schlitzer et al described the heterogeneity of this 
population and concurrently found that pre-DCs were pre-committed to the generation of 
either CD4+ cDCs (pre-CD4 cDCs) or CD8+ cDCs (pre-CD8 cDCs). These cells are 
phenotypically defined by their expression of  Ly6C and SiglecH in the bone marrow and 
blood - SiglecH-Ly6C-Zbtb46-GFP+CD11c+MHCIIintFlt3+CD117int pre-cDCs are 
committed to the generation of CD24+ and CD103+ cDC1s via the autoactivation of Irf8 
(Grajales-Reyes et al., 2015) while SiglecH-Ly6C+Zbtb46-GFP+CD11c+CD115+ pre-
cDCs are committed to SIRPα+cDC2s (Schlitzer et al., 2015).  Table 1-1 summarizes the 
surface markers used to delineate the populations of progenitor and differentiated cells of 




Table 1-1: Surface marker expression of populations from the cDC and monocyte lineages 
Population CDP Pre-
DCs




cKit  +  lo/neg  - lo/neg  +  -  -  -  -  -  -
Flt3  +  +  +  +  +  -  +  +  +  -  -
M-CSFR  +  -  -  -  +  +  -  -  -  +  +
SIRPα lo  lo  lo  lo  +  -  -  +  -  +  +
CD11b  -  -  -  -  -  -  - +  -  +  +
Ly6C  -  -  -  -  -  + lo lo  +  +  -
MHCII  -  -  -  -  -  - hi hi int  +/-  +/-
CD11c  -  +  +  +  -  -  +  +  +  -  +/-
DEC205  -  -  -  -  -  -  +  -  -  -  -
CD24  +  -   -  -  -  -  +  -   -  -
XCR1  -  -  -  -  -  -  +  -  -  -  -
ESAM  -  -  -  -  -  -  -  +/-  -  -  -
PDCA1  -  -  -  -  -  -  -  -  +  -  -
CD45RA  -  -  -  -  -  -  -  -   +  -  -
SiglecH  -  +  -  -  -  -  -  -  +  -  -









A number of comparisons have been drawn between non-lymphoid and lymphoid tissue 
cDCs. Non-lymphoid tissue cDCs consist of subsets that are described as either 
CD24+CD103+ or CD11b+. In the gut, the 2 DC populations are CD103+CD11b- and 
CD103+CD11b+ (Bedoui and Greyer, 2014; Ginhoux et al., 2009; Schreiber et al., 2013).  
CD8α+ cDCs in the spleen have a number of similar properties to CD103+ cDCs in non-
lymphoid tissues like the kidney, lungs and skin (Ginhoux et al., 2009; Schraml et al., 
2013). These properties include high expression of MHCII in order to present antigen to 
CD4+ T cells, and the dependence on the transcription factor Id2 and Irf8 (Ginhoux et al., 
2009). Additionally, CD103+CD11b- and CD103+CD11b+ lamina propria cDCs rely on 
Flt3l for their development as they originate from the CDP and pre-cDC (Bogunovic et 
al., 2009). Functionally, like CD8α+ cDCs, CD103+ cDCs are specialized at cross-
presentation (Bedoui and Greyer, 2014). 
Despite their similarities in terms of ontogeny and functional capability, there are certain 
differences between CD8α+ and CD103+ DCs. CD103+CD11b- cells from the peripheral 
lymph nodes are more competent at the induction of a Th17 cell phenotype, express 
unique pattern recognition receptors and respond dramatically to GM-CSF as compared 
to CD8α+ cDCs (Greter et al., 2012; Jiao et al., 2014). Mice lacking either GM-CSF or its 
receptor have dramatically reduced levels of CD103+CD11b+ lamina propria and skin 
cDCs with minor changes in the cDC populations in lymphoid organs (Bogunovic et al., 
2009; Kingston et al., 2009a; Varol et al., 2007). Additionally, there are CD103-
CD11b+CD64- cells in the gut that exhibit Flt3L dependency, express CCR2, but are not 
derived from Ly6Chi monocytes (Scott et al., 2014) while certain DCs in the gut express 
CD103 and CD8α concomitantly (Fujimoto et al., 2011). These differences in phenotype 
and function indicate a change in transcriptional programme in response to the 
environment that cDCs are exposed to in spite of having a common origin.  
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1.3.1.2 Transcription factors involved in development of cDCs 
 
A number of transcription factors have been found to be critical for the development of 
distinct subsets of cDCs. ZBTB46, a small DNA-binding zinc-finger protein, was found 
to be the transcription factor that is  uniquely expressed in cells committed to the cDC 
lineage (Meredith et al., 2012; Satpathy et al., 2012a). By creating a GFP reporter knock-
in mouse model on Zbtb46, Satpathy et al were able to confirm microarray reports of the 
expression of Zbtb46 in the cDC lineage. cDCs in the spleen, resident and migratory cDCs 
in the skin-draining lymph node and resident cDCs in the tissues like the lamina propria 
and lung, as well as pre-cDCs in the BM expressed high levels of the reporter ZBTB46-
GFP (Satpathy et al., 2012a). 
The creation of a mouse strain that had the inducible diphtheria toxin (DT) receptor linked 
to a cherry reporter introduced between the 4th and 5th exons of the Zbtb46 gene, allowed 
for both, monitoring of cellular expression of the transcription factor and induced 
depletion of the cells expressing it. These zDCDTR/DTR mice when treated with diphtheria 
toxin had reduced levels of CDP, pre-cDCs and cDC subsets in the tissues as well as in 
the secondary lymphoid organs (i.e. skin draining lymph nodes and spleen) (Meredith et 
al., 2012). Moreover, the macrophages, monocytes and pDCs that are affected by DT 
treatment of the CD11c-DTR mice, remained consistent in the zDC-DTR mice (Meredith 
et al., 2012). Thus, Zbtb46 expression highlights cells that are committed to the cDC 
lineage of which pDCs and monocytes are not a part. Additionally, the zDC lSlDTR mice 
when crossed onto the Csf1r Cre mice have a dramatic reduction in the percentage of cDCs, 
and not monocytes, upon diphtheria injection (Loschko et al., 2016a). Thus far, the 




cDC1s have distinct characteristics in that they are the only cDCs to express the 
chemokine receptor XCR1 (Bachem et al., 2010; Crozat et al., 2011; Dorner et al., 2009) 
and the lectin CLEC9a (Poulin et al., 2012) and serve the specialized function of cross-
presentation  (Gutiérrez-Martínez et al., 2015; del Rio et al., 2007). cDC2s are a 
heterogeneous population of cells that albeit are positive for the integrins CD11c and 
CD11b and major histocompatibility complex class II (MHCII) and do not distinctly 
express a cDC2-specific surface marker or transcription factor. Zbtb46 is the only 
transcription factor that uniformly characterizes cDC1 and cDC2s. The Zbtb46-GFP 
mouse model being a knock-in for the gene, caused a functional dysregulation of the gene. 
cDCs developed fully in the complete knock-in, indicating that the transcription factor 
was not specifically required for the development of the cells of the lineage. Instead, what 
was noticed was that these cells continued to express high levels of G-CSF-R and LIF-R 
which are usually reduced on fully mature cDCs. Additionally, overexpressing the gene 
resulted in a reduction in granulocyte potential (Satpathy et al., 2012a). The transcription 
factor could thus act to de-sensitize the DC lineage to other non-DC factors – a role played 
by a number of lineage-determining transcription factors in other cell lineages. 
 DNA-binding protein Inhibitor 2 (Id2) (Hacker et al., 2003), basic leucine zipper 
transcription factor ATF-like 3 (BatF3) (Hildner et al., 2008), NFIL3 (Kashiwada et al., 
2011) and  interferon regulatory factor 8 (Irf8) (Schiavoni et al., 2002), have all been 
found to be crucial to the development of cDC1s. Each of these transcription factors play 
a role at a different stage of development of the cell population. BatF3, for example, is 
required to induce maturation and differentiation of pre-CD8 cDCs into CD24+cDCs 
(cDC1) but is dispensable for the development of the pre-cDCs from the CDP (Grajales-
Reyes et al., 2015). Irf8 on the other hand, affects the development of CD8α+ cDCs from 
the progenitors and also influences their functional capabilities (Vander Lugt et al., 2014; 
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Tamura et al., 2005). These studies demonstrate the homogenous nature of the CD8α+ 
cDCs. 
Mice knocked out for Irf4, recombining binding protein suppressor of hairless (RBPJ) 
(Caton et al., 2007), RelB (Wu et al., 1998) and PU.1 (Guerriero et al., 2000) have 
severely reduced levels of cDC2s at steady state. The reduction of cDC2s however, is 
only partial demonstrating the heterogeneity of the population. Reizis and colleagues 
noted that the CD8α-CD11b+ cDCs are further divided based on their reliance on Notch2 
signalling to become either CD4+ T cell priming ESAMhi cDCs or cytokine producing 
ESAMlo cDCs (Lewis et al., 2011). Additionally, Tussiwand et al noted the developmental 
requirement of the transcription factor KLF4 in ESAMlo cDCs and their role in the 
induction of Th2 responses. ESAMhi cDC2s, on the other hand generate Th17 responses 
that are required for the clearance of pathogens like Citrobacter rodentium  (Tussiwand 




Figure 1-1: cDC development. Adapted from (Satpathy et al., 2012b). Irf8 drives the 
differentiation of MDPs to CDPs which then express Zbtb46 to develop the cDC lineage. Pre-
cDCs are heterogeneous with some (green) being non-committed while others begin to express 
greater levels of lineage-specific transcription factors that determine their fate as either cDC1(Irf8, 
Batf3, Id2)(purple) or cDC2(Irf4)(yellow). cDCs are further differentiated into ESAM- and 
ESAM+ cDC2s.    
 
1.3.2 Monocytes and Macrophages 
1.3.2.1 Ontogeny of monocytes and macrophages 
Ilya Metchnikoff’s first description of phagocytes in starfish larvae (Hydra) and their 
phagocytic ability earned him the Nobel Prize in Physiology or Medicine in 1908 and the 
status of the ‘Father of innate cellular immunity’ (Kaufmann, 2008). Based on the 
properties of efficient phagocytosis, macrophages and monocytes were grouped within 
the reticuloendothelial system as it was thought that they shared a common origin with 
endothelial cells by Aschoff in 1924. However, increasingly, the differences in 
morphology and function indicated that they were in fact from different lineages and 
could not be grouped together (Davies et al., 2013).   
Ralph van Furth, James G. Hirsch and Zanvil A. Cohn laid the foundation of the 
mononuclear phagocyte system (MPS)- a system which encompassed macrophages and 
their precursors- monocytes and bone marrow progenitors and excluded lymphocytes 
(van Furth et al., 1972). This was intriguing given the fact that the original discovery of 
macrophages had been made in lower form organisms which did not have any monocytes 
but did macrophages (van Furth et al., 1972; Kaufmann, 2008). Additionally, 
macrophages had already been found to have different principal sources (ie. either blood 
or tissue) and have distinct functions in various tissues (Sabin et al., 1925). 
The understanding that the ‘classification’ of macrophages was a collection of cells of 
different origins came much later in the 20th century. It was originally thought that 
hematopoietic precursors arose within the yolk sac and then travelled to specific 
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hematopoietic organs for development into blood cells (Medvinsky and Dzierzak, 1996). 
However, such a concept made it difficult to understand how progenitors from the yolk 
sac until embryonic day 9 (E9) were unable to form definitive colonies of differentiated 
cells when injected into mouse spleens (called colony-forming-unit-spleen (CFU-S)) - 
yolk sac derived hematopoietic progenitors were not the precursors to adult blood cells. 
Hematopoietic progenitors from the yolk sac were able to differentiate into a number of 
blood cells in vitro, if provided with the appropriate cytokines and growth factors, 
namely,  GM-CSF, M-CSF and Flt3L.  On the other hand, it was found that hematopoietic 
progenitors from the aorta-gonad -mesonephros (AGM) from day E10.5 and 11 gave rise 
to substantially more CFU-S. It was thus concluded that there were 2 waves of blood cell 
development- one from the yolk sac at E9.5-10.0 and one from the AGM region at E10.5 
- 11.0 (Medvinsky and Dzierzak, 1996).  
More recent studies have shed light on the involvement of macrophage development in 
organogenesis. Geissmann and colleagues have categorized the presence of pre-
macrophages (pMacs) that arise from erythro-myeloid precursors (E8.5) that come from 
the yolk sac. These cells colonize the whole embryo at E9.5 and begin to undergo 
differential transcriptional programmes that are responsible for varied organ-specific 
characteristics of each class of macrophage (Mass et al., 2016). Thus, yolk-sac derived 
macrophages colonize the embryo during organogenesis which gives rise to tissue 
resident macrophages seen postnatally. These cells are able to maintain themselves 
without the need for replenishment from circulating monocytes (Yona et al., 2013). The 
AGM-derived precursors are the pre-liver source of hematopoietic cells. Subsequently 
only the AGM-derived precursors continue to contribute to adult blood hematopoietic 
cells (Medvinsky and Dzierzak, 1996; Müller et al., 1994). Adult HSCs give rise to the 
macrophage dendritic cell progenitor (MDP) which is thought to be a dedicated 
progenitor capable of giving rise to monocytes and cDCs (Auffray et al., 2009). These 
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progenitors develop into committed precursor populations for monocytes- the common 
monocyte precursor (cMop) which is capable of giving rise to the 2 major populations of 
monocytes namely, Ly6Chi and Ly6Clo monocytes (Hettinger et al., 2013). Ly6Chi 
monocytes are recruited to tissues during inflammation where they differentiate into 
F4/80lo macrophages (Schulz et al., 2012). 
Thus, macrophages in tissues originate in the yolk sac being sustained through self-
renewal in situ. Circulating monocytes that arise from adult bone marrow, are recruited 
to sites of inflammation in tissues and develop a population of macrophages that are 
transcriptionally distinct to yolk-sac derived macrophages and have been broadly found 
to be F4/80lo  (Figure 1-2). 
 
Figure 1-2: A schematic of development of macrophages. Reproduced from Wynn et 
al., 2013).Macrophages derive from 3 sources. The first is the yolk sac that derives the 
F4/80bright macrophages that populate the tissues during embryogenesis. The second is the 
fetal liver from which hemtopoiesis does occur but its generation of macrophages is less 
well-defined. The 3rd is the bone marrow which contains HSCs that derive from the fetal 
liver. Macrophages that originate from these progenitors are F4/80low and go through 




1.3.2.2 Key transcription factors involved in monocyte and macrophage development 
 
A few transcription factors have been found to be critical for the development of 
macrophages from HSCs, which include PU.1, C/EBPα and Maf-B. Although 
dispensable for their origin, PU.1 is highly expressed in HSCs (Dakic, 2005) and remains 
at elevated levels in neutrophils, B cells and macrophages while gradually diminishing in 
cells that progress toward erythropoiesis (Lloberas et al., 1999). Overexpression of PU.1 
instructs the development of the monocyte/macrophage lineage while simultaneously 
downregulating the development of other cell types such as granulocytes and erythrocytes 
(Burda et al., 2010). PU.1 exerts its role not only by direct binding to DNA elements in 
either antagonistically or synergistically with other transcriptional regulators to promote 
macrophage development, but also by binding to microRNAs. For instance, the ectopic 
expression of miRNA146a, a PU.1 target, in HSCs results in their differentiation into 
macrophages in vivo in the peritoneum (Ghani et al., 2011). Thus, PU.1 directs the 
development of HSCs into macrophages through multiple mechanisms.  
PU.1 selectively drives differentiation towards macrophage development. 
Overexpressing it in bone marrow-derived mast cells results in the generation of 
macrophages (Ito et al., 2009). While HSCs are programmed toward a 
monocyte/macrophage lineage with increased expression of PU.1, the end-point 
phenotype of these cells has been documented to be DC-like. Pre-T cells ectopically 
expressing PU.1 have been re-programmed to generate DC-like cells while C/EBPα 
overexpression results in the generation of macrophages (Laiosa et al., 2006). Bakri et al, 
describe how constitutive expression of PU.1 results in the generation of DCs rather than 
macrophages while Maf-B is required for the induction of a macrophage phenotype 
(Bakri et al., 2005). Hematopoietically-derived DCs from both human and mouse have a 




Figure 1-3: Model of macrophage versus DC phenotype instructed by PU.1 and 
MafB. (Reproduced from Bakri et al., 2005) PU.1 plays a crucial role in the development 
of the monocyte/macrophage lineage from multi-potent cells. Its role in the development 
of macrophage versus DC phenotype further to this is represented above. Elevated levels 
of PU.1 push toward a more DC phenotype while inhibiting the development of 
macrophage phenotypes by binding to MafB. If the levels of MafB are higher, the multi-
potent cell or monocyte will develop into a macrophage. 
 
The further downstream action of PU.1 in the phenotype and function of macrophages 
has also been discussed. PU.1 modulates the transcription of about 3000 genes and its 
binding sites are found near a number of macrophage-lineage specifying genes such as 
M-CSFR (Ross et al., 1998), GM-CSFR (Hohaus et al., 1995) but also close to phenotypic 
markers such as FcRIb (Perez et al., 1994), CD11b , etc. PU.1 also mediates the steady 
state trans-activation of Ciita promoters pI and pIII (LeibundGut-Landmann et al., 2004; 
Yoon and Boss, 2010) as well as IFN-ɣ stimulated promoter pIV (Ito et al., 2009). PU.1 
has also been reported to have a role in the alternative activation of macrophages towards 
an M2 phenotype, with conditional removal of PU.1 in vivo showing a dramatic reduction 
in M2-driven  airway epithelial hypersensitivity (Qian et al., 2015). 
Another crucial transcription factor involved in myelopoiesis, is NUR77 that is encoded 
by Nr4a1. Ly6Clo monocytes (Hanna et al., 2011) and a population of thymic 
macrophages (Tacke et al., 2015) are specifically dependent on Nr4a1 for their 
development. The dependency of different cDC and monocyte populations on the various 
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transcription factors of what is known from the current literature is summarized in Table 
1-2.  
1.3.2.3 Phenotype and functions of monocytes and macrophages 
 
Monocytes are a major component of the circulating population of immune cells that form 
part of a lineage that is identified by its expression of M-CSFR (CD115) and lysozyme 
(LyzM). M-CSF-R is expressed from the earliest stages of yolk-sac macrophage 
development, while LyzM is expressed much later in liver hematopoiesis (Lichanska et 
al., 1999). Murine cells are insensitive to diphtheria toxin as they lack its receptor(Cha et 
al., 2003). Transgenic mice that are genetically manipulated to conditionally express the 
receptor to knock-out specific populations by DT treatment of the LyzMcrex Csf1rlslDTR 
mice, which express a cre recombinase under the LyzM promoter along with promoting 
DTR sensitivity in Csf1r expressing cells,  leads to the depletion of monocytes and 
macrophages, and not cDCs, in the BM, blood, spleen and tissues such as the lamina 
propria (Schreiber et al., 2013). Another crucial marker of differentiation between the 
subsets of monocytes is Ly6C. Ly6Clo monocytes patrol the vasculature (Auffray et al., 
2009) and are dependent on the transcription factor NUR77 for their development (Hanna 
et al., 2011). Ly6Chi monocytes on the other hand circulate at steady state and are 
recruited by inflammatory mediators secreted by the Ly6Clo monocytes as well as other 
immune cells and endothelial cells to the site of inflammation. Monocyte subsets thus 
play distinct roles as sentinels of the immune system.  
Macrophages reside in virtually every mammalian tissue (Wynn et al., 2013) and express 
both F4/80 and CSF-1R. F4/80 is often used to differentiate between populations of 
different origins- F4/80bright macrophages arise from the yolk sac and F4/80low 
macrophages originate from the erythro-myeloid progenitors that give rise to HSCs 
(Schulz et al., 2012). While these relative levels of F4/80 expression on macrophages is 
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not the clearest form of discrimination between different origins of the cells, the F4/80bright 
yolk-sac derived tissue-resident macrophages are also less proliferative as they are 
independent of the transcription factor crucial for maintaining the proliferative state of 
hematopoietic progenitors- c-Myb (Mucenski et al., 1991; Schulz et al., 2012) . In 
addition to this population, organs like the gut, dermis and heart are continually 
supplemented with monocyte-derived macrophages. Fate-mapping experiments in the 
dermis have shown that the F4/80hi macrophages are replenished by the CCR2-dependent 
Ly6Chi monocytes that give rise to an intermediate population of F4/80lo macrophages 
which progressively acquire an F4/80hi phenotype (Bain et al., 2016; Tamoutounour et 
al., 2013). The heart is one of the few organs that exhibit considerable numbers of the 
yolk-sac derived macrophages in adulthood but also have CCR2-dependent monocyte-
derived macrophage populations especially after cardiac inflammation (Epelman et al., 
2014).  CD103-CD11b+ macrophages in the gut are continually replenished by recruited 
monocytes (Bain et al., 2013; Varol et al., 2007). This difference in origin could 
contribute to the phenotypic and functional differences observed in the many macrophage 
populations in these tissues.  
By large, macrophages act to maintain homeostasis in a tissue-specific manner.  Each 
tissue-specific macrophage differs from the others in form and function depending on the 
tissue of residence. For example, red pulp macrophages in the spleen digest and recycle 
heme to maintain systemic iron levels (Chow et al., 2013) while microglia prune synapses 
during development (Paolicelli et al., 2011). These differences would appear to arise from 
changes in the transcriptional programme of macrophages which result from the 
microenvironment in which they reside (Gosselin et al., 2014; Lavin et al., 2014; Okabe 
and Medzhitov, 2014). Additionally, macrophages continually change their 
transcriptional profile with chronic insults like fibrosis, obesity and cancer, converting to 
a more ‘metastable’ phenotype in response to various tissue-specific stimuli (Wynn et al., 
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2013). This in turn, makes it more difficult to classify all macrophages within defined 
groups. Increasingly, published reports are pointing toward a need for a deeper, more 
diverse classification of the various sub-types of macrophages found at steady-state and 
during inflammation (Wynn et al., 2013).  
Thus, tissue resident myeloid populations at steady state constitute cDC1s, cDC2s, yolk-
sac derived macrophages and monocyte-derived macrophages. The key transcription 
factor Zbtb46 can be used to discriminate cDCs (both immature and mature) from 
monocytes and macrophages. Macrophages derived from HSCs are discriminated by the 
expression of transcription factors c-Myb (Schulz et al., 2012) and Id3 (Mass et al., 
2016).Thus by the use of transcription factors, the lineages of steady-state myeloid 
populations can be distinguished from each other
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Table 1-2: Comparison of transcription factors 
 
(Abram et al., 2014; Clausen et al., 1999; Hettinger et al., 2013; Hildner et al., 2008; Meredith et al., 2012; Satpathy et al., 2012a; Tamura et al., 2005; Tussiwand et al., 2015) 
(Hettinger et al., 2013)





Irf4  -  -  +  -  + lo  -  -
Irf8 +  +  -  +  -  +  +  +
Zbtb46  -  -  -  -  -  -  -  -  -
Batf3  -  -  +  -  -  -  -  -
E4BP4  -  -  -  +  +  -  -
LyzM  +/-  +  +
E2-2  -  -  -  -  -  +  -  -  -
Id2  -  -  +  +  -  -
Nr4a1  -  -  -  -  -  -  -  -  +
Klf4  -  -  +  +





Irf4  -  -  +  -  +  +  -
Irf8 +  +  -  +  -  +  +  lo lo
Zbtb46  -  +  +  +  +  -  -  -  -
Batf3  -  -  +  +  -  -  -
E4BP4  +  -  -  -  -  -  -  -  -
LyzM  -  +/-  +  +
E2-2  -  -  -  -  -  +  -  -  -
Id2  -  -  +  +  +  -  -  -
Nr4a1  -  -  -  -  +  -  -  -  +

































1.4 Growth factors at steady state and inflammation 
A number of growth factors play a crucial role in the development of both the monocyte 
and cDC lineages. These include GM-CSF, Flt3L and M-CSF. To understand the role 
that each growth factor plays in the ontogeny and function of each myeloid population, I 
shall discuss each in the next sub-section. 
 
1.4.1 Flt3L 
Flt3 (fmo-like tyrosine kinase-3) or flk-2 (fetal liver kinase-2) was originally discovered 
in populations enriched for stem cells (Matthews et al., 1991). 60% of Lin-Sca-1+c-kit+ 
cells are Flt3+ (Adolfsson et al., 2001). The expression of Flt3 on hematopoietic 
progenitors is transient. Flt3l-/- mice have reduced populations of lymphocytes and 
neutrophils in addition to a fall in the GM-dependent precursors (McKenna et al., 2000). 
Administration of supra-physiological levels of FLT3L however, does not influence the 
relative amounts of lymphoid cells in circulation or in the bone marrow (Waskow et al., 
2008). 
The cell populations most dramatically affected within the Flt3l-/- mice are the CD8α+ 
and CD8α- spleen cDCs (McKenna et al., 2000). Importantly, Flt3l-/- cDCs induce similar 
levels of T cell stimulation as their Flt3l+/+ counterparts (McKenna et al., 2000). Flt3-/- 
and Flt3l-/- mice have reduced cellularity in the bone marrow and spleen and show a 
particularly low level of cDCs and cDC-committed precursors (MDP, CDPs, Pre-DCs) 
in the BM (McKenna et al., 2000; Waskow et al., 2008) indicating a requirement of FLT3 
for their development. Additionally, exposure to super-physiological levels of Flt3L 
increased MDPs and peripheral cDCs and pDCs. Expression of the receptor FLT3 was 
also required for the peripheral expansion and maintenance of CD11chiMHCII+ cDCs as 
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mixed adoptive transfer experiments of Flt3-/- and WT MDPs into WT recipients showed 
increased amounts of CFSE dilution in the WT donor CD11c+ cells (Waskow et al., 2008). 
Thus, Flt3 is required for the development of cDCs from MDPs and for their peripheral 
expansion (Figure 1-4).  
In the case of inflammation due to an infection, Flt3L is released in the serum of infected 
mice at high concentrations, for e.g. in Plasmodium chabaudi infections (Guermonprez 
et al., 2013). Released by mast cells due to increased type I IFN receptor signalling in the 
case of P.chabaudi infection, the elevated levels of Flt3L causes elevated levels of CD8α+ 
and CD8α- cDCs in the spleen. However, the levels of FLT3 are highly regulated as over 
expression during infection can lead to detrimental outcomes (Alaniz et al., 2004). 
1.4.2 M-CSF 
Macrophage colony-stimulating factor (M-CSF) or Csf1 was originally isolated from 
human urine and used as a constituent in solid-state culture medium to grow macrophage 
colonies that also contained granulocytes (Stanley et al., 1975) However, later on L929-
cell conditioned medium (from the cell line named L cells) was used as a source of 
potently active M-CSF (Stanley and Heard, 1977) which Stanley and Heard later renamed 
Colony stimulating factor-1 (CSF-1).  
CSF-1 is produced by several cell types including macrophages, osteoblasts, stromal cells 
and endothelia and its main contribution to hematopoiesis has largely been attributed to 
the development of macrophages - Csf1-/- and Csf1r-/- mice lack macrophages in a number 
of tissues, including osteoclasts-a loss that leads to an osteopetrotic phenotype in the Csf1-
/- mice (Witmer-Pack et al., 1993; Yoshida et al., 1990). While studies have also found 
that the cytokine is required for the development of Langerhans cells at steady state 
(Ginhoux et al., 2006) and plays a role in cDC development in vivo (MacDonald et al., 
2005). Administration of CSF-1 results in the increase in pDC and cDC numbers (Fancke 




Figure 1-4: Ontogeny of the mononuclear phagocyte system:Adapted from Guilliams 
et al, 2014. Classification system of various cells of the MPS. Macrophages rely on M-
CSF(CSF1), IL-34 and GM-CSF (CSF-2) to develop into macrophages from the 
embryonic stage. Under steady state, monocytes remain in circulation or replenish only 
certain tissue macrophages such as that of the gut, but differentiate in response to 
inflammation into macrophages or dendritic cells. At this point they are called ‘monocyte-
derived’ to distinguish them from embryonically or hematopoietically-derived 






First identified as a growth factor involved in the generation of granulocyte and 
macrophages colonies in vitro, GM-CSF (or Csf2) has proved to have a key role during 
inflammation. At steady state, mice lacking the Csf2r or Csf2 show relatively little 
difference in the development of myeloid populations. However, in several disease states 
in humans and in disease models in mice, GM-CSF appears to have a pathogenic role, 
inducing heightened pathology in arthritis, experimental autoimmune encephalomyelitis 
(EAE) and  asthma to name a few (Hamilton, 2002). Its relevance at steady state is not 
clear given that Csf2r-/- mice display little to no differences in the numbers of tissue 
resident macrophage (except alveolar macrophages), circulating monocytes or lymphoid 
tissue resident cDCs (Wynn et al., 2013). The one population GM-CSF does appear to 
influence is the non-lymphoid tissue cDCs.  
1.1.1.1 GM-CSF on c-DCs: 
GM-CSF (CSF2) plays a crucial role in the development of cDCs at steady state. A study 
by Shortman and colleagues utilized GM-CSF-R-/- (Csfr2b-/-) or GM-CSF-/- (Csf2-/-) mice 
have normal numbers of both sub-populations of cDCs in the spleen, i.e., cDC1 and cDC2 
but a decrease in both the subsets in the lymph nodes (Vremec et al., 1997). Although it 
was not clearly outlined in the study, the threefold reduction in the lymph node cDCs was 
possibly a reflection more of the migratory than the resident populations of cDCs (Vremec 
et al., 1997). Indeed, Merad and colleagues later showed that the migratory cDC1 
(CD103+) subset in the draining lymph nodes of the lung, skin and gut were all reduced 
several fold in the Csf2rb-/-Csf2rb2-/- double knockout mice (Greter et al., 2012) 
emphasizing a specific reliance of cDCs from non-lymphoid tissue cDCs on GM-CSF. 
Csf2r--/- mice when injected with Flt3L have increased levels of cDC1s but not cDC2s 
(Daro et al., 2000). This shows a dependency of the cDC2s or a fraction of them on CSF-
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2R. Although, pre-cDCs rely on Flt3L to differentiate into terminally differentiated cDCs 
in secondary lymphoid organs, they appear to rely on ligand binding of CSF-2R to 
differentiate into CD103+CX3CR1
- lamina propria DCs (Bogunovic et al., 2009). 
Administration of GM-CSF at supra-physiological levels results in the expansion of cDCs 
in the spleen and thymus (Daro et al., 2000; Vremec et al., 1997). Thus, GM-CSF 
contributes to the development of non-lymphoid tissue cDCs at steady state and aids in 
further expansion of cDCs in secondary lymphoid organs which might prove useful 
during inflammation when there is an increase in the growth factor.  
 
 
Del Rio et al also reported the need for GM-CSF in culture to derive CD103+ cDCs (Rio 
et al., 2008). By contrast, Murphy and colleagues noted that although the 
CD103+CD24+CD11b-CD11c+ cells were reduced in the lung and the inguinal lymph 
nodes of Csf2rb-/- mice, they were not completely removed in the Batf3-/- mice but simply 
have reduced expression levels of CD103 (Edelson et al., 2011; Hildner et al., 2008). In 
vitro studies in this paper show that the addition of GM-CSF to a Flt3l culture of BM 
cells results in the generation of CD103 expression on the CD24+MHCII+ cells in culture 
which do not appear in a similar culture of Csf2rb-/- BM (Mayer et al., 2015). Thus, the 
expression of CD103 on the migratory DCs is dependent on GM-CSF and these migratory 
cDCs are partially dependent on GM-CSF for their development.  
GM-CSF not only increases the numbers of CD11b+ cDCs in the spleen but also increases 
their antigen degradation capacity (Daro et al., 2000). GM-CSF is also capable of 
promoting development of additional immune cells. For instance GM-CSF and TNF- 
exposed CD34+ human cord blood cells generate CD14+-derived DCs that are capable of 
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inducing immature B cells to differentiate into IgM-producing cells in response to CD40 
ligation and IL-2 (Caux et al., 1997).  
Whole bone marrow cultured in GM-CSF will derive cells that have a cDC-like 
phenotype and transcriptomic signature (Inaba et al., 1992). Culture in GM-CSF alone 
results in approximately 75% of Zbtb46-GFP+ cells while GM-CSF + IL-4 promotes 96% 
Zbtb46-GFP expression among the resulting progeny (Satpathy et al., 2012a). However, 
Flt3-/-Csf2r-/- mice also have similar levels of splenic cDCs as the Flt3-/- mice (Waskow 
et al., 2008). Thus, although GM-CSF supplemented cultures paved the way for research 
in DC biology by promoting amplification of DC cell numbers in vitro, GM-CSF-R 
signalling plays a limited role in the development of cDCs in secondary lymphoid organs.  
 
Table 1-3: Requirement of various growth factors for DC lineage development 
  
1.1.1.2 MHCII+ cells are induced by elevated levels of GM-CSF 
A number of in vitro and in vivo studies have demonstrated that GM-CSF induces the 
expression of MHCII on myeloid cells (Daro et al., 2000; Hanada et al., 1996). This 
increase in MHCII is seen on both monocytes and dendritic cells (Daro et al., 2000; 
Randolph et al., 1999). GM-CSF, upon engaging with its receptor, brings about the 
activation of specific signalling pathway intermediates -  STAT5 in a Janus JAK2-
























GM-CSF        
M-CSF        
Flt3L        
40 
 
signalling cascade leading to the activation of CIITA (Choi et al., 2009), the transcription 
factor that drives the expression of MHC class II (LeibundGut-Landmann et al., 2004). 
 The increase in MHCII+ cells is not only seen in response to excessive levels of GM-
CSF but also in response to infectious agents like Leishmania, Listeria and 
Lipopolysaccharide (LPS) (Greter et al., 2012; Meredith et al., 2012; Olekhnovitch et al., 
2014). 
Upregulated MHCII expression is seen particularly within the cDC population. Inducing 
an increase in circulating GM-CSF by either administration of recombinant protein, recall 
response to mBSA or by an established tumour engineered to produce GM-CSF 
constitutively (Dranoff et al., 1993; Naik et al., 2006), results in an increased number of  
CD11b+ c-DCs in the spleen as compared to controls, with enhanced expression of 
MHCII (Hanada et al., 1996; Storozynsky et al., 1999; Vremec et al., 1997). Ly6Chi 
monocytes are recruited to the site of GM-CSF production and the draining lymph nodes 
and then convert into a population that is DC-like in its expression of co-stimulatory 
molecules in CD80, CD86 and MHCII (León et al., 2007). These DC-like cells have the 
highest levels of MHCII in a culture with GM-CSF and IL-4, as compared to cultured 
macrophages and CD11b+Ly6G-Ly6Chi inflammatory cells (Xu et al., 2007). Indeed, 
monocytes cultured in GM-CSF and IL-4 generate cells that are Zbtb46+ (Briseño et al., 
2016). Distinguishing these cells from cDCs is challenging. Thus, with increased levels 
of GM-CSF, the relative contributions of different types of DCs is manipulated.  
1.1.1.3 GM-CSF in inflammation. 
Inflammation is characterized by the generation and accumulation of a number of 
inflammatory factors such as cytokines IL-1, TNF-, IFN-, IL-10, chemokines and 
growth factors GM-CSF and Flt3l (Guermonprez et al., 2013; Serbina et al., 2003; Zhan 
et al., 2011) that induce the recruitment of immune cells. These are crucial at the site of 
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inflammation as they act on myeloid cells to induce co-stimulatory marker expression 
like CD40, CD80 and CD86, which are collectively required to promote T cell 
stimulation. The role of GM-CSF specifically, is context-dependent. It has been reported 
to have both tolerogenic roles (Mortha et al., 2014) and inflammatory roles (Cook et al., 
2004; Croxford et al., 2015). From the several studies on GM-CSF, it appears that its role 
is possibly indirect and context-dependent. Furthermore, GM-CSF has been found to 
induce the generation of DCs and macrophages both - in vitro (Inaba et al., 1992) and in 
vivo (Vremec et al., 1997), and during inflammation (Cook et al., 2004; Croxford et al., 
2015; Daro et al., 2000). 
In comparison with DCs that were expanded in Flt3l-treated mice, DCs expanded with 
GM-CSF showed very similar levels of CD4+ and CD8+ T cell activation indicating no 
difference in their ability to present antigen. However, they showed a significant increase 
in their ability to take up antigen and process it as evidenced by the degradation of 
fluorescently trackable DQ-OVA (Daro et al., 2000).  
In vivo models used to study the effect of GM-CSF include a recall response to methylated 
bovine serum albumin (mBSA). Such models have also shown an increase in the 
production of CD11b+CD11c+MHCII+ cells in the spleen in response to elevated levels 
of GM-CSF (Cook et al., 2004; Naik et al., 2006). 
1.5 Induction of mo-DCs and iNOS-producing cells 
As described earlier, macrophages and DCs are highly heterogeneous. Furthermore, 
during inflammation, Ly6Chi monocytes are recruited to sites of inflammation and 
differentiate into macrophages and DCs (Sprangers et al., 2016). The resultant cells are 
widely termed inflammatory macrophages and inflammatory DCs that have unique 
properties that distinguish them from their steady state counterparts. Inflammatory 
macrophages have been found to generate a strong pro-inflammatory response by 
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secreting various cytokines such as TNF- and reactive oxidative species in the presence 
of parasites  as well as anti-inflammatory responses via the production of IL-10 and TGF-
 during conditions of stress such as cardiac overload (Lavine et al., 2016; Liaskou et al., 
2013; Nahrendorf et al., 2010). In such cases the distinction between the origin of the 
macrophages is of great consequence (Lavine et al., 2016). Inflammatory DCs or mo-DCs 
have been reported to have anti-inflammatory responses in the case of viral infections 
(Ohyagi et al., 2013) while promoting the pathogenic Th2 immune reponses to house 
dute-mite allergen (Plantinga et al., 2013) depending on the conditions of inflammation 
(Sprangers et al., 2016). These divergent outcomes from MPS development point toward 
characteristics of plasticity or heterogeneity in the progenitor cell populations, namely, 
monocytes.  
1.5.1 Monocyte-derived cells 
Monocytes are recruited in large numbers to the site of inflammation, outnumber both 
macrophages and cDCs present in the tissue (Geissmann et al., 2003; Randolph et al., 
1999). Ly6Chi monocytes can differentiate into macrophages or DCs (Askenase et al., 
2015). However, classification of these cells are challenging as to the lack of markers at 
steady state to clearly differentiate between cells that have expanded in situ and those that 
have been recruited and differentiated from monocytes. During inflammation, markers 
such as CD11b, CD11c and MHCII that are classically expressed on all myeloid cells, are 
upregulated. Additionally, these monocyte-derived cells could acquire similar functions 
to macrophages (improved phagocytosis, killing of pathogens etc.) or DCs (improved 
antigen presentation) depending on the site at which they develop, making classification 




1.5.2 Phenotype of Mo-DCs 
MoDCs are phenotypically similar to CD11b+ cDCs in that they are CD11b+CD11c+ 
(Daro et al., 2000) and are present in the spleen (Naik et al., 2006) and lymph nodes 
(Davidson et al., 2013; Plantinga et al., 2013) during inflammation. These phenotypic 
markers are not unique enough to distinguish them from other myeloid populations such 
as macrophages (CD11b+CD11c+F4/80+) and CD8α- cDCs (CD11b+CD11c+MHCII+).  
Sallusto and Lanzavecchia first documented the expression of the mannose receptor 
(CD206) on human DCs and DCs derived from peripheral blood cultured in the presence 
of GM-CSF and IL-4. These GM-CSF induced DCs utilize CD206 to selectively uptake 
particulate antigens, process and present them onto MHCII (Sallusto and Lanzavecchia, 
1994a). CD209a or DC-specific ICAM3 grabbing non-integrin (DC-SIGN) was also 
documented to be expressed on GM-CSF-induced-DCs by day 7 of differentiation from 
human monocytes and found to specifically bind to ICAM3 on T cells with greater 
affinity than to LFA-1 (Geijtenbeek et al., 2000). When Mo-DCs were described in vivo, 
Cheong et al. defined them based on their expression of a combination of CD206 and 
CD209a (DC-SIGN) in response to administration of LPS. This expression correlated to 
the in vitro expression of these markers on monocyte-derived DCs i.e. the result of 
cultures in GM-CSF (Geijtenbeek et al., 2000). Additionally, mo-DCs have also been 
found to express markers like FcɛRI in the lung (Plantinga et al., 2013) and CD64 in the 
lung and gut (Plantinga et al., 2013; Tamoutounour et al., 2012). However, a common 
marker expressed on these cells in all tissues and all systems of inflammation is lacking 
Mo-DCs display several characteristics resembling cDCs, such as the ability to illicit T 
cell proliferation and IFNɣ production ex vivo. Mo-DCs are found in the T cell areas of 
the lymph nodes, are CCR7-dependent, and are phenotypically and anatomically different 
from the sub-capsular and medullary macrophages that express CD206 and CD209b 
(SIGN-R1) at steady state (Cheong et al., 2010). Intriguingly, mo-DCs were found also 
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to be Flt3-independent, express CD14  and dramatically reduced in the LyzMCRE x  iDTR 
mouse model (Cheong et al., 2010) indicating that they were more closely associated with 
the myeloid lineage. 
 
These markers have since been used to define mo-DCs that arise in response to LPS. 
However, not all markers are used for identification and a combination of one (CD209a, 
CD206 or CD14) with high expression of CD11c, MHCII and CD11b continue to be used 
as a phenotypic description of ‘Mo-DCs’ (Meredith et al., 2012). This has led to confusion 
surrounding these cells, specifically regarding their origin from either the monocyte or 
DC lineage, their phenotypic definition, and their correlation to macrophages and cDCs 
and to other inflammatory progeny of the mononuclear phagocyte system. Thus, there is 
currently no consensus on the definition of mo-DCs. 
1.5.3 Ontogeny of Mo-DCs 
Mo-DCs have been described in various models of inflammation, including pathologies 
in the lung such as asthma (Plantinga et al., 2013), in the gut in models of colitis 
(Tamoutounour et al., 2012; Zigmond et al., 2012), and in secondary lymphoid organs 
like the spleen and lymph nodes in infectious models with Listeria (Greter et al., 2012) 
and Leishmania (León et al., 2007). Mo-DCs are also widely identified from 
inflammatory fluids from patients with tumour ascites or rheumatoid arthritis (Segura et 
al., 2013)  
Largely, mo-DCs were thought to arise from Ly6Chi monocytes, but there are conflicting 
results from different studies. Using the Flt3-/- mouse models, Cheong et al. showed that 
the CD11c+MHCII+CD209a+CD206+ cells that arose in response to LPS, did not rely on 
Flt3 expression indicating that they were distinct from the cDC lineage (Cheong et al., 
2010). Flt3l-/- mice administered with house dust mite allergen (HDM) have similar levels 
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of mo-DCs (FcɛR1+CD64+) cells as WT controls (Plantinga et al., 2013). LPS- injected 
WT and Zbtb46-DTR (zDCDTR/DTR) mixed bone marrow chimeras had reduced levels of 
zDC-DTR CD14+CD11c+MHCII+ cells in the skin draining lymph nodes. This showed 
that these cells were dependent on the cDC- lineage (Meredith et al., 2012).  The use of 
genetic models and stringent gating strategy without a common phenotypic definition, 
might be the reason for this confusion. 
The expression of Ly6C on mo-DCs differs with each study. A careful examination of 
the various studies shows that the expression of Ly6C is context-dependent and also relies 
on whether the researcher includes populations that are iNOS/TNF+ or cells that are 
MHCIIhi and arise in response to inflammation. iNOS/TNF+ cells are found to be Ly6Chi 
(Serbina et al., 2003) while the MHCIIhi CD11b+CD11c+ gated mo-DCs are Ly6Clo 
(Cheong et al., 2010; Plantinga et al., 2013). I could thus speculate that Ly6CloMHCIIhi 
cells might be transcriptionally and phenotypically different to inflammatory cells that 
produce iNOS and arising from a unique precursor. 
1.5.4 Function of Mo-DCs 
Mo-DCs are better at antigen uptake and processing than cDCs (Daro et al., 2000). In 
vitro culture of B and T cell-depleted murine bone marrow in GM-CSF results in the 
development of DC aggregates that are efficient at induction of MHCII-restricted T cell 
activation (Inaba et al., 1992). House dust-mite (HDM) allergen sensitized mo-DCs, and 
not tissue DCs, when adoptively transferred into naïve mice that were then given a booster 
dose of allergen, respond with a strong Th2 mediated immune reaction with eosinophil 
infiltration into the lung indicating the central role of mo-DCs in the uptake and 
presentation of antigen to T cells in vivo (Plantinga et al., 2013). Within this model, 
migration of mo-DCs to draining lymph nodes in the case of Th2 immune responses have 
been found to be largely CCR7 dependent (Plantinga et al., 2013). By eliciting a number 
of pro-inflammatory cytokines such as IL-1 and IL-6 (Cook et al., 2004) and chemokines 
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like CCL2, CCL7 (Plantinga et al., 2013), mo-DCs gain the capacity to recruit other 
immune cells to the site of inflammation. Ly6ChiCCR2+ mo-DCs rely on GM-CSF to 
exert their effect in certain pathologies such as EAE (Croxford et al., 2015). Ccr2cre x 
Csf2rfl/fl mice when injected with myelin oligodendrocyte glycoprotein (MOG) peptide 
developed Ly6ChiMHCII+ Mo-DCs but did not develop EAE as it was noted that their 
expression of IL-1 was greatly diminished (Croxford et al., 2015). Human monocytes 
when cultured in GM-CSF, also produced much higher levels of IL-1 than controls 
(Croxford et al., 2015). Thus, GM-CSF appears to control the functional role of mo-DCs 
in regards to their capacity for antigen presentation and the production of inflammatory 
cytokines.   
  
1.5.5 iNOS expression by monocyte-derived cells 
Inducible nitric oxide synthase (iNOS) is an enzyme that is induced upon inflammation 
in macrophages (Beckerman et al., 1993). The enzyme aids in the production of nitric 
oxide (NO) that carries out bactericidal activity and has been considered toxic to the cell 
producing it in excessive amounts. Nos2-/- mice are more susceptible to infection by 
Listeria monocytogenes (L.m.) iNOS expression by activated monocytes was first 
documented by Pamer and colleagues (Serbina et al., 2003) who coined the term Tip-DCs 
for TNF- and iNOS-producing DCs to describe the cells that resulted from the activation 
of CCR2-dependent Ly6Chi monocytes in response to an L.m. infection. Supporting the 
notion of their origin from Ly6Chi monocytes, LyzMcrex Csf1rlslDTR mice upon infection 
with L.m. have a significantly reduced level of iNOS+ TNF+ cells in the spleen 
(Schreiber et al., 2013). Other than iNOS expression this phenotype of 
MHCII+CD11c+CD11b+matches that of mononuclear phagocytic cells that arise under 
conditions of elevated levels of GM-CSF. As a results iNOS+ cells have been considered 
a type of GM-CSF induced mo-DC (Greter et al., 2012; Naik et al., 2006).  Zigmond et 
47 
 
al. examined the role of iNOS+ cells in vivo in a mouse model of colitis and reported that 
Ly6Chi monocytes give rise to iNOS+ cells, a phenotype which is followed by a DC-like 
phenotype at a later time point (Zigmond et al., 2012). This report will examine the 




1.6 Objectives and overall aims 
1.6.1 Rationale of the study 
Mo-DCs and iNOS-producing cells are considered to be part of the same population of 
cells despite the lack of convincing evidence other than concomitant expression of  
MHCII, CD11c and CD11b (Naik et al., 2006). Studied in various organs with different 
models of inflammation, various markers have been used to phenotype these cells, the 
most selective so far being Fcɛr1 and CD64 in the lung and gut (Plantinga et al., 2013; 
Segura and Amigorena, 2013; Tamoutounour et al., 2012) during allergic asthma and 
colitis, respectively. But whether these markers appear in other models of inflammation, 
for example in response to LPS where they have been phenotyped as CD209a+CD206+ 
remains to be determined. Another aspect that remains to be deciphered is the origin of 
mo-DCs. While iNOS+ cells are thought to derive from Ly6Chi monocytes, the question 
of whether mo-DCs belong to the monocyte or DC lineage remains unanswered. 
1.6.2 Objectives of this study 
This study aimed to answer the following questions 
 Is there a distinct precursor population for mo-DCs and iNOS+ cells? 
  Are mo-DCs and iNOS+ cells the same? 
 Can mo-DCs and iNOS+ cells be distinguished from other myeloid populations at 
the site of inflammation? 










Chapter 2 will discuss the material and methods used during this thesis including mouse 
models used and the various techniques used to transcriptionally define the cell 
populations discussed. 
Chapter 3 will describe the phenotype of a novel precursor population of Ly6Chi 
monocytes that bear at steady state, the characteristic of mo-DCs. Their association with 
the monocyte and cDC lineages will be addressed.  
Chapter 4 will address the cell types that arise in response to GM-CSF given its central 
role in the derivation of mo-DCs. 
Chapter 5 will interrogate the ontogeny of iNOS+ cells and will compare these to cells 
that arise in response to GM-CSF. 





















2 Materials and Methods 
 
2.1 Animal models: Mice 
C57Bl/6 mice were bought from Charles River Laboratories, UK. All mice used were 
between 6-12 weeks old and age- and sex- matched for all experiments. Genetically 
modified mice are described in Supplemental Procedures. They were maintained under 
specific pathogen-free conditions in accordance with the UK Animals (Scientific 
Procedures) Act, 1986. 
2.1.1 Genetic knockouts 
2.1.2 Ccr2-/-mice: 
Generated as previously described by Boring et al, Ccr2-/- mice were a gift from Prof. 
Frederic Geissmann (Boring et al., 1997).  
2.1.3 Nr4a1-/- mice: 
Generated by Lee et al (Lee et al., 1995), these mice were housed within King’s College 
London by the laboratory of Prof. Frederic Geissmann. Littermate controls and knock-
outs were generaously provided by Frederic Geissmann. 
2.1.4 Sfpi1+/-mice: 
Generated by McKercher et al, Sfpi1+/- (C57Bl/6) breeders were generously provided by 
Prof. Frederic Geissmann  (McKercher et al., 1996). Sfpi1+/- mice were bred within the 
conventional unit of King’s College London and used from matings of Sfpi1+/- males with 
C57BL/6 females.  
2.1.5 Zbtb46-GFP mice (Satpathy et al., 2012) 
Originally described by Murphy and colleagues, Zbtb46-GFP mice (C57BL/6) were 
housed at the animal facility at Queen Mary, University of London and were a kind gift 
from Dr. Maria Longhi.  
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2.1.6  pIII +pIV-/-, pIV-/-, pI-/- and Ciita-/- mice: 
Various knockouts for the promoters of Ciita – pIII +pIV-/- mice (C57BL/6) (LeibundGut-
Landmann et al., 2004), pIV-/- (C57BL/6)(Waldburger et al., 2001), pI-/- (C57Bl/6) 
(Dubrot et al., 2014) were generated as described before and were housed at Geneva 
Medical School, Switzerland within the lab of Dr. Stephanie Hugues. Maintenance and 
experimentation on these mice were carried out by Dr. Juan Dubrot Armendariz of the 
same laboratory. 
2.1.7 Zbtb46Crex ROSAloxSTOPloxYFP mice 
Zbtb46Cre mice were generated by  Loschko et al (Loschko et al., 2016b) and were crossed 
onto a mouse expressing the transcriptional STOP element flanked by loxP sites (that are 
recognized by Cre recombinase) within the ubiquitously expressed ROSA locus – the 
ROSA loxSTOPlosYFP mice (Jakob Loshko, 2016). This provided a conditional knockout 
specifically in cells that expressed Zbtb46. Zbtb46Crex ROSAlSlYFP were housed within the 
The Rockefeller University, New York, USA. Bone marrow from these mice was 
provided by Prof. Michel Nussenzweig, transported on dry ice to our laboratory and used 
to re-constitute age- and sex-matched lethally irradiated C57BL/6 mice.  Mice were 
allowed to completely re-constitute their hematopoietic system whist in quarantine for 8-
12 weeks before use.  
2.1.8 zDCDTR/DTR mice  
Generated as described before (Meredith et al., 2012), zDCDTR/DTR mice were housed 
within The Rockefeller University, New York, USA. Bone marrow from these mice was 
provided by Prof. Michel Nussenzweig, transported on dry ice to our laboratory and used 
to re-constitute age- and sex-matched lethally irradiated C57BL/6 mice.  Mice were 
allowed to completely re-constitute their hematopoietic system whist in quarantine for 8-
12 weeks before use. In order to knock out cells expressing Zbtb46, 20ng of diphtheria 
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toxin /g weight of the mouse was administered intra-peritoneally 20 hours prior to 
sacrifice.  
2.1.9 Nos2Tomato-CrexROSAloxSTOPloxtdTomato  
Nos2Tomato-Cre mice were created in the Institut Clinique de la Souris (Illkirch, France)  
The tdTomato-ires-Cre cassette was inserted by homologous recombination into the 
RP23-341J22 bacterial artificial chromosome (BAC) within the 2nd exon of the Nos2 gene 
with the ATG of the tdTomato replacing the endogenous ATG. This was done through 
the collaboration with Gregoire Lauvau (Albert Einstein College of Medicine, New York 
,USA) and Frederic Geissmann (King’s College London, UK). 
These mice were then crossed onto Rosa26-tdTomato mice (Madisen et al., 2012) to generate 
a fluorescence within the 585 channel in order to fate map iNOS+ cells (Bechade et al., 
2014). The cross is called Nos2Tomato-CrexROSAloxSTOPloxtdTomato and were housed 
within Institut de Biologie de l’Ecole Normale Superieure, Paris, France. 
Bone marrow from these mice was provided by Dr. Alain Bessis, transported on dry ice 
to our laboratory and used to re-constitute age- and sex-matched lethally irradiated 
C57BL/6 mice.  Mice were allowed to completely re-constitute their hematopoietic 
system whist in quarantine for 8-12 weeks before use. 
2.1.10 Flt3L-/- 
Generated as described before (McKenna et al., 2000), the Flt3L-/- mice (C57BL/6) were 
maintained within the Francis Crick Institute, London, UK and were generously donated 
by Prof. Caetano Reis e Sousa.  
2.1.11 Bone marrow Chimeras:  
8-10 week old C57bl/6 mice were hematopoietically-lethally irradiated at 11Gy; bone 
marrow from Zbtb46-Cre-loxSTOPloxYFP (Loshko et al, 2016) , Zbtb46-iDTR mice 
(Meredith et al., 2012) or NOS2-Tomato-CrexROSAloxSTOPloxtdTomato (Bechade et al., 2014)was 
54 
 
injected intravenously at a dose of 5 x 106 cells in100l into these irradiated recipients. 
To allow full reconstitution, the mice were used at 8-16 weeks after transplantation. Ccr2-
/- (CD45.2+) and WT (CD45.1+) mixed bone marrow chimeras were produced in 
hematopoietically-lethal irradiated (11Gy) CD45.1+ recipients by transplanting them with 
CD45.1+ WT and Ccr2-/- (CD45.2+) bone marrow in equal parts. CD45.1+ recipients that 
received 100% CD45.2+ C57Bl/6 bone morrow were used as a control for the complete 
replacement of recipient bone marrow with donor-derived bone marrow. 
2.2 Genotyping 
2.2.1 DNA Isolation 
Genomic DNA was isolated by digesting ear biopsies of animals in a digestion buffer 
with ProteinaseK at 56oC for 2 -14 hours before being centrifuged to remove debris and 
placed on ice. Supernatants containing the DNA were then mixed with equal volumes of 
100% cold isoproponal to allow the DNA to fall out of solution. Upon centrifugation, the 
pellets were washed with cold 70% ethanol. Pellets were allowed to dry with only a small 
volume of supernatant left before 100l of water was used to dissolve the DNA. Samples 
were stored at 4oC until required for analysis. 
2.2.2 Genotyping protocol for Sfpi+/- mice 
Single reaction for 2 PCR products was carried out using the HotStartTaq kit (Qiagen). 
Each reaction contained 2l of genomic DNA (prepared as mentioned above), 0.5l of 
each primer, 12.5l of HotStartTaq reagent (Qiagen), 2.5l of CoralLoad DNA loading 
buffer (Qiagen) and DNase free water to perform a 25ul PCR reaction. Primers used for 
the genotyping of the Sfpi1+/- mice were: 
Forward: 5’- GCC CCGGAT GTGCTT CCC TTA TCA AAC-3’ 
Reverse Neo: 5’CGC ACG GGT GTT GGG TCG TTT GTT CGG-3’ 
Reverse WT: 5’TGC CTCGGC CCT GGG AAT GTC -3’ 




Knock-out band: 980bp 
 
Figure 2-1: Sfpi1 genotyping gel of a WT and heterozygous mouse against a 1kb ladder. 
 
The PCR reaction was run for 30 cycles of the following temperatures and time intervals: 
Denaturation at 95oC for 45s, annealing at 600C for 45s and elongation at72oC for 90s 
after an initial hold of 95oC for 15mins.  
Post-PCR reactions were run on 1.5% agarose gels made with TBE buffer (Life 
technologies) and containing ethidium bromide (Santa Cruz Biotechnology) alongside a 
1kb DNA ladder (NEB). PCR products were visualized using Bio-Rad Gel Doc EZ 
System. 
2.3 Preparation of cell suspensions from various tissue 
2.3.1 Preparation of mouse bone marrow cell suspension 
Murine bone marrow was obtained from both tibia and femurs from each mouse. The 
ends of each bone were cut and the bone flushed using a 23G syringe with cold FACS 
buffer into centrifuge tubes. Cell suspensions were maintained on ice. After 
centrifugation at 320rcf for 4mins at 4oC, cell pellets were resuspended in Ack RBC lysis 
buffer (Life technologies) and incubated at RT for 2 mins before being diluted with FACS 
buffer and pelleted again. The resulting pellets were resuspended in fresh FACS buffer 
and left on ice until stained with appropriate antibody cocktails. 
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2.3.2 Preparation of mouse blood cells 
 
Murine blood was obtained by cardiac puncture after exposure to an increasing gradient 
of CO2. Blood was collected using a 23G syringe coated on the inside with 2000IU/ml 
(10x) Heparin (Sigma Aldrich) and deposited in microcentrifuge tubes containing 100ul 
of 100mM EDTA (Life technologies) and 10ul of 20,000 IU/ml (100x) Heparin on ice. 
This mixture was then added to 1.5ml of Ack RBC lysis buffer and incubated on ice for 
7 mins. Cell suspensions were centrifuged at 320rcf for 4mins at 4oC and Ack lysis was 
repeated. After centrifugation, cell pellets were resuspended in fresh FACS buffer and 
left on ice until stained with appropriate antibody cocktails. 
2.3.3 Preparation of mouse splenocytes 
 
Mouse spleens were collected in Digestion buffer (HBSS+1%FBS), cut into small pieces 
and incubated with CollagenaseD (0.375U/ml) and DNaseI (10µg/ml) for 20 mins at 
37oC. The reaction was stopped by placing the spleens on ice and adding EDTA at a final 
concentration of 2mM. Spleens were then smashed through 100um filters and the cell 
suspensions centrifuged at 320rcf for 4mins at 4oC.  Ack lysis at RT for 5mins was 
stopped by dilution with FACS buffer. Cell suspensions were centrifuged and cell pellets 
resuspended in fresh FACS buffer. 
2.4 Flow cytometry 
2.4.1 Enrichment of cells for fluorescence assisted cell sorting 
 
For experiments requiring the sorting of specific cell populations or enrichment of Ly6Chi 
monocytes for in vitro cultures, cell suspensions that were prepared as detailed above, 
were incubated with biotin-labelled antibodies for the lineage (containing anti-CD3ɛ, 
anti-CD19, anti- NK1.1, anti-CD45RA, anti-Ter119, anti-ckit, anti-Ly6G) for 20 mins on 
ice. Cells were washed to remove excess antibody and incubated with MACS beads (30l 
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beads/200l buffer/80-100x 106 cells) for 20 mins in the fridge. Cells were then 
centrifuged and resuspended in FACS buffer to be passed through a pre-washed depletion 
(LD) column (Miltenyi). The flow-through was collected and 2ml of FACS buffer was 
passed through the column to retrieve any non-lineage cells that may have adhered to the 
column. The flow through was then centrifuged and the pellet resuspended in FACS 
buffer for staining with appropriate antibody cocktails. 
2.4.2 Flow cytometry reagents 
 
Fluorochrome or biotin- conjugated antibodies were used to stain single cell suspensions 
for flow cytometry. that were bought from eBioscience (Hatfield, UK) and Biolegend 
(London, UK). 
Marker Clone 
CD19  MB19-1 
Ly6G  1A8 
CD3ɛ  145-2C11 
NK1.1  PK136 
CD45RA  HI100 
ckit  2B8 
MHCII I-A/I-E  M5/114. 15.2 
Ly6C  HK1.4 
CD11b  M1/70 
CD115 AFS98 
CD16/32  93 








Ter119  Ter119 
  
 
2.4.3 Intracellular FACS staining 
 
 For staining intracellular levels of iNOS, cells were fixed and permeabilized using BD 
Cytofix/Cytoperm Fixation kit as per manufacturer’s instructions and stained with anti-
iNOSA488 or -iNOS-PE (clone: CXNFT) purchased from eBioscience. For staining 
PU.1, cells were fixed and permeabilized using FoxP3/ Transcription factor staining 
buffer set (eBioscience) according to manufacturer’s instructions. Anti-PU.1 rabbit 
monoclonal antibody (clone: 9G7) and the corresponding isotype were purchased from 
Cell Signaling Technology (New England Biolabs (UK) Ltd). 
2.5 Adoptive Transfer experiments 
2.5.1 Adoptive transfer of FACS sorted cells 
 
For adoptive transfer of FACS sorted cells, cell suspensions of whole organs were made 
(see earlier). Cell suspensions were exposed to Ack lysis and further enriched using 
MACS beads and a depletion column (LD column)(Miltenyi) (see above). Cells were 
then stained with appropriate fluorochromes and sorted using the BD FACSAria II. 3.3 x 
105 cells of each population were sorted into complete RPMI, centrifuged and 
resuspended in RPMI alone to be injected i.v. into CD45.1+ congenic recipients, in a total 
volume of 120l per mouse.  
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2.5.2 Adoptive transfer of whole bone marrow 
 
For whole bone marrow transfers, single cell suspensions of bone marrow (prepared as 
above) were depleted of red blood cells by exposure to Ack RBC lysis buffer (Life 
technologies) and counted. 40 x 106 whole bone marrow cells from Sfpi1+/+ or Sfpi1+/- 
mice were transferred into B16-GM-CSF treated congenic CD45.1+ mice on day9 and 
analyzed on day11 after tumor injection; For L.m. infected recipients, 20x106 whole bone 
marrow cells were transferred into congenic CD45.1+ recipients 6 hours before L.m. 
infection i.v.. 
2.5.3 Reagents:  
 
Complete medium used for cell culture was RPMI with Glutamax, (Life technologies) 
and 10% FBS (Life technologies) and 50uM beta-mercaptoethanol (Sigma). FACS buffer 
used was made of PBS (Life Technologies) with 1% bovine serum albumin (Apollo 
Scientific) and 2mM EDTA (Life technologies). 
2.5.4 Cell Isolation and fluorescence-activated cell sorting.  
 
Single-cell suspensions of the bone marrow of each mouse were prepared by flushing the 
bones of both hind limbs (2 tibia and 2 femurs) with ice cold FACS buffer (PBS (Life 
technologies) with 1% BSA (Apollo Scientific Ltd) and 2mM EDTA (Life 
Technologies)). Spleens were collected, cut into small pieces and incubated with 
Collagenase D (Roche) and DNaseI (Roche) in HBSS (PAA) + 5% Fetal Bovine Serum 
(Life technologies) for 20 mins. They were then smashed through 100um cell strainers 
(BD Falcon) to obtain cell suspensions. To lyse the red blood cells, bone marrow 
suspensions were pelleted and resuspended in 2ml of Ack lysis buffer (Life technologies), 
incubated for 2 mins at room temperature and then diluted with FACS buffer. After 
centrifugation at 320rcf for 4 mins at 4oC, cells were either re-suspended in antibody 
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cocktail in FACS buffer or permeabilized/fixed for intracellular staining. Cells were 
analysed using BD LSR Fortessa. For sorting, bone marrow or spleen cells were 
resuspended to an approximate concentration of 7000cells/µl. They were then sorted on 
a BD FACS Aria (special order machine) fitted with 405nm, 488nm, 561nm, 633nm 
lasers and sorted through 100m nozzle with 4-way purity. Purity checks were run on 
samples used for microarrays and were used when purity was found to be >95%. 
Both instruments were housed at the Biomedical Research Centre Flow Core Facility 
(Guy’s and St Thomas’ NHS Foundation Trust and King’s College London). Flow 
cytometry analysis was done using FlowJo software (TreeStar). 
2.6 Giemsa Staining 
Cytospins of FACS sorted R1, R2, R3 and P were fixed with methanol for 5 mins, stained 
with 1:20 Giemsa stain in deionized water for 45 mins and then washed and air dried. 
Slides were imaged on Motic AE2000 with 40x magnification. Images were modified for 
brightness with ImageJ (NIH). 
2.7 In vitro culture experiments 
2.7.1 In vitro GM-CSF Cultures  
 
Total BM or 104 sorted Ly6ChiCD115+ monocytes (total or R1, R2, R3 subsets) cells were 
cultured in 20ng/ml of GM-CSF in complete RPMI with 6000 live MS-5 cells or whole 
bone marrow congenically marked, as indicated per experiment, as ‘feeders’, plated on 
the same day. Cells analysed were pre-gated to be DAPI- and CD45+. 
2.7.2 In vitro L.m. infections:  
 
In vitro cultures of primary sorted cells with Listeria monocytogenes (L.m.) was done 
overnight at an MOI of 0.01 or 0.1 as indicated in complete RPMI1640 medium 
supplemented with MCSF (20ng/ml) (Peprotech), GM-CSF(3ng/ml) (Peprotech) and 
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human Flt3L(100ng/ml) (CellDex). BMDMs were derived from Sfpi1+/- or Sfpi1+/+ BM 
cultured for 8-10 days in DMEM medium (Life technologies) supplemented with 10% 
FBS and 10% MCSF containing L-929 cell culture supernatant. These were re-plated as 
0.45 x 106 cells/well in a 24-well non-tissue culture treated plate to be stimulated with 
LPS (1µg/ml) or L.m. at MOI 1 or 10 for 16 hours. Cells were collected, stained with 
fluorochrome conjugated antibodies and analysed by FACS. 
2.8 B16-GM-CSF tumor experiments  
Melanoma cell lines B16 and B16 expressing GM-CSF (B16-GM-CSF)(Dranoff et al., 
1993) were maintained in RPMI1640 medium supplemented with Glutamax (Life 
technologies), 10% fetal bovine serum (Life technologies), 1% penicillin-streptomycin 
(Life Techonologies) and 50uM beta-mercaptoethanol (Sigma) and used from between 
passages 4 and 10. Cells were checked for viability with Trypan Blue and 1.5-3 x 105 live 
cells were injected subcutaneously in sterile RPMI 1640 medium alone. 
2.9 Infection 
Listeria monocytogenes or the ΔActA mutant of the same (ΔActA Listeria) were grown 
and sub-cultured in brain heart infusion broth at 370C until an OD600 value of 0.12-0.15 
was obtained to use bacteria in their exponential growth phase. 4 – 5 x 103 wild type CFU 
(Listeria) or 106 ΔActA mutant CFU of  L.m. were injected intravenously in sterile PBS. 
2.10 Microarray processing and analysis:  
The NuGEN Ovation Pico WTA v2 kit was used to process 1ng RNA per sample into 
SPIA amplified cDNA. The Encore Biotin Module (NuGEN) was used to fragment and 
biotin-label the cDNA. Hybridisation cocktails were prepared as recommended by 
NuGEN and hybridised to Affymetrix Mouse Gene 1.0 ST arrays overnight. Arrays were 
washed and stained using Affymetrix Fluidics Station FS450 and GeneChip 
Hybridisation Wash Stain kit and scanned in GCS3000 7G scanner with Autoloader. Raw 
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data files (DAT and CEL) were generated in Affymetrix GeneChip Command Console 
software (AGCC). 
Affymetrix CEL files were converted into gct files using the ExpressionFileCreator 
Module within Gene Pattern Software (Broad Institute) (Reich et al., 2006). The RMA 
algorithm withquantile normalization and background correction was used. No thresholds 
or filters were applied for assessing the relative expression of all genes assayed on the 
microarray. Heat maps were generated with this data on Gene-E software 
(https://software.broadinstitute.org/GENE-E/). Heat maps show relative raw expression 
values for each gene, comparing one sample to the others. Colour bars therefore indicate 
highest to lowest values for each gene. 
To create the Volcano plots, MutiplotPreprocess Module within the Gene Pattern 
Software (Broad Institute) was used to derive fold change and p-values from the 
expression dataset of the aforementioned microarrays to be used in the 
MultiplotVisualizer Module. This latter module was used to highlight the genes more 
highly expressed in R2 or R3 above a threshold of p-value set at 0.05 and fold change of 
1.2. These selected genes were then overlaid on comparisons done between R1 and R2, 
and R1 and R3 to obtain the plots shown in Fig.1F. 
2.11 PCA analysis and hierarchical clustering: 
 Microarray data of R1, R2 and R3 were compared with ST1.0 array data available on 
ImmGEN for Pre-DCs (GSE68590) (Tussiwand et al., 2015)and CDP (GSE 15907) 
(www.immgen.org) on Qlucore Omics Explorer (Sweden) and plotted as 2D plots on 
Prism (Graphpad).  Hierarchical clustering of data sets was performed using Gene-E 
software (Broad Institute). 
2.12 qPCR on bulk sorted populations 
Cells were sorted as described and centrifuged. Supernatant was removed 
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and cells were resuspended in RLT buffer from the RNeasy kit (Qiagen). mRNA was 
extracted using the columns as per manufacturer’s instructions. mRNA was resuspended 
in RNase-free water and the concentration and quality measured by nanodrop (Thermo 
Scientific). Equal amounts of mRNA (between 0.1ng – 5µg) from each sample were taken 
to produce cDNA using the manufacturer’s First Strand cDNA synthesis protocol with 
the RevertAid™  H minus Reverse Transcriptase (Thermo Scientific). Random Primers 
(Oligo dT primers) were mixed with template RNA and incubated at 65oC for 5 mins and 
Ribolock (Thermo Scientific), dNTP mix, Reaction buffer (5x) and mMulV reverse 
transcriptase enzyme were added and incubated at RT for 10 mins, 42oC for 1hr and at 
70oC for 5 mins to inactivate the enzyme. A 1 in 10 dilution of this cDNA was used to 
perform qPCR with Sensimix™SYBR® (Bioline) as per manufacturer’s instructions. 
Primers used for testing Zbtb46 were: Forward 5’- AGA GAG CAC ATG AAG CGA 
CA-3’, Reverse: 5’-CTG GCT GCA GAC ATG AAC AC-3’. Results were normalized 
against Actin B levels for each sample. Primers used for Actin-B were: and Forward: 5’- 
ATG CTC CCC GGG CTG TAT-3’ and Reverse: 5’-CAT AGG AGT CCT TCT GAC 
CCA TTC-3’. 
2.13 Multidimensional reduction analysis:  
Automated t-distributed stochastic non-linear embedding (t-SNE) algorithm was used to 
visually (viSNE) analyse (Amir el et al., 2013) bone marrow monocytes acquired by 
FACS for 7 fluorochromes. The online (web-based) software implementation of viSNE 
(Cytobank) (Kotecha et al., 2010) was used to analyse the presence of different 
populations within the Ly6ChiCD115+ BM monocytes. No a priori gating was used and 
an unbiased automated analysis was conducted. The resulting viSNE maps were overlaid 
with each monocyte population, R1, R2 and pre-DC R3 that were gated separately by 
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conventional FACS analysis. The colour scheme for all four viSNE maps was adjusted to 
represent the Flt3 expression – blue colour denoting lower levels and red – higher.  
2.14 Single cell qPCR 
Single cells were FACS sorted from bone marrow into 9ul of Cell Direct pre-Amp master 
mix in 96-well qPCR plates. Complementary DNA synthesis and specific target 
amplification of 45 genes (including 3 housekeeping genes- Hprt, ActB, Gapdh) was 
performed using CellsDirect One Step qRT-PCR kit (Invitrogen) with 48 Taqman assays 
(Life technologies) at 0.2x. Reverse transcription was performed within the same plates 
using the following cycle: 40oC for15 mins, 50oC for 15 mins, 60oC for 15 mins. Enzyme 
inactivation was done at 95oC for 2mins followed by 22x (95oC for 15s, 60oC for 4mins). 
cDNA was then diluted 1 in 5 in low EDTA TE buffer. Samples were stored at -20oC 
until used in the BioMark. 81 cells of R2, and 44 cells of R1 and R3 each were compared 
along with control well including 10 cells and no cell controls and dilutions of cDNA 
from 105 cells to 1 cells to check for primer viability. 5l of diluted cDNA + Taqman 
mastermix+ Sample loading reagent and 5 µl of each Taqman assay + Assay loading 
reagent were loaded into their respective wells on 4 M48.M48 Dynamic Arrays. Samples 
and Assays were then loaded into the reaction chambers of the Dynamic Array using the 
IFC ControllerMX(Fluidigm), and then transferred to the BioMark HD for qPCR (95oC 
for 10 min; 40 cycles of 95oC for 15 s and 60oC for 60 s). Data obtained from the ‘Real 
time PCR analysis’ software (Fluidigm) was analysed using Gene-E software. 




Table 2-1: List of primers used for single-cell qPCR 
















































These genes were selected for their discriminating capacity based on the PCA analysis 
between sorted populations of R1, R2 and R3 along with genes with previously described 
expression in monocytes and DCs. Below is a heat map of the microarray data on sorted 
populations R1, R2 and R3, of all the genes assayed in the single-cells analysis. Genes 
highlighted in red are those that feature in the variables list from the PCA (Figure 2-2).  
 
Figure 2-2: Heat map of gene expression on R1, R2 and R3. Microarray analysis of 
bulk-sorted populations R1, R2 and R3 of the genes that were most differentially 






2.15 Statistical Analysis  
Data was analysed for statistical significance by unpaired Student’s t-test. Differences 
were considered significant for p<0.05. *p<0.05, **p<0.005, ***p<0.0005, 
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3 Heterogeneity of Ly6Chi monocytes 
 
3.1 Introduction and Objectives 
3.1.1 Introduction 
3.1.1.1 The role of monocytes and cDCs in the development of ‘mo-DCs’ 
cDCs and monocytes arise from distinct progenitors and represent members of distinct 
lineages that are characterised by elevated expression of transcription factors (e.g. Zbtb46 
for cDCs (Meredith et al., 2012; Satpathy et al., 2012a), LyzM in monocytes (Cross et al., 
1988)). During steady-state hematopoiesis, the development of monocytes and pre-cDCs 
arise from unique precursors such as cMop and CDP respectively.  cDCs are classically 
characterized as cells that are reliant on Flt3L for their development (McKenna et al., 
2000). Interestingly, ‘Mo-DCs’  have been reported to be both Flt3L-independent 
(Bogunovic et al., 2009; Croxford et al., 2015; Plantinga et al., 2013) and Flt3L-dependent 
(Meredith et al., 2012) suggesting that mo-DCs may arise from a heterogeneous 
population of precursor cells. It is important to note that each report had a slightly 
different gating strategy to characterize their target cell population. For example, 
Plantinga et al utilized CD11c+MHCII+CD11b+MAR-1+CD64+cells (Plantinga et al., 
2013) while Meredith et al. described mo-DCs as CD11b+CD11c+MHCIIhiCD14+ cells 
(Meredith et al., 2012) which further complicates the matter and requires clarification.  
Other studies also allude to the origin of mo-DCs from the cDC lineage. cDC lineage 
deleting zDCDTR/DTR mice allow the induced depletion of all cells expressing Zbtb46. 
Meredith et al. noted that mixed bone marrow chimeras of WT and zDC-DTR mice did 
not have mo-DCs (defined as CD11b+CD11c+MHCIIhiCD14+). This would suggest that 
mo-DCs originate from the cDC lineage (Meredith et al., 2012).  
During inflammation, Ly6Chi monocytes are recruited in large numbers to the inflamed 
tissue where they differentiate into macrophage or DC-like cells (Askenase et al., 2015). 
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The local tissue-resident macrophages and cDCs also become activated and express 
higher levels of co-stimulatory molecules. Dependent on the conditions of inflammation, 
such as the type of pathogen involved (Listeria, Leishmania, etc.) (Segura and 
Amigorena, 2013; Serbina et al., 2008), the dose of antigen (Cook et al., 2004) and the 
cytokines present in the microenvironment, recruited Ly6Chi monocytes can develop into 
cells capable of producing iNOS and TNFα (Serbina et al., 2003)  (referred to as Tip-
DCs) or  have a more regulatory role by producing TGF-β and IL-10 (Bain et al., 2013). 
Additionally, they contribute to the population of MHCIIhi cells within tissues that are 
capable of presenting antigen to T cells (Cheong et al., 2010). These MHCIIhi cells are 
referred to as monocyte-derived dendritic cells or ‘mo-DCs’. Thus, Ly6Chi monocytes 
exhibit plasticity in response to various stimuli. 
Cheong et al. described mo-DCs as cells that were CD209a+CD206+ which migrate to the 
lymph nodes in response to LPS stimulation in vivo. Interestingly, these cells were absent 
in Ccr2-/- mice and bore CD14  (Cheong et al., 2010) – 2 characteristics of murine 
monocytes (Geissmann et al., 2003). This suggests that the CD209+CD206+ MoDCs 
indeed come from Ly6Chi monocytes. Additionally, Murphy and colleagues elaborated 
on the distinction between LPS-induced DCs and CD11cintCD11b+Ly6Chi Tip-DCs; cDC 
lineage reporting Zbtb46gfp/+ mice highlighted that the Tip-DCs found in the spleens of 
Listeria monocytogenes (L.m) infected mice were ZBTB46-GFP- indicating that they did 
not belong to the cDC lineage (Satpathy et al., 2012a). Conversely, the administration of 
LPS induced DCs in the spleen which were defined as CD11b+MHCIIhiCD206+ cells, 
were ZBTB46-GFP+ (Satpathy et al., 2012a). This suggested that there are 2 DC-like 
inflammatory populations, of which one belongs to the DC lineage and one does not.  
The Zbtb46gfp/+ and zDCDTR/DTR mice provide a snapshot of the cells that are currently 
expressing Zbtb46 but do not indicate the lineage that the cells originate from. The 
strongest evidence supporting the notion that cells of monocyte origin can differentiate 
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into DCs comes from the transcriptional profiling of mo-DCs in a model of colitis carried 
out by Jung and colleagues (2012). Mo-DCs were found to express Zbtb46 and Flt3 
among other DC signature genes and were absent from Ccr2-/- mice (Zigmond et al., 
2012). Interestingly, the DC-like phenotype followed from an iNOS-producing stage. 
However, experiments such as ex vivo analysis of the iNOS+ cells for the expression of 
Zbtb46 and Flt3 was not done in this study, leaving questions open as to whether the 
Ly6Chi monocytes that become iNOS+ evolved into DC-like cells with time or whether 
the DC-like phenotype appeared from distinct Ly6Chi cells. 
Another hypothesis for the diverse phenotypes associated with Ly6Chi monocytes during 
inflammation is a previously uncharacterised heterogeneity within the population. I 
hypothesized that this heterogeneity might be represented by populations that have a pre-
destined role in the development of either more macrophage features or more DC-like 
features. The discrepancies in the origin and phenotypic description of mo-DCs requires 
further clarification and is addressed in the present chapter. 
3.1.2 Objectives 
 
Classically, Ly6Chi monocytes have been considered to be a homogenous population 
which leads to the development of macrophages and DCs during inflammation. A major 
aim of my thesis is to investigate the possibility of a novel population of Ly6Chi 
monocytes that could be responsible for the development of cells with DC‑like features 
during inflammation. In order to achieve this, phenotypic and genetic features commonly 
associated with monocytes and/or dendritic cells were tested at steady state in the bone 
marrow, blood and spleen. In particular, the specific aims addressed in this chapter are: 
 To investigate the heterogeneity of Ly6Chi monocytes. 
 To establish the precursors for mo-DCs and inflammatory macrophages. 
 To describe at a genetic level the specific function of these precursors. 
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3.2.1 Ly6Chi monocytes are a heterogeneous population 
 
3.2.1.1 Ly6Chi monocytes contain Flt3+ subsets 
Ly6Chi monocytes do not have any unique transcription factors by which to distinguish 
them from other populations. The best way to identify Ly6Chi monocytes is by using 
characteristic surface markers analysed by flow cytometry. Conventional gating strategies 
for Ly6Chi monocytes require the use of the M‑CSFR (CD115/CSF-1R) and SIRPα 
(CD172α) or the integrin CD11b after the exclusion of all other lineages (T cells, B cells, 
NK cells, RBCs, pDCs). This allows the selection of Ly6Chi and Ly6Clo monocytes. 
However, upon a closer examination of the expression of Flt3 and CD11c on these cells, 
it could be noted that Ly6Chi monocytes are in fact divisible into 3 sub-populations‑ 
Flt3‑CD11c‑ cells, Flt3+CD11c‑ and Flt3+CD11c+ cells. These were named R1, R2 and R3 
respectively for the purpose of our study (Figure 3-1).  
 
Figure 3-1: Ly6Chi monocyte heterogeneity revealed using Flt3 and CD11c. WT 
Ly6Chi monocytes were gated after the exclusion of 
CD19+CD3e+NK1.1+Ter119+CD45RA+Ly6G+ckit+ cells (Lineage). The 
MHCII‑SIRPα+CD115+cells display 2 main levels of Ly6C expression. DC‑related 
marker‑ Flt3 and CD11c were assessed on Ly6Chi monocytes. R1 (blue), R2 (red), and 




I next investigated the heterogeneity of the Ly6Chi monocytes in circulation. Indeed, Flt3+ 
cells were visible within the Ly6Chi monocytes in the blood and spleen and in similar 
proportions as in the bone marrow (Figure 3-2) 
 
Figure 3-2: Ly6Chi monocyte heterogeneity is perpetuated in the blood and spleen 
WT blood Ly6Chi monocytes were gated on Lineage‑ 
(CD19‑CD3ɛ‑NK1.1‑Ter119‑CD45RA‑Ly6G‑ckit‑) SIRPα+CD115+ cells. WT spleen 
monocytes were gated after the exclusion of CD11c+MHCIIhi cDCs. 
 
3.2.1.2 Does the R3 population of Ly6Chi cells belong to the cDC lineage? 
Pre-cDCs are commonly gated as Lin‑MHCII‑CD11c+Flt3+ cells in the bone marrow and 
blood (Liu et al., 2007) and are thought to be the immediate precursors of differentiated 
cDCs. R3, albeit gated within the Ly6Chi monocyte gating strategy, fit the pre-cDC 
definition of cells. An overlay of the R3 on the gating strategy set out by Liu et al showed 
that R3 was in fact a CD115+ pre‑cDC population (Liu et al., 2007) and was a 
contaminating population within conventionally gated Ly6Chi monocytes 
(Lin‑CD115+SIRPα+Ly6Chi cells) (Nascimento et al., 2014; Yona et al., 2013) (Figure 
3-3). Ginhoux and colleagues also described the use of Ly6C and SiglecH in determining 
sub‑populations within the Flt3+SIRPαlo total pre‑DCs that are either non‑lineage primed 
76 
 
or are primed towards either cDC1 or cDC2 commitment (Schlitzer et al., 2015). R3 
mostly overlapped with the SiglecH‑Ly6Chi cells indicating that they were the 
cDC2‑committed pre‑cDCs with a small proportion of non‑lineage primed pre‑cDCs that 
did not overlap with the CD115- pre-DCs, P (Figure 3-3). 
 
 
Figure 3-3: Correlation of R3 with pre‑DC populations. 
MHCII‑CD115+SIRPα+Ly6C+Flt3+CD11c+ R3 cells (red) were overlaid on the 
conventional gating strategy for pre‑DCs (Liu et al., 2007)(lower gating panel) as well as 
the more refined delineation of the cDC1 and cDC2 subset-primed pre‑DC populations 
(Schlitzer et al., 2015). 
3.2.1.3 R2 and R3 cells are not precursors 
Double positive expression of Flt3 and CD115 is seen on non-committed progenitor 
populations in the BM. It was thus important to test if the R2 population was indeed a 
progenitor cell population. cKit is expressed on all hematopoietic progenitor populations- 
half of which co-express lineage-specific markers (Matthews et al., 1991; Ogawa et al., 
1991). I thus tested for the Ly6Chi monocyte heterogeneity within cKit- cells. The 
percentages of these populations were unaffected after removal of cKit+ cells (Figure 3-4). 
I thus concluded that R2 and R3 were lineage-committed non-precursor cells. 
77 
 
Nonetheless, I maintained the use of cKit in all further experiments as part of the lineage 
exclusion gate. 
 
Figure 3-4: Flt3+CD115+ cells are not cKit+. Comparison of anti‑cKit staining and 
isotype control on BM Lineage‑MHCII‑ cells prior to analysing Ly6Chi monocytes with 
respect to Flt3 and CD11c. 
 
3.2.2 The relationship between R2 and Ly6Chi monocytes 
3.2.2.1 R2 cells are CCR2-dependent. 
A salient feature of Ly6Chi monocytes is their dependence on CCR2 for egress from the 
bone marrow into the blood (Geissmann et al., 2003; Kurihara et al., 1997). Phenotyping 
of R1 and R2 monocytes and R3 and P pre‑DCs showed that CCR2 was expressed highly 
on R1 and R2 in contrast to the R3 or P populations (Figure 3-5a). 
To test the requirement of CCR2 on Flt3+ monocytes, I analysed the BM and blood of 
Ccr2‑/‑ mice. R1 and R2 were dramatically reduced while total pre‑DCs remained at 
similar levels in Ccr2-/- mice as compared to their WT counterparts in the blood (Figure 
3-5b).  
To ensure a cell-intrinsic role of CCR2 in the egress of BM R2 cells I tested the presence 
of R1 and R2 in the BM and blood of Ccr2‑/‑ and Ccr2+/+ mixed BM chimeras. The 
percentage of CCR2-sufficient R2 cells in the blood far exceeded CCR2-deficient cells. 
R3 and P pre‑DCs maintained equal proportions of both genotypes in the BM and blood 
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(Figure 3-5c). I therefore concluded that R2 is a Ccr2-dependent Ly6Chi monocyte subset, 




Figure 3-5: R2 cells are CCR2-dependent. a.) Bone marrow monocytes R1 and R2, and 
pre-cDCs R3 and P, were tested for Ccr2 expression. b) Ccr2+/+ and Ccr2‑/‑ blood were 
assessed for the presence R1 and R2 Ly6Chi monocytes, and R3 and P pre‑cDCs. Graphs 
shows absolute numbers of cells from Ccr2‑/‑ or Ccr2+/+ blood normalized to the absolute 
number of Ccr2+/+ cells. c.) Ccr2: WT bone marrow chimeras. R1, R2, R3 and P from the 
BM and blood of Ccr2‑/‑ (CD45.2) and WT (CD45.1) mixed bone marrow chimeras 
assessed for the percentage of congenic (CD45.1) marker expression. Graphs show mean 
± SEM; n=4-6, **p<0.005, ***p<0.0005, ns= non-significant; Student’s t-test. 
 
3.2.2.2 R1, R2 and R3 are independent of Nr4a1-dependent lineage 
To test the relationship, if any, of R1, R2 and R3 to the Nr4a1‑dependent Ly6Clo 
monocytes, Nr4a1‑/‑ mice were assessed for any modifications to the R1, R2, R3 and P 
populations. As has been previously reported (Hanna et al., 2011), Ly6Clo monocytes do 
not develop in Nr4a1-/-  mice as compared to WT controls. In our analysis of the Nr4a1-/- 
mice, R1, R2, R3 and P were not affected (Figure 3-6).   
 
Figure 3-6: R2 and R3 are not influenced by NR4A1 Nr4a1-/- mice were compared to 
WT controls and percentages of each Ly6Chi monocyte population, Ly6Clo monocytes 






3.2.2.3 R2 cells resemble Ly6Chi monocytes  
Transcriptional analysis of R1, R2 and R3 by the use of microarrays on each population 
showed that R1 expressed the macrophage signature while R3 expressed the cDC 
signature very strongly (Figure 3-7a). R2 exhibited an intermediate phenotype but 
expressed a stronger macrophage signature than that of cDCs. To phenotypically assess 
the similarity of R2 cells to Ly6Chi monocytes or R3 pre-DCs, a Giemsa stain of cytospin 
samples of FACS sorted populations R1, R2, R3 and P revealed the typical horse-shoe 
shaped nuclei characteristic of monocytes in R1 and R2. R3 and P had irregular nuclei as 




Figure 3-7:R2 cells resemble monocytes a) DC and macrophage gene signature in R1, 
R2 and R3 from 3 biological replicates sorted in 3 separate experiments. Microarray data 
of R1, R2 and R3 showing their relative mRNA expression of genes that belong to the 
cDC (upper panel) and macrophage (lower panel) gene signatures obtained from 
ImmGen. b) Giemsa stain of R1, R2 monocytes and R3 and P pre-cDCs. Cytospin 
samples of  flow-cytometrysorted R1, R2, R3 and P were fixed and stained with Giemsa 
stain and photographed at 400x. Scale bar=10µm  
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3.2.3 Ly6Chi monocytes and the cDC lineage 
3.2.3.1 Dependence of R2 and R3 on Flt3L 
One of the key features of the DC lineage is its dependence on Flt3L for development 
(Karsunky et al., 2003). Flt3 is widely expressed on a number of hematopoietic 
progenitors (McKenna et al., 2000). With progressive differentiation, Flt3L-dependency 
is restricted to the DC lineage (McKenna et al., 2000). Flt3l-/- mice are deficient in pre-
cDCs in the BM and blood as well as terminally differentiated cDCs in the spleen (Liu et 
al., 2007). In order to determine Flt3 dependence of the Flt3+ Ly6Chi cells (R2), Flt3l‑/‑ 
mice were assessed for cell numbers of R1, R2, R3 and P. R1 and R2 remained at much 
the same levels as WT counterparts, while R3 and P cells were dramatically reduced 
(Figure 3-8). This showed that while R3 and P were DC‑committed, the expression of Flt3 




Figure 3-8: R2 cells are Flt3L-independent: WT and Flt3l‑/‑ bone marrow and blood 
were assessed for the presence of R1, R2 and R3 within Lineage‑SIRPα+CD115+Ly6Chi 
cells. Graphs show mean ± SEM of R1, R2, R3 and P in WT and Flt3l‑/‑ blood; n=4-5, 
**p<0.005, ***p<0.0005, ns= non-significant; Student’s t-test. 
 
3.2.3.2 Zbtb46 is not expressed in R2 cells.  
Another technique used to accurately determine the ontogeny of a cell population, is fate 
mapping. The Zbtb46Crex ROSAlSlYFP mice conditionally and then permanently label any 
cell and its daughters upon expression of the transcription factor ZBTB46. This highlights 
any cell that originated within the cDC lineage. Phenotypic analysis of the BM and blood 
showed that Ly6Chi monocytes‑ R1 and R2, as well as pre‑cDCs‑ R3 and P, showed very 
low background staining with YFP (Figure 3-9a). In the spleen however, R3 and P pre-
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DCs expressed 25-30% of YFP, while R1 and R2 continued to express background levels 
of the fluorescent molecule (Figure 3-9a). This showed that even after egress from the 
bone marrow, R1 and R2 did not express sufficient levels of the cDC‑specific 
transcription factor ZBTB46.  
The analysis of the spleen showed that these mice have a rather stringent labelling of cells 
given that cDC1s that had previously been found to be homogeneously derived from the 
cDC lineage (Hildner et al., 2008; Tamura et al., 2005; Waskow et al., 2008) – was only 
50% positive for YFP (Figure 3-9b). I also noted that CD11b+ESAM+ cells had a higher 
proportion of YFP+ cells than ESAM- cells corroborating data from Reizis and colleagues 
that showed that the ESAM+ cells bear a stronger DC phenotype than the ESAMlo CD11b+ 
cDCs (Lewis et al., 2011). 
Murphy and colleagues constructed a reporter mouse that introduced an IRES‑GFP 
reporter gene in the place of the 2nd exon of the Zbtb46 gene (Satpathy et al., 2012a). This 
construct allows for the reporting of the expression of Zbtb46 within a cell and unlike the 
Zbtb46Cre x ROSAlslYFP mice, does not fate map the daughter cells of a Zbtb46 expressing 
cell. The Zbtb46-GFP mice provide a ‘snapshot’ of the Zbtb46+ cells. 
R1 and R2 monocytes did not express higher than background levels of GFP while the 
pre‑cDCs R3 and P expressed much higher levels (~ 84‑90% positive) (Figure 3-9c). This 





Figure 3-9: Zbtb46 labelling in R1, R2 monocytes and R3 and P pre-DCs. Bone 
marrow, blood and spleen of R1, R2, R3 and P were analysed for reporter expression in 
Zbtb46CRE x ROSAlslYFP mice  (a,) and Zbtb46gfp/+ (c) bone marrow, blood and spleen. b) 
CD8α+, ESAMhiCD11b+ and ESAMloCD11b+ cDCs in the spleen of Zbtb46CRE x 
ROSAlslYFP mice were assessed.  
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While reporter mice can provide insight into lineage commitment of a given cell 
populations, I also wanted to accurately address the mRNA levels of Zbtb46. In addition, 
I also tested the mRNA levels of CD8α+ cDC-specific lectin receptor - Clec9a (Poulin et 
al., 2012). CLEC9a is known to be expressed in committed progenitors of the CD8α+ 
cDCs. I wondered whether this might provide insight into whether there was a difference 
in the pre-commitment of R3 and P pre-cDCs to CD8a+ cDCs (cDC1) or CD11b+ cDCs 
(cDC2). I found that R1 and R2 expressed negligible levels of both markers while R3 
expressed high levels of Zbtb46 and Clec9a (Figure 3-10).  
 
 
Figure 3-10: qRT‑PCR analysis for Zbtb46 and Clec9a. mRNA from FACS‑sorted 
R1, R2, R3 and P along with cDC1 and cDC2, was tested for cDC1 specific Clec9a and 
cDC1 and cDC2‑ specific Zbtb46. Data of R1, R2, R3 and P is representative of 3 
experiments while cDC1 and cDC2s were tested as controls in 1 experiment.  
 
3.2.3.3 Influence of Irf8 on the development of R1 and R2 monocytes. 
The interferon response factors IRF4 and IRF8 have an overlapping role in the stimulation 
of DC development while also having individual roles in the stimulation of cDC subset 
specific gene expression (Tamura et al., 2005). Irf8 has been found to control the 
development of the cDC1s and to a certain extent the pDCs (Tamura et al., 2005). IRF4 
controls the development of the CD4+ DCs (cDC2s) while the double negative 
(CD4‑CD8a‑) DCs are influenced by both Irf4 and Irf8 (Tamura et al., 2005). 
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Additionally, Irf8 plays an important role in the myeloid cell lineage selection as is seen 
by controlling the development of terminally differentiated macrophages from bipotent 
myeloid cell progenitors in in vitro cultures of Irf8 overexpressing cell lines (Tamura et 
al., 2000).  
Irf8‑/‑ mice are immune-deficient and develop chronic myelogenous leukemia‑like disease 
(Holtschke et al., 1996). In order to test the reliance of both the monocytes, R1 and R2 on 
this transcription factor, the Irf8‑/‑ mice were phenotyped for relative numbers of the 
monocytes in the bone marrow and blood. Irf8‑/‑ mice had dramatically reduced levels of 
both monocyte subsets as well as of Ly6Chi pre‑cDCs, R3 (Figure 3-11). This indicated a 
possible role of the transcription factor IRF8 on the development of Ly6Chi monocytes as 
well as the cDC2‑ committed pre‑cDCs, R3, albeit this role might not be cell‑intrinsic 
given the systemic effect on the mice. It also does not help discriminate between the 2 




Figure 3-11: Irf8-/- mice exhibit reduced levels of R1, R2 and R3. Bone marrow and 
blood of Irf8+/+ and Irf8-/- mice were analysed for the presence of R1, R2 and R3. Graphs 
show mean ± SEM of R1, R2, R3 in WT and Irf8‑/‑ blood; n=4, *p<0.05, **p<0.005, ns= 
non-significant; Student’s t-test. This experiment was performed by Dr. Hannah Garner. 
3.2.4 Phenotypic and transcriptomic description of Flt3+Ly6Chi monocytes 
3.2.4.1 Transcriptomic analysis 
Microarray analysis of R1 and R2 monocytes with R3 pre-cDCs provided a basis for 
transcriptomic analysis of the 3 populations along with comparisons of published data on 
other populations (such as pre-cDCs and CDPs). A hierarchical clustering of the data 
shown in Figure 3-12 shows that R1 and R2 cluster very close together while R3 clusters 
separately. In addition, total pre‑cDCs and CDPs cluster under separate branches (Figure 
3-12). Analysing these populations by a PCA analysis also showed that R1 and R2 cluster 




Figure 3-12: Clustering analysis of R1 and R2 monocytes with cDC precursors. a) 
Hierarchical clustering of 2 samples each of R1, R2 and R3 along with CDP and pre-DC 
populations using One-minus Pearson Correlation. b) Principle component analysis of the 
above populations along principle components PC1 (72%), PC2 (24%), and PC3 (2%). 
Microarrays were performed by the King’s Genomics Centre, Waterloo, London.  
A volcano plot analysis of microarray data also helps with 2 aspects of understanding the 
dynamics of these populations. Firstly, the similarity in gene expression and secondly, 
the differentially expressed genes between the populations. With regards to the first 
aspect, Figure 3-13a shows that R1 and R2 have very similar gene expression patterns 
with most genes exhibiting less than 2-fold change in expression. R3 however, had a 
distinctly different gene expression pattern to both R1 and R2, albeit having a closer 
relationship to R2 than R1 (Figure 3-13a). 
Volcano plots are also useful in the identification of differentially expressed genes 
(DEGs). Using a threshold value of 2‑fold change and a p-value < 0.05, I listed genes that 
were uniquely expressed in R1 or R2 or R3 in comparison to the other 2 populations. For 
clarity, genes expressed highly in R2 are highlighted in blue while those more highly 
expressed in R3 are highlighted in red. Overlaying these genes on comparisons of each 
population with R1 shows their relative similarity to R1 in terms of mRNA expression. 
Interestingly, R2 DEGs are more strongly expressed in R1 than in R3. Furthermore, R3 




Figure 3-13: Differential gene expression in R2 cells a) Differential gene expression 
analysis of fold change versus statistical t-test p-value on microarray data of R1, R2 and 
R3. Top panel highlights genes most differentially expressed in a comparison between 
R2 and R3 with R2-specific genes highlighted in blue and R3- specific one in red (fold 
change>2, p<0.05). Candidate genes are marked on either side. The same highlights have 
been applied to comparisons of R1 and R2 (left) and R1 and R3 (right). Numbers in the 
bottom corners of each plot indicate the numbers of genes most highly upregulated in the 
population indicated above it for the indicated comparison. b and c). Microarray data of 
R1, R2 and R3 (average of 3 replicates) for members of FcɣR family (b) and CD209 (c) 
that were expressed above baseline. d and e) flow cytometry analysis of FcɣRII/III (d) 
and CD209a (e) (black lines) on steady state R1, R2 and R3 in the blood as compared to 




Given that the identification of monocytes and cDCs relies on a combination of surface 
markers that are widely expressed within the myeloid population (eg. CD11b, CD11c, 
MHCII), I wished to find other surface markers that would not only distinguish these 
Ly6Chi monocytes from other myeloid cells but also from each other.  
I searched within the differentially expressed genes to identify markers that can be 
associated with each population. I found that R1 highly expressed the family of FcRs in 
comparison to the R3 population. R2 showed an intermediate expression level of FcɣRIIb 
and FcɣRIII between R1 and R3 (Figure 3-13b). Among the genes most highly expressed 
in R3 as compared to R1 were several lectin receptors. Of these Cd209a was particularly 
well expressed in R3 while R2 had an intermediate phenotype and R1 showed minimal 
expression of Cd209a (Figure 3-13c). CD209a analysis in the bone marrow proved futile 
as no expression was observed, possibly because surface expression does not occur until 
the cells have left the BM. 
Reasoning that mRNA expression within the populations in the BM might lead to surface 
expression in the blood, I tested for the markers on R1, R2 and R3 in the blood. CD209a 
was highly expressed in R3 and R2 while R1 did not express it. FcRII/III was detected 
on R1 and R2 but not R3 (Figure 3-13 d,e). Thus R2 cells were distinguished by their co-
expression of FcRII/III and CD209a. 
 
3.2.4.2 R1 cells express inflammatory genes at steady state. 
In assessing the transcriptional profile of the R1, R2 and R3, it was noted that several 
inflammation‑associated genes were upregulated in R1 (Figure 3-14). These included 
vATPases (eg. lysosomal markers (eg., TLRs (Tlr1, Tlr2), Nod‑like receptors (NLRs) 
(eg. Nod1, Nod2) and interferon‑stimulated genes (eg. Cxcl10, Isg20). These were at 
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much higher expression intensities than R2 monocytes or R3 pre‑DCs. This indicated that 
R1 is genetically pre‑disposed to develop an inflammatory response as compared to R2. 
 
       
       
Figure 3-14: Transcriptomic analysis of R1, R2 and R3 for inflammatory markers. 
Microarray analysis of R1, R2 and R3 in 3 biological replicates from 3 independent 
experiments for genes associated with inflammatory signals. TLR- Toll-like receptors, 
RLHs – RIG like Helicases, ISGs: Interferon stimulated genes, NLRs- NOD like 
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3.2.5 MHCII expression on Flt3+Ly6C+CD115+ cells 
 
3.2.5.1 R2 upregulates MHCII surface expression in the blood 
Within the BM, it is crucial to exclude macrophages from the myeloid populations when 
gating on Ly6Chi monocytes. In order to do this, I excluded the MHCII+ cells in the gating 
strategy of R1, R2 and R3 in the bone marrow. as they were found to be predominantly 
Ly6CintF4/80hi cells, i.e. macrophages (Figure 3-15).  
 
Figure 3-15: MHCII+ BM are macrophages. Flow cytometry analysis of MHCII+ cells 
for Flt3, CD11c, CD11b, CD115 and F4/80 within Lineage-cells from the BM of C57Bl/6 
mice. 
In the blood however, MHCII could be expressed on a number of APCs which cannot be 
excluded from analysis. Upon inclusion of the MHCII+ cells, I corroborated previous 
results of there being an MHCII+ population within Ly6Chi monocytes (Jakubzick et al., 
2013)(Figure 3-16a).  These MHCII+ cells contained some cells that were CD11c+ but 
were 50% Flt3+. I could thus conclude that the Flt3+Ly6Chi cells were predominantly 
MHCII+, i.e., R2 monocytes. R3 pre‑DCs contribute to at least half of the MHCII+ 
CD115+Ly6C+ cells. Intriguingly there appeared to be a trend toward increased levels of 
MHCII expression in Ly6Clo monocytes (Figure 3-16b). This could be due to gradual loss 




Figure 3-16: Flt3+ R2 cells are enriched for MHCII expressing cells in the blood, 
.a). Lin-CD115+SIRPa+Ly6Chi cells analysed for Flt3, MHCII and CD11c expression. b) 
Analysis of the percentage of MHCII+cells within the Flt3+Ly6Chi monocyte gate. c) 
Percentage of MHCII+ cells within R1, R2 and R3. d) Average relative mRNA 
expression of MHCII-associated genes in R1, R2 and R3. 
 
with increased expression of MHCII in the blood. The Flt3+ cells within the Ly6Clo 
monocytes were all MHCII+. It is difficult to ascertain whether these cells are R2 and R3 
populations that are gradually losing their expression of Ly6C. 
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Gating for each population within the Ly6Chi monocytes and analysing the MHCII levels 
on each of these populations showed that R2 had approximately 40% MHCII+ cells while 
R3 was about 30% MHCII+ (Figure 3-16c). R1 had less than 2% MHCII+ cells. This was 
reflected in the microarray analysis of the MHCII associated genes as well (Figure 3-16d). 
R2 therefore relates to the MHCII+ population previously described in the blood and 
spleen (Randolph et al., 1999).  
3.2.5.2 MHCII is upregulated on R2 in in vitro culture overnight 
I next tested the upregulation of MHCII in R2 cells after leaving the BM by flow 
cytometry sorted monocytes and pre‑DCs following ex vivo culture in complete media 
overnight. R2 monocytes upregulated similar levels of MHCII as was seen in the blood. 
R3 also upregulated MHCII while R1 monocytes did not (Figure 3-17). This showed that 
R2 was distinctly capable of cell‑intrinsically upregulating MHCII. 
 
Figure 3-17: MHCII is upregulated on R2 monocytes and R3 pre-DCs. 
Representative plots of overnight cultures of fluorescence assisted cell sorted R1, R2 R3 
and P representative of 2-3 independent cultures. 
 
3.2.5.3 pI promoter of Ciita is responsible for the expression of MHCII 
The expression of MHCII on a cell is driven by the transcription factor CIITA. It has been 
previously reported that the promoter regions of CIITA are activated in a cell‑specific 
manner. pI has been reported to be activated in macrophages, monocytes and cDCs, pIII 
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in B cells and pIV is activated in response to IFNɣ (Kitamura et al., 2012; Yoon and Boss, 
2010). 
In order to identify the promoter responsible for the upregulation of MHCII on R2, I 
analysed the pI‑/‑, pIII‑/‑ and pIII-/-pIV‑/‑ mice along with WT and Ciita‑/‑ mice as controls. 
Using intracellular staining for MHCII in the BM and surface staining in the blood, it was 
observed that the pI promoter was uniquely responsible for the expression of MHCII on 
R2 as expression levels were reduced as compared to those of Ciita‑/‑ mice (Figure 3-18). 
MHCII expression on all cells was unaffected in the WT, pIII‑/‑ and pIII-/-pIV‑/‑ mice. This 





Figure 3-18: Expression of intracellular MHCII is pI-dependent p1-/-, pIV-/- and pIII-
/-pIV-/- bone marrow was compared with WT controls for the expression of intracellular 
MHCII on R1, R2, R3 and P. Graph shows mean ± SEM of the percentage of intracellular 
MHCII staining within the indicated parent population; n=4, *p<0.05, ***p<0.0005; 
Student’s t-test. Comparisons that were not show significant differences were left blank. 
This experiment was performed by Dr. Juan Dubrot Armendariz. 
 
3.2.6 Transcriptional regulation of Ly6Chi monocytes 
3.2.6.1 The role of PU.1 in the development of R2 monocytes 
After assessing the differences in the transcriptional phenotype of the Ly6Chi monocytes‑ 
R1 and R2, their differentiation, and surface expression of MHCII in the blood, it became 
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clear that each population was primed for divergent functions.  I therefore questioned if 
a specific transcription factor was responsible for the generation of functionally distinct 
populations. 
PU.1 is known to be a master transcriptional regulator in the development of macrophages 
(McKercher et al., 1996). The decision at the MDP stage between development into 
monocytes or cDCs is made by the competition between Maf‑B and PU.1 with PU.1 
determining a more DC lineage commitment and Maf‑B, macrophage commitment (Bakri 
et al., 2005). Thus, I wondered if PU.1 might regulate the DC-like phenotype of R2 (eg. 
pI regulated MHCII expression, C‑type lectin‑ CD209a, expression). Intra‑nuclear 
staining for PU.1 versus isotype controls, showed minimal differences in the bone marrow 
(Figure 3-19). This difference was more evident within the blood. Furthermore, R2 (and 
also pre‑DC R3) expressed much higher levels of PU.1 than R1 (Figure 3-19). 
 
Figure 3-19: PU.1 expression in R1, R2, R3 and P. BM and blood R1, R2, R3 and P 
were stained for PU.1 (Black shaded) and compared against isotype controls (shaded 
grey). 
3.2.6.2 PU.1 hemizygosity results in the diminution of PU.1hi cells‑R2 and R3. 
To test if R2 and R3 rely on PU.1 for their development, I analysed the steady state levels 
of these populations in the bone marrow, blood and spleen of Sfpi1+/‑ mice versus WT 
littermate controls. Our study was limited to the use of Sfpil+/- mice as the Sfpi1‑/‑ mice 
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die in utero or shortly after birth (McKercher et al., 1996; Scott et al., 1994). Firstly, I 
noted there was a reduction in the number of Ly6Clo cells in the BM and blood (Fig. 3-
20a) of the Sfpi1+/- mice while the relative percentage of Ly6Chi monocytes remained the 
same. 
 
Figure 3-20: MHCII+ cells are reduced in BM and Blood in Sfpi1+/- mice. Phenotypic 
analysis of Ly6ChiMHCII+, Ly6ChiMHCII+ and Ly6C-MHCII+ cells in BM and blood of 
Sfpi1+/+ and Sfpi1+/- mice. Grey bars indicate intraceullular staining for MHCII. Graphs 
show mean±SEM of n=3,representative of 3 experiments. *p<0.05, **p<0.005, 





Furthermore, the MHCII+ cells in the bone marrow (intracellular) and blood 
(extracellular) were vastly reduced in the Sfpi1+/‑ mice as compared to their wild type 
controls (Figure 3-20 b,c). This was expected as PU.1 is known to transcriptionally control 
the expression of MHCII (Kitamura et al., 2012). Finally, within the Ly6Chi monocyte 
populations, R2 and R3 were greatly diminished in the bone marrow and R2 even more 
so in the blood  (Figure 3-21). This showed that R2 and R3 rely on PU.1 for their 
development in the bone marrow. 
 
Figure 3-21: R2 and R3 rely on PU.1 for their development in vivo. Sfpi1+/+ and 
Sfpi1+/- mice were assayed for the presence of R1, R2 and R3 in the bone marrow and 
blood. Graphs show mean ± SEM for n=3 for 3 experiments with identical results. 
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3.2.7 R2 is a heterogeneous population 
Throughout our analysis of the 3 populations, R2 always presented an intermediate 
phenotype between R1 and R3. Additionally, finding surface markers that were distinctly 
expressed in R2 alone proved impossible. Phenotyping experiments showed that the 
population of R2 was heterogeneous for markers such as CD11b, CD209a, or FcRII/III. 
It thus became evident that R2 was in fact a heterogeneous population.  
In order to test this, I used another approach to study the FACS data of Ly6Chi monocytes 
in the BM. Multi‑dimensional reduction approach using the t-SNE algorithm, allows a 
2‑dimensional visualization of all 7 parameters (Lineage, MHCII, SIRPa, CD115, Flt3, 
CD11c, Ly6C) used to analyse every acquired cell without any a priori information 
regarding the gating strategy of each population. An overlay of the separately gated cell 
populations, on the unbiased clustering obtained through t‑SNE, showed that R3 clustered 
separately from R1 and R2 (Figure 3-22). Additionally, based on just these 7 markers, 
R2 could be differentiated into 3 populations that clustered with R1, one of which 
clustered on the edge indicating a more distinct expression pattern to R1 (Figure 3-22) 
 
Figure 3-22: Multi-dimensional reduction analysis of Ly6Chi monocytes. t-SNE 
analysis of bone marrow Ly6Chi monocytes previously gated on Lin-CD115+SIRPa+ cells. 
Overlay of separately gated R1, R2 and R3 on t-SNE analysis of total Ly6Chi monocytes 
reveals single-cell expression and clustering within each monocyte population.  
 
To further analyse the heterogeneity in the R2 populations, a single-cell qPCR analysis 
for 45 genes on 44 single cells of the R1 and R3 populations, and 82 cells of the R2 
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population was performed. This experiment was performed by Thibaut Perchet and was 
analysed by myself. This experimental approach provided an unsupervised analysis of R2 
to (i) determine how the population clusters with R1 monocytes and R3 pre-DCs, (ii) to 
determine if there is a unique population within R2 that might be the precursor population 
to mo-DCs and (iii) for the identification of a unique gene expression pattern to identify 
these cells. The genes assayed were among those that most highly discriminated by 
microarray data of FACS‑sorted populations R1, R2 and R3 in a PCA analysis (Figure 
3-23). Additionally, some transcription factors (e.g. Irf8, Sfpi1) were added to the list in 
the interest of finding any further evidence of a different transcriptional profile between 






Unsupervised clustering of the genes showed that specific monocyte‑related (eg. FcɣR2b, 
Fcɣr3) or DC‑related genes (eg. Irf4, Sfpi1, Kmo) clustered together and apart from the 
other (Figure 3-24). 
Unsupervised clustering analysis of all the cells assayed showed that R2 was indeed 
heterogeneous (Figure 3-24). A majority of cells (60%) of R2 clustered with R1 indicating 
the strong transcriptional relationship between the 2 populations which mirrored the 
volcano plot analysis of the sorted populations (Figure 3-13). 30% of R2 clustered with 
Figure 3-23:List of most highly discriminating genes between R1, R2 and R3. 
Heat map showing the relative expression pattern of genes most highly upregulated 
in FACS sorted populations R1, R2 and R3 over the others. Genes in red indicate 
those that resulted from PCA analysis of the same. Genes in black were tested due 
to previous experimental analysis. 
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R3 (Figure 3-24). This cluster of cells was unique to only R2 indicating that there was a 
population within R2 that exhibited the properties of a precursor to mo-DCs (Figure 3-24, 
Figure 3-25a,b). Intriguingly, about 10% of R2 clustered separately from the other 
populations having a unique transcriptional profile of co‑expression of Fcɣr3 and CD209a 




















Figure 3-24: Heterogeneity in the R2 population. Hierarchical clustering dendogram 
(top and left margins) derived from -ΔCt values from single-cell multiplex qPCR analysis 
of 44 R1 (Blue), 81 R2 (red) and 44 R3 (green) single cells for 42 genes and 3 
housekeeping genes (not shown). Resulting clusters are indicated at the bottom as C1, 
C2, C3, C4 and C5. Dendogram displays the hierarchical clustering based on Euclidean 





Figure 3-25: Quantitative analysis of single cell qPCR data on populations and 
clusters within Ly6ChiCD115+ cells. a ) Representation in percentage of R1, R2 and R3 
populations within the 5 clusters defined in fig.3-21. b) Representation in percentage of 
the 5 clusters within R1, R2 and R3 populations.c) Single-cell expression of MHCII-
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related genes, Zbtb46, FcɣR3, CD209a in R1-R3 populations or C1-5 clusters. Each dot 
represents the -ΔCt value of a single cell. 
Given that the protein expression of CD209a could not be seen within the BM, I could 
not use these markers to define R2 when analysing the cells by FACS and so continued 




3.3 Discussion and chapter overview 
Excluded from discussions on the development of monocytes and cDCs, monocyte-
derived DCs or mo-DCs have been left under a branch of their own. Left incomplete with 
contradictions on their origin (Cheong et al., 2010; Meredith et al., 2012; Satpathy et al., 
2012a) and broad definition, the term ‘monocyte-derived DCs’ has loosely defined a 
population of cells induced upon inflammation. This chapter has attempted to bring 
clarity to the field by considering the presence of a novel dedicated precursor.   
CX3CR1
intCD11b+ cells had been found to be capable of generating both iNOS+ cells as 
well as MHCIIhi cells that expressed the DC specific transcription factor ZBTB46 after 
adoptive transfer into a mouse model of colitis (Zigmond et al., 2012). This study, along 
with others showing that mo-DCs were Ccr2-dependent provided a certain amount of 
certainty that the precursors of monocyte-derived DCs originated within the Ly6Chi 
monocyte population. By looking for DC-related marker expression (Flt3, CD11c) I were 
able to identify 2 populations within conventional Ly6Chi monocyte gating that had not 
been documented before. Flt3+CD11c+ R3 cells that I found to be a pre-cDC 
contamination within Ly6Chi monocytes could explain the appearance of the dendritic 
cell phenotype arising from widely gated Ly6Chi monocytes used in adoptive transfer 
experiments such as the one referenced above (Biswas et al., 2015; Zigmond et al., 2012).  
Flt3+CD11c- R2 cells were an entirely novel population identified in this study. Being 
Flt3+CD115+, it was intriguing to find that they were neither progenitor cells (cKit-) nor 
belonging to the cDC lineage (Flt3l-independent, Zbtb46-). This Ccr2-dependent, Nr4a1-
independent population stood apart from Ly6Clo monocytes and identified 
transcriptionally and phenotypically with Flt3-CD11c- Ly6Chi monocytes. Very few genes 
were exclusively expressed within the R2 population making its identification a 
challenge. By identification of a combination of markers, namely FcRII/III and CD209a, 
that could be stained on the surface of the cells in the blood, I were able to establish a 
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phenotypic characterisation of this novel population. As a consequence, I were able to 
distinguish the R2 population from Flt3-CD11c- Ly6Chi monocytes as well as from pre-
cDCs. 
An additional point of interest is the enrichment of MHCII+ cells within the R2 
population. Ly6Chi monocytes had been documented previously as being able to transfer 
antigen to draining lymph nodes while they upregulated MHCII (Jakubzick et al., 2013). 
Very little was known about these MHCII+Ly6Chi monocytes at steady state (Kingston et 
al., 2009b). In this chapter, I have assessed the relative percentages of the MHCII+Ly6Chi 
monocytes, and report that they account for 65% of the Flt3+ population (which 
encompasses R2 and R3) and only 17% of the Flt3- population (R1). Thus characterising 
R2 allows for the study of the Ly6Chi monocytes that upregulate MHCII in the blood. 
Understanding the mechanism that drives the derivation of a cell population is critical to 
understanding its origin. I found that the transcription factor PU.1 plays a central role in 
the promotion of Flt3+ R2 cells over Flt3- R1 cells in the BM and blood. PU.1 regulates 
the transcription of a number of target genes which include Flt3 and the transcription 
factor that drives MHCII expression – CIITA, via promoters pI and pIII at steady state 
(Kitamura et al., 2012; Yoon and Boss, 2010). Given that pI-/- mice lacked the 
MHCII+Ly6Chi monocyte population, our study suggests that PU.1 could control the 
MHCII+ R2 cells via the pI promoter.  
While gating for Flt3 expression within the Ly6ChiCD11c- monocyte population allows 
for the study of a population of MHCII-enriched, Ccr2-dependent cell population that 
upregulated CD209a and FcRII/III in the blood, it was not possible to ignore the fact that 
all phenotypic analyses of the cells showed heterogeneity (CD209a, FcRII/III, CD11b 
and MHCII expression, Ccr2-dependency). It appeared that the FACS-based 
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identification of these cells may not be accurate enough to identify the single unique 
population within R2 that might act as a precursor to Mo-DCs. 
Single-cell analysis showed that 10% of R2 formed a unique cluster with its own 
transcriptional profile, unique from that of Flt3-CD11c- R1 monocytes and Flt3+CD11c+ 
pre-cDCs. I could not find specific markers to identify this sub-population. This was 
possibly due to the fact that the single-cell qPCR tested genes were selected based on 
those that had the highest fold change in a PCA analysis of bulk-sorted R1, R2 and R3. 
This ensured that genes that were most highly upregulated in R1 or R3 and most co-
expressed in R2 topped the list and the genes tested were not comprehensive. In order to 
find a specific marker exclusively expressed on the unique cluster within R2 cells in the 
future I would need to perform RNA-seq analysis or a multiplex FACS analysis of all the 
known surface-expressed CD markers on Ly6Chi monocytes from the BM and/or blood. 
Within, the scope of this study however, I noted by microarray, FACS and single-cell 
qPCR analysis that FcRII/III and CD209a provided a strong means of identification of 




















4 The influence of GM-CSF on R1 and R2 monocytes 
 
4.1 Introduction  
4.1.1 The role of GM-CSF in MPS development 
Granulocyte-macrophage colony stimulating factor (GM-CSF) was originally discovered 
as the culture constituent required to stimulate the production of colonies of granulocytes 
and macrophages from mouse bone marrow in solid agar cultures (Bradley and Metcalf, 
1966; Pluznik and Sachs, 1966).  Subsequent in vivo experiments demonstrated the 
critical role of GM-CSF in early myeloid development. GM-CSF is required for the 
development of tissue cDCs (Greter et al., 2012) and monocytes precursors within the 
bone marrow (Van De Laar et al., 2012). GM-CSF also influences the expression of 
CD103+ on migratory cDCs and the ability of cells to engage in cross-presentation  (Zhan 
et al., 2011). Furthermore, the heterogeneity in cell type and activation state observed in 
such cultures is testament to the wide effects of GM-CSF on the myeloid populations in 




Figure 4-1: The influence of GM-CSF on myeloid development. Reproduced from 
Van de Laar et al, 2012. GM-CSF strongly influences the development of DCs and 
monocytes from the early hematopoietic developmental stage. Additionally, it has an 
important role in the development of cDCs at later stages of development especially in 
the context of inflammation such as in the formation of of iNOS-producing cells (in this 
figure referred to as Tip-DCs) 
 
4.1.2 Influence of GM-CSF on the generation of mo-DCs 
Unlike M-CSF and Flt3L, steady state levels of circulating GM-CSF are low. This is 
because the   developmental requirement of the growth factor is low due to the high 
biological activity (Barreda et al., 2004). Pathogens and other inflammatory mediators 
bring about systemic increase in GM-CSF (Hamilton, 2002) while  in vivo administration 
promotes the expansion of CD11b+ DCs in the spleen (Daro et al., 2000). In the presence 
of either GM-CSF alone (Inaba et al., 1992) or in combination with IL-4 (Sallusto and 
Lanzavecchia, 1994b), monocytes from murine bone marrow or human peripheral blood 
are able to generate large numbers of CD11c+MHCII+ cells in vitro that are able to prime 
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T cells (Daro et al., 2000). Recent studies have utilized additional markers of 
differentiation to better characterize resulting progeny of GM-CSF supplemented 
cultures.  A study by Reis e Sousa and colleagues has demonstrated that a culture of total 
murine bone marrow with GM-CSF yields both macrophage-like cells 
(CD11b+MHCIIintPD-L2+CD64+CD115+CD14+) and DC-like cells (CD11b+MHCIIhiPD-
L2hiCD135+CD14+) (Helft et al., 2015). Gao et al. divided the murine bone marrow 
progeny on the basis of their activation states and expression of PD-L2. The PD-L2lo cells 
were capable of differentiating into PD-L2hi cells upon LPS stimulation, with a 
transcriptional profile that fit that of an activated cell type (Gao et al., 2013). Due to the 
generation of a DC-like phenotype from monocytes in vitro, the resulting progeny of GM-
CSF supplemented cultures is often referred to as mo-DCs (monocyte-derived dendritic 
cells) or GM-DCs (GM-CSF induced DCs).  
The current functional understanding of mo-DCs is that they are required within the tissue 
as antigen-presenting cells (APCs) able to take up and process antigen far better than their 
CD11b+ cDC counterparts (Daro et al., 2000; Plantinga et al., 2013) . However, in vitro 
co-culture assays for antigen-specific T cell proliferation detected no differences between 
the T cell activation elicited by mo-DCs versus CD11b+cDCs (Cook et al., 2004; Daro et 
al., 2000).  Although, their specialized role in an immune response remains elusive, mo-
DCs are very responsive to inflammatory stimuli such LPS, TNF-α and recombinant-
CD40L (Caux et al., 1997; Zhong et al., 2009),. In comparison to cDCs derived from 
Flt3L-supplemented bone marrow cultures (Fl-DCs), GM-DCs have greater 
immunogenicity- capable of producing inflammatory mediators like NO, TNF-α, IL10 
and CCL2, upon TLR activation (Xu et al., 2007).  Thus, iNOS-producing cells fall within 
the classification of monocyte-derived inflammatory cells. Additionally, mo-DCs can be 
derived from CD11b+Ly6ChiLy6G- monocytes while Fl-DCs cannot (Xu et al., 2007).  
The aforementioned in vitro studies provide evidence of the origin of mo-DCs and iNOS-
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producing cells from monocytes in response to GM-CSF. In vivo evidence for the 
existence of mo-DCs relies largely on experiments utilizing Ccr2-/- mice which do not 
develop mo-DCs in response to an inflammatory stimulus (Croxford et al., 2015; Greter 
et al., 2012). Thus, the definition of ‘Mo-DCs’ has become that of an inflammatory 
population of cells reliant on GM-CSF and derived from Ccr2-dependent monocytes. 
4.1.3 Phenotypic distinction between Mo-DCs, cDCs and macrophages 
 
Mo-DCs that arise in response to exogenous GM-CSF in vivo were originally defined as 
CD11b+CD11c+ and MHCIIhi (Daro et al., 2000). More recently, using models of 
systemic LPS administration, ‘mo-DCs’ have been described with more specific markers 
such as CD206 and CD209 (Cheong et al., 2010; Greter et al., 2012) in the spleen, FcR1 
and CD64 in the lung (Plantinga et al., 2013) and in models of colitis have been 
characterised as expressing CD64 in the gut (Tamoutounour et al., 2012).  These markers 
are crucial to distinguish them from other myeloid populations that express CD11b and 
CD11c to a similar extent, namely the tissue-resident macrophages and cDCs.  
There is a need to characterize specific surface markers on mo-DCs that can distinguish 
them from other myeloid populations to better characterize this specific population of 
cells in the context of steady state and inflammation. The distinction between mo-DCs 
and ‘inflammatory macrophages’ in vivo is unclear. Largely they are considered within 
the mo-DC classification but are not phenotypically distinguished from them. In vivo 
inhibition of GM-CSF results in the reduction of CD115+Ly6C+F4/80+ inflammatory 
macrophages in models of antigen-induced peritonitis and lung inflammation (Lenzo et 
al., 2012). Thus, both ‘mo-DCs’ and ‘inflammatory macrophages’ are reliant on GM-
CSF. 
One possible method of better characterising these inflammatory cells is by accurately 
determining the lineage to which they belong in vivo. Defining the mo-DCs as 
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CD14+CD11b+CD11c+MHCIIhi, Meredith et al. showed that mo-DCs were absent from 
LPS treated Flt3l-/- mice and DT-treated mixed bone marrow chimeras of WT and 
zDCDTR/DTR bone marrow (Meredith et al., 2012). Given the dependency of cDCs on Flt3L 
and Zbtb46 for development, Meredith et al inferred that ‘mo-DCs’ derived from the 
cDC-lineage. Conversely, a number of studies detail the requirement of Ccr2 to develop 
mo-DCs in different inflammatory settings such as LPS administration, EAE, and colitis 
(Cheong et al., 2010; Croxford et al., 2015; Zigmond et al., 2012). These studies are 
testament to the heterogeneity within the ‘Mo-DC’ definition. 
It is unclear whether all Ly6Chimonocytes have the capacity to become iNOS+ cells or 
dendritic cells or if a subset within this wider definition is specialized to produce each of 




4.1.4 Objectives of Chapter 4 
 
Given the complexity in macrophage, cDC and mo-DC development in response to 
elevated levels of GM-CSF, it might also be considered that these GM-CSF-dependent 
cell populations are ontogenically distinct, arising from unique monocyte or DC 
precursors. I hypothesized that the previously described heterogeneity within the Ly6Chi 
monocyte population in the bone marrow, blood and spleen, could help explain this. The 
focus of this chapter will be to study the cells among the precursor monocyte subsets that 
respond to GM-CSF described in Chapter 1. 
The objectives of this chapter are the following: 
 To investigate the influence of GM-CSF on each Ly6Chi monocyte population- 
R1 and R2 
 To study the role, if any, of PU.1 on the generation of mo-DCs 
  To distinguish mo-DCs from cDCs. 
 To establish a phenotypic definition of mo-DCs and discriminate between them 




4.2.1 Impact of GM-CSF on Ly6Chi monocytes in vitro 
4.2.1.1 Phenotype of GM-CSF-induced progeny of Ly6Chi monocytes  
As discussed previously, the culture of murine bone marrow in GM-CSF results in 
heterogeneous progeny- macrophages and GM-DCs, that are largely monocyte-derived 
and yet display distinct phenotypic outcomes (Gao et al., 2010; Helft et al., 2015). In this 
chapter, I address the possibility that the heterogeneity in GM-CSF induced progeny 
arises from heterogeneity within Ly6Chi monocytes, i.e. that either R1 or R2 is capable 
of generating more DC-like features while the other generates macrophages.  
Bone marrow Lin-MHCII-Ly6Chi monocytes were sorted for their expression of Flt3 and 
CD11c into R1 (Flt3-CD11c-) and R2 (Flt3+CD11c-) monocytes and Lin-MHCII- cells 
were sorted into R3 (CD115+Flt3+CD11c+) and P (CD115-Flt3+CD11c+) pre-cDCs. Equal 
numbers of each population were plated in the presence of 20ng/ml of GM-CSF along 
with 105 cells of congenically labelled whole bone marrow as feeder cells for 7 days.  R2 
responded to GM-CSF to a greater degree than pre-DCs or R1 monocytes with a trend 





Figure 4-2: In vitro GM-CSF culture of R1, R2, R3 and P. 10,000 flow cytometry 
sorted CD45.1+ Ly6Chi R1 and R2 monocytes, alongside CD115+ R3 and CD115- P pre-
cDCs were cultured in GM-CSF for 7 days. They were plated with whole bone marrow 
from congenically marked CD45.2+ mice acting as feeder cells. Absolute numbers of   
recovered cells were counted from DAPI- cells and quantified as shown. Flow cytometry 
data is representative of 3 experiments with similar results. Graphs show mean ± SEM 
from grouped data of all 3 experiments(n=3).    
Although there was a greater response to GM-CSF by R2, the numbers obtained following 
7 days in culture were greatly diminished, possibly due to cell death in vitro as only 2000 
cells were retrieved in comparison to the input of 10,000 cells. Thus, I attempted shorted 
culture periods with GM-CSF. 
Medzhitov and colleagues reported the use of PDL2 and CD86 to define cell populations 
within a monocyte-derived BM culture that were phenotypically and functionally distinct 
(Gao et al., 2013). I therefore tested FACS-sorted R1 and R2 monocytes alongside pre-
cDCs as controls, for PDL2 and CD86 (Gao et al., 2013). Most recently, Helft et al 
determined that these cells were in fact a mixture of macrophage cells (Flt3- PDL2lo) and 
121 
 
DC-like cells (Flt3+PDL2hi) (Helft et al., 2015) differently able to stimulate T cells in the 
context of MHC-I and MHC-II.  
 I incubated the sorted cells for 5 days in 20ng/ml of recombinant GM-CSF (rGM-CSF). 
Using the total cells in culture (CD45.2+ and CD45.1+) as a control for equal culture 
conditions in all wells, I noted that R2 produced the highest levels of PDL2+CD86+ cells 
as compared to the other monocyte or pre-DC populations in a 5-day culture with GM-
CSF (Figure 4-3). 
 
Figure 4-3: R2 is responsible for the production of PDL2+CD86+ cells. 10,000 FACS 
sorted CD45.2+ R1, R2, R3 and P cells were plated with CD45.1+ feeder whole bone 
marrow cells in 20ng/ml GM-CSF. Upper panel shows the total percentage of 
PDL2+CD86+ cells obtained in culture after 5 days. The progeny of CD45.2+ sorted cells 




4.2.1.2 Role of PU.1 in the generation of PDL2+CD86+ cells 
Having shown that R2 was capable of generating PDL2+ CD86+ cells in culture, I 
hypothesized that these cells would also rely on the master transcription factor, PU.1. 
Sfpi1+/- mice have half the alleles for PU.1 than WT mice.  If PDL2+CD86+ cells derived 
exclusively from PU.1hi R2 cells, it could be expected that Sfpi1+/- BM cultures would not 
develop PDL2+CD86+ cells as Sfpi1+/- bone marrow has far fewer R2 monocytes (Chapter 
3).  
In order to improve the numbers of cells that survive in culture with GM-CSF, I replaced 
the CD45.1+ bone marrow with the MS-5 cell line as feeder cells. MS-5 is a mouse stromal 
cell line that has been found to aid in murine and human progenitor cell survival and 
proliferation (Issaad et al., 1993) via uncharacterized soluble molecules (Kobari et al., 
1995) and a cell-contact dependent mechanism via the expression of neuropilin-1 
(Tordjman et al., 1999). Additionally, I tested the expression of cell surface markers at 
day5 instead of day7 to test for earlier cell differentiation and the upregulation of 
activation markers like PDL2 and CD86. The culture resulted in the production of 
PDL2+CD86+ cells that were MHCIIhi. A large number of cells also remained 
PDL2loCD86lo and were the same in both Sfpi1+/+ and Sfpi1+/- cultures (Figure 4-4). 
However, the numbers of PDL2+CD86+ cells were greatly diminished in Sfpi1+/- BM 
culture as compared to the Sfpi1+/+ counterpart. Thus, PDL2+CD86+ cells are a PU.1-




Figure 4-4: Role of PU.1 in the development of PDL2+CD86+ cells in vitro. Sfpi1+/- 
and Sfpi1+/+ whole bone marrow cells were cultured with MS-5 cells in 20ng/ml GM-CSF 
for 5 days. Absolute numbers of PDL2+CD86+ cells and PDL2loCD86lo cells were 
counted from the recovered progeny and are depicted in the graphs alongside. Flow 
cytometry data is representative of 4 independent cultures and cumulative numbers are 
depicted in the graphs.n=4 **p<0.005; Student’s t-test. 
 
4.2.1.3 FcɣRII/III and CD209a expression on in vitro progeny of R1, R2 and R3 
 
Having found that PU.1-dependent R2 was capable of giving rise to sufficient numbers 
of PDL2+CD86+ cells in our feeder culture system with GM-CSF, I wondered whether 
these cells could be defined based on highly expressed markers as revealed by the mRNA 
levels in the bone marrow and as a surface phenotype in the blood on R1, R2 and R3 
(Chapter3), such as CD209a and FcɣRII/III. This would allow us to define surface 
markers that can be used to distinguish these cells at steady state and in response to GM-
CSF.  
Since in previous experiments, R3 and P pre-cDCs gave similar results in surface marker 
expression in response to GM-CSF, I focused on phenotyping R2 in comparison with R1 
Ly6Chi monocytes and R3 CD115+ pre-DCs. R1, R2 and R3 were cultured in 20ng/ml of 
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GM-CSF with MS-5 feeders. The culture was carried out for  2 days as I speculated that 
with such small numbers of cells sorted by flow cytometry, shorter time points would 
ensure survival and a sufficient amount of differentiation. The progeny were assessed for 
the expression of FcɣRII/III, CD209a as well as PDL2 and CD86 to relate to the 
PDL2+CD86+ cells described previously to derive from R2  (Figure 4-4) (Gao et al., 2013).  
 
Figure 4-5: R2 cells generate FcɣRII/III+CD209+PDL2+MHCII+ cellsa., b.)10,000 
FACS sorted cells were cultured in GM-CSF for 2 days and assayed for expression for 
FcɣRII/III, CD209a, PDL2 and MHCII. Representative FACS plots of 4 independent 
cultures are shown. b) Grey histograms indicate the CD209a- population while 
CD209a+cells are depicted in black histograms as gated in FACS plots above. 
 
The progeny showed distinct expression levels of FcɣRII/III, CD209a and PDL2.   R1 
generated FcɣRII/III+CD209- cells while R3 generated CD209a+ cells that were 
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FcɣRII/IIIint-neg.  R2 generated all three populations but the progeny were predominantly 
CD209+ FcɣRII/IIIint (~60%) (Figure 4-5a). 
R1 generated a large number of CD209a-PDL2+ cells while R2 generated cells that were 
both PDL2+CD209+ as well as PDL2+CD209- cells. The level of MHCII expression on 
the PDL2+CD209+ cells was much higher than in the CD209a- counterparts (Figure 4-5b). 
Intriguingly, R3 also produced PDL2+CD209+ MHCII+ cells but these were in fewer 
numbers and of a lower MFI in CD209 than those generated by R2. This provided us with 
some insight on characterizing R1, R2 and R3 populations using the surface markers 
FcɣRII/III, CD209a and PDL2. 
4.2.1.4 PDL2+MHCIIhicells rely on PU.1 for their development in vitro 
To test the reliance of the PDL2+MHCIIhicells on PU.1, Sfpi1+/+ and Sfpi1+/- bone marrow 
monocytes were cultured in GM-CSF for 2 days. Wild type controls gave rise to the 
FcɣRII/III+PDL2+MHCIIhiCD209+ cells (red) while the Sfpi1+/- monocytes developed 
mainly into FcɣRII/III+PDL2+MHCII-CD209- cells (blue) (Figure 4-6). This showed the 





Figure 4-6: FcɣRII/III+CD209+cells are PU.1 dependent. Whole bone marrow from 
Sfpi1+/+ or Sfpi1+/- mice were cultured in vitro with 20ng/ml GM-CSF on MS-5 feeder 
cells. FACS plots for CD209, FcɣRII/III, PDL2 and MHCII expression are shown.  
FcɣRII/III+CD209- cells (blue) and FcɣRII/III+CD209+ cells (red) are overlaid on an 
analysis of the same cells for expression of PDL2 and MHCII. Graphs show data from 4 
independent cultures. n=4 
4.2.2 The impact of GM-CSF on monocytes R1 and R2 in vivo 
In order to study the influence of GM-CSF on the myeloid population in vivo, I used a 
B16 melanoma cell line, that is engineered to constitutively produce GM-CSF (B16-GM). 
The cells must be at approximately 75% confluency to be injected in order to get a 
sizeable tumour by day12-14 (Dranoff et al., 1993). A single sub-cutaneous injection of 
105 cells results in the development of a visible tumour by 9 days which enlarges 
gradually until the end-point of 13 days. As controls, naïve C57Bl/6 mice and C57Bl/6 
mice injected with B16 control cells that lack expression of GM-CSF, were used. 
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4.2.2.1 Blood MHCII+Ly6C+/- cells in blood expand in response to GM-CSF 
As an initial approach to understanding the overall outcome of in vivo exposure to GM-
CSF, the cells of the bone marrow, blood and spleen of mice treated with B16-GM or 
B16 cells, were phenotyped for their expression of monocyte markers CD11b, CD115 
and Ly6C as well as for MHCII (Figure 4-7). MHCII+ monocytes presented a ‘waterfall’ 
of Ly6C+ to Ly6C- cells in mice treated with B16-GM tumours. A clear increase in 
numbers as well as in percentage of MHCII+ cells (both Ly6C+ and Ly6C- cells) was 
observed in circulation in response to GM-CSF (Figure 4-7) 
  
Figure 4-7: Phenotyping blood monocytes in B16-GM treated mice. Gating strategy 
and analysis of blood from B16-GM- versus B16 – treated mice on d13 after sub-cutaneous 
injection of live melanoma cells. Lin- (CD19-CD3e-Ter119-Ly6G-CD45RA-ckit-NK1.1-) 
cells were gated for CD115/ M-CSF-R expression and further divided into Ly6ChiMHCII-
(blue), Ly6C+MHCII+ (red) and Ly6CloMHCII+ (green) cells (a.). These are quantified in 
b. in absolute number of each cell population /mouse.  
 
4.2.2.2 B16-GM treated mice show an increase in MHCII+Ly6C- splenocytes 
In a similar way to the blood, an increase in MHCII+ myeloid population was observed 
in the spleen (Figure 4-8). In the gating strategy for splenocytes, cells negative for all 
other lineage markers (Ter119: RBCs, CD3ɛ : T cells, CD19: B cells, NK1.1: NK cells, 
ckit: progenitor cells, CD45RA: pDCs) were gated for CD11b, Ly6C and MHCII to gate 
128 
 
on myeloid cells. Although it could be assumed that these CD11b+Ly6Cint-loMHCII+ cells 
are the same as those in the blood, the surface markers used to characterize these cells in 
the spleen could foreseeably be confused with that of CD11c+CD11b+ cDCs. In fact, an 
overlay of the CD11b+Ly6Cint-lo MHCII+ cells on conventional gating of splenic cDCs 
shows this gate includes the CD11b+ DCs (Lin-CD11c+MHCII+) (Figure 4-8) 
 
Figure 4-8: Phenotyping spleen cells in B16-GM treated mice. Gating strategy and 
analysis of lineage– (CD19-CD3e-Ter119- CD45RA-ckit-NK1.1-) cells in the spleens of 
B16 and B16-GM-CSF treated mice by FACS (a). Ly6ChiMHCII-(blue), Ly6C+MHCII+ 
(red) and Ly6CloMHCII+ (green) cells are gated on Lin-CD11b+ cells quantified in 
absolute number per treated spleen (b). An overlay of the Ly6ChiMHCII-(blue), 
Ly6C+MHCII+ (red) and Ly6CloMHCII+ (green) cells is shown on Lin-Ly6G- 




Although there was a pronounced increase in the number of MHCII+ cells in the spleen, 
I wanted to confirm that this was not due to increase of the CD4+ 
(CD11c+MHCII+CD11b+) cDCs. In fact, previous reports showed that they reduced (Naik 
et al., 2006). An initial conventional gating of the cells showed there was an increase in 
what could be thought to be CD11b+ cDCs in response to B16-GM injection (Figure 4-9). 
 
Figure 4-9: cDCs decrease in response to elevated in vivo levels of GM-CSF. a) 
Representative FACS analysis of CD8a+ (cDC1) and CD11b+(cDC2) cDCs in the spleens 
of naïve versus B16-GM-CSF treated mice. Graph shows the cumulative data of 3 
experiments normalized to the naïve for the respective population. n=3 b) Analysis of 
CD4+ cells in Lin-CD11b+MHCII+ cells in B16 versus B16-GM-CSF  treated mice. c) 
Analysis of PDL2+ population (Red line) within the Lin-CD11c+MHCII+CD11b+ cells 
versus isotype control (grey shaded). 
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However, upon a more careful examination of the GM-CSF induced CD11b+ myeloid 
cells, I noted that the Lin-MHCII+CD11c+CD11b+CD4+ cells did in fact decrease (Figure 
4-9a,b). Additionally, I also tested these GM-induced CD11b+ cells for a GM-DC marker-
PDL2 (Gao et al., 2013), that had previously only been discussed in the context GM-CSF 
cultures. I found that 60% of GM-CSF-induced CD11b+ cells were PDL2+ (Figure 4-9c). 
This provided evidence of the similarity between the GM-CSF induced cells derived in 
vitro and in vivo. 
4.2.2.3 Phenotypic description of MHCII+ cells 
 
The increase in MHCII+ cells in response to GM-CSF in vivo, has been reported in 
previous studies using models of recall antigen with adjuvant (Naik et al., 2006) and with 
tumours expressing GM-CSF (Lesokhin et al., 2012). In order to test if these cells were 
an expansion of the reported monocyte populations documented in Chapter 1, a 
phenotypic analysis of these MHCII+ cells as compared to Ly6ChiMHCII- cells was 
performed. It was noted that these cells were heterogeneous for their expression of 
macrophage markers CD115 and CD206 (Sallusto and Lanzavecchia, 1994a) as well as 
for GM-DC-specific markers like CD209a (Geijtenbeek et al., 2000) and activation 




Figure 4-10:Characterization of MHCII+CD11b+ cells. FACS analysis of Lin-
CD11b+MHCII+CD4- splenocytes for CD64, CD115, Flt3, PDL2, CD209 and FcɣRII/III 
(black lines) against isotype controls (grey shaded) in naïve and B16-GM treated mice.  
 
4.2.3 Phenotypic characterization of GM-induced MHCII+ cells 
 
The phenotype of the MHCII+ cells made it evident that this GM-induced expanding 
population was heterogeneous. I sought to segregate mo-DCs and inflammatory 
macrophage subsets within it, using markers that have been described on monocytes and 
cDCs but that were also found among genes that were highly expressed on the monocyte 
subsets described in this report at steady state. 
Firstly, in order to ensure that the MHCII+CD11b+ cells did not include cDCs, I excluded 
the CD4+ population. Of the markers tried so far I found that FcɣRII/III and CD209a 
formed distinct subsets of cells within the MHCII+CD11b+CD4- population. B16-GM-
CSF, and not B16, generated 2 distinct populations that were FcɣRII/III+ and either 




Figure 4-11: GM-CSF induces MHCII+ FcɣRII/III+CD209+/- cells in vivo.  
Spleens from mice injected with B16, B16-GM or PBS, were analysed 13 days after 
injection. Lin-CD11b+MHCII+CD4- cells were phenotyped for FcɣRII/III and CD209. 
Quantification of FcɣRII/III+CD209+/- cells in B16-GM-CSF treated versus naïve control 
mice. n=5. 
The spleens of B16- treated mice phenotypically resembled that of the naïve mice. B16 
tumours did not elicit the generation of FcɣRII/III+CD209+- and FcɣRII/III+CD209- cells 
(Figure 4-11). Therefore, I used naïve mice as controls for the B16-GM tumour recipients. 
 
4.2.3.1 FcɣRII/III+CD209+ and FcɣRII/III+CD209- cells are CCR2-dependent.  
A salient feature of any cell type originating from Ly6Chi monocytes is their reliance on 
CCR2 for their egress from the bone marrow (Geissmann et al., 2003; Kurihara et al., 
1997). In order to test the reliance of the CD4-CD11b+MHCII+FcRII/III+CD209+/- cells 
on CCR2, I treated Ccr2-/- and control mice with B16-GM-CSF tumours to study the 
recruitment of the FcɣRII/III+CD209+/- cells to the spleen. The spleens from B16-GM-
CSF-treated Ccr2-/- mice showed a dramatic reduction in both the FcɣRII/III+CD209+ and 
FcɣRII/III+CD209- cells (Figure 4-12).  
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Although, the FcɣRII/III- cells were present in the naïve and B16-treated mice, there was 
a possibility that they could be replenished by recruited monocytes that did not then 
express FcRII/III. Analysis of the FcɣRII/III-CD209+/- cells showed that they were 
unaffected, indicating an independence from Ly6Chi monocytes. 
 
Figure 4-12: FcɣRII/III+CD209+/- cells rely on CCR2. Representative flow cytometry 
analysis of Lin-CD11b+MHCII+CD4- B16-GM treated spleens of Ccr2-/- and WT mice. 
Graphs depict mean±SEM of percentage of each population within the Lin-
MHCII+CD11b+ cells of n=5; *p<0.05, Student’s t-test. 
 
4.2.3.2 B16-GM induced FcɣRII/III+CD209+/- cells have a monocytic phenotype.  
I next wondered if each FcɣRII/III+ population could represent distinct macrophages or 
dendritic cell populations. To comprehensively analyse the Lin-CD11b+MHCII+ cells, I 
tested the FcɣRII/III+CD209+ and FcɣRII/III+CD209- cells for the expression of 
previously described macrophage and DC markers. Using CD4+ cDCs as a control, 
FcɣRII/III+CD209+ and FcɣRII/III+CD209- were found to be CD115+ and Flt3- against 
appropriate isotype controls. This corroborated previous data on Mo-DCs from Cheong 
et al (Figure 4-13) (Cheong et al., 2010). 
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An interesting aspect with regards to the MHCII expression was that the 
FcɣRII/III+CD209+ cells had the highest expression of MHCII indicating that these cells 
could be the most capable or most primed for MHCII-restricted T cell activation (Figure 
4-13). 
Another aspect of differentiation between the cells was PDL2 and PDL1. It has been 
previously noted that PDL1 is expressed highly on cDCs at steady state while PDL2 is 
expressed on macrophages during inflammation in a murine model of allergic asthma 
(Singh et al., 2011).  The FcɣRII/III+CD209+/- cells were PDL2+ while the CD4+cDCs 
were PDL1+ as compared to isotype controls (Figure 4-13). Given the distinct role of PD-
1 ligands- PDL1 and PDL2, in polarizing T cell responses toward Th1 or Th2, 
respectively (Akbari et al., 2010), it might be important to note the differential expression 




Figure 4-13: Phenotype of FcɣRII/III+/- and CD209+/- MHCII+ cells FACS analysis 
for Flt3,CD115, ESAM1, MHCII, PD-L2 and PD-L1 (shaded black) against isotype 
controls (shaded grey) on FcɣRII/III+CD209-, FcɣRII/III+CD209+, FcɣRII/III-CD209+ 
and FcɣRII/III-CD209- and CD4+ cells from Lin-CD11b+MHCII+ splenocytes from mice 
treated with B16-GM for 13 days. Numbers adjacent to histograms indicate the mean 
fluorescent intensity (MFI) of the indicated marker on each population. 
 
The FcɣRII/III+CD209+/- cells expressed a number of macrophage markers such as FcɣRI 
(CD64) and Mertk as well as markers that have been previously attributed to mo-DCs- 
FcɛR1 (Plantinga et al., 2013) and CD206 (Cheong et al., 2010) (Figure 4-14). There was 
not much difference in the levels of expression of these markers between the 
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FcɣRII/III+CD209+ and FcɣRII/III+CD209- cells (Figure 4-14).  Additionally, they 
expressed similar levels of CCR2 (Figure 4-14)  
 
Figure 4-14: Monocyte and 'Mo-DC' markers on FcɣRII/III+/-CD209+/- cells Lin-
CD11b+MHCII+ cells were gated into FcɣRII/III+/-and CD209+/- cell populations. 
Monocyte and Mo-DC markers were assayed on each of the populations in comparison 
with CD4+ cDCs (Lin-CD11b+MHCII+).  
Thus, B16-GM induced FcRII/III+CD209a+ and FcRII/III+CD209a- cells exhibited a 
monocyte/macrophage phenotype and also resembled previous reports of ‘Mo-DCs’. The 




4.2.3.3 DC lineage and FcɣRII/III+CD209a+/- cells. 
Although the FcɣRII/III+CD209+/- cells express a number of monocyte markers and 
displayed a reliance on CCR2, it could not be excluded that these cells belonged to the 
DC lineage. To investigate this using the best lineage tracing method currently available 
for cDCs, I analysed the expression of YFP in the these GM-induced populations in  
Zbtb46CRE x ROSAloxSTOPloxYFP mice (Zbtb46CRExROSAlslYFP) (Loschko et al., 2016a). YFP 
expression was close to background levels in the FcɣRII/III+ cells as compared to the 54% 
positive expression levels seen in CD4+cDCs (Figure 4-15). 
The Zbtb46CRExROSAlslYFP mice had a very stringent YFP expression pattern and this 
turned out to be similar to that described by the Nussenzweig and colleagues  (Loschko 
et al., 2016a). I wondered if with a reporter mouse, I might obtain a representation of the 
levels of expression of the transcription factor expressed by the FcɣRII/III+ cells I thus 
used the Zbtb46gfp/+ mice.  
GFP was strongly expressed in the cDCs as had been previously reported (Satpathy et al., 
2012a). However, the FcɣRII/III+CD209+/- cells had much lower levels of GFP 
expression. Although the percentage of GFP+ cells within the FcɣRII/III+CD209+ cells 
was slightly higher than in the FcɣRII/III+CD209- cells, this difference was not significant 
(Figure 4-15). This showed that the FcɣRII/III+CD209+/- cells were not part of the DC 




Figure 4-15: FcɣRII/III+CD209+/- cells do not express Zbtb46. FACS analysis of the 
FcɣRII/III+CD209+/- cells and CD4+ cDCs of the Lin-CD11b+MHCII+ splenocytes for 
YFP expression in Zbtb46Cre x ROSAlslYFP and GFP expression in Zbtb46gfp/+ mice. Mice 
were injected with B16-GM 14 days prior to analysis. Graph shows data from 5 
Zbtb46gfp/+ mice. n=5 
 
4.2.4 Reliance of FcɣRII/III+CD209a+/- cells on the transcription factor PU.1 
4.2.4.1 Sfpi1+/- mice display a reduction in FcɣRII/III+CD209+ cells. 
FcɣRII/III+CD209+ and FcɣRII/III+CD209- cells had thus far proven to be of similar 
origin and phenotype. I next wondered if they had any difference in their reliance on 
PU.1- the transcription factor found to play a role in the development of CD209a+ cells 
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in vitro (Fig.1-7). The spleens of B16-GM-CSF treated Sfpi1+/- and Sfpi1+/+ mice showed 
that PU.1 hemizygocity dramatically reduced the FcɣRII/III+CD209+ cells. The 
FcɣRII/III+CD209- cells, on the other hand, remained equivalent to controls (Figure 
4-16a). FcɣRII/III+CD209+ cells thus relied on PU.1 for their development.  
 
Figure 4-16: PU.1 positively regulates GM-induced FcɣRII/III+CD209+ cells. a) Lin-
CD11b+CD4- splenocytes in Sfpi1+/+ and Sfpi1+/- cells were analysed for the presence of 
FcɣRII/III+CD209- and FcɣRII/III+CD209+ cells. b) Representative FACS analysis of 
spleens from congenic recipient B16-GM treated Sfpi1+/+ mice adoptively transferred 
with either Sfpi1+/+ or Sfpi1+/- (CD45.2+) bone marrow. Graph shows mean ± SEM of 
n=6; *p<0.05; Student’s t-test. 
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To test for the cell-intrinsic requirement of PU.1 on FcɣRII/III+CD209+ cells, I performed 
an adoptive transfer experiment of Sfpi1+/- or Sfpi1+/+ whole bone marrow into 
congenically marked B16-GM-CSF-treated recipients. FcɣRII/III+CD209+ cells were 
absent from donor Sfpi1+/- cells above (Figure 4-16b). The FcɣRII/III+CD209- cells, on 
the other hand, were not influenced by the lack of PU.1. This showed a cell intrinsic 
requirement for PU.1 in the FcɣRII/III+CD209+ cells- a feature that distinguished it from 
FcɣRII/III+CD209- cells. 
 
4.2.4.2 Origin of FcɣRII/III+CD209+/- cells.  
Having noted the strong expression of monocyte/macrophage markers, the reliance on 
CCR2, and the difference in reliance on PU.1, the FcɣRII/III+CD209+/- cells were tested 
for their distinct origin from the 2 Ly6Chimonocyte populations described in Chapter 3. I 
performed an adoptive transfer experiment of Ly6ChiFlt3-CD11c- R1 cells and 
Ly6ChiFlt3+CD11c- R2 cells into B16-GM-treated mice. An analysis of the spleens of the 
recipients showed that R1 was capable of generating FcɣRII/III+CD209- cells alone. R2, 
on the other hand, was capable of generating FcɣRII/III+CD209+ cells in addition to 
CD209a- cells (Figure 4-17).  
In addition to firmly establishing that R2 acts as the precursor Ly6Chi monocyte 
population to FcɣRII/III+CD209a+ cells, this experiment also emphasized the 




Figure 4-17: FcɣRII/III+ CD209a+ cells derive from PU1hiFlt3+CD115+CD11c- (R2) 
cellsRepresentative FACS analysis of spleens from recipient B16-GM- treated CD45.1+ 
mice adoptively transferred with 3.3 x 105 cells of R1 or R2 from congenically labelled 
wild-type mice. Graph shows the percentage of CD209a+ cells within the CD45.2+ donor 




4.3 Discussion and overview of Chapter 4 
The increase in GM-CSF during inflammation has previously been shown to give rise to 
inflammatory populations of macrophages and DCs. In this chapter, I have characterised 
these inflammatory populations both in vitro and in vivo, providing phenotypic 
descriptions of the same and an ontogenic basis for their differences.  
By culturing sorted populations of (Flt3-CD11c-) R1 and (Flt3+CD11c-) R2 monocytes or 
Sfpi1+/+and Sfpi1+/- bone marrow with GM-CSF, I determined that Sfpi1-dependent R2 
cells can generate of PDL2hiCD86+ cells. Additionally, the use of FcɣRII/III and CD209a 
to characterize these progenies showed that R2 responded to GM-CSF by upregulation of 
both receptors. I were thus able to explain the heterogeneity in GM-CSF cultures 
described previously (Gao et al., 2013; Helft et al., 2015; Inaba et al., 1992)and in the 
context of their origin. The PDL2loCD86lo population found in these cultures were 
produced by R1 cells. I further characterised them as being FcɣRII/III+CD209a-MHCIIlo 
and independent of PU.1 for their development. I would therefore describe these cells as 
‘inflammatory macrophages’ (Inf-Macs). 
In addition to studying the response of these cells in vitro to GM-CSF, I studied their 
phenotypic characterisation in vivo in response to systemically elevated levels of GM-
CSF. B16 cells are a C57BL/6 melanoma cell line that eventually metastasizes to the lung. 
By sacrificing the mice at a relatively early time point of 12-14 days, I could analyse the 
spleens of mice that showed localized expansion of the melanoma and no other obvious 
pathology. B16-GM melanomas induced splenomegaly accompanied by an influx of 
myeloid cells.  
Phenotypically, the expanded myeloid population expressed high levels of MHCII and 
could be divided based on their expression of FcɣRII/III and CD209a. Extensive 
phenotyping of these cells showed that FcɣRII/III+CD209a-  and FcɣRII/III+CD209a+ 
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cells were equally PDL2+CCR2+Flt3-ESAM1-PDL1-CD115+ with similar levels of 
previously described mo-DC attributed markers like CD206 and Fcɛr1. Fate-mapping and 
genetic reporting of Zbtb46 expression also showed that these cells did not originate from 
the cDC lineage nor did they acquire a cDC transcriptional programme. They proved to 
be CCR2-dependent indicating that they derived from Ly6Chi monocytes.  
A critical point of difference between the FcɣRII/III+CD209a-  and FcɣRII/III+CD209a+ 
cells was that the FcɣRII/III+CD209a+ cells were PU.1-dependent being reduced 
dramatically in B16-GM treated Sfpi1+/- mice. This became apparent when adoptive 
transfer experiments of Sfpi1+/+ or Sfpi1+/- BM into B16-GM treated recipients showed 
that PU.1 was required for the generation of FcɣRII/III+CD209a+ mo-DCs but not 
FcɣRII/III+CD209a- Inf-macs. 
The response to GM-CSF both in vitro and in vivo of the Ly6Chi monocyte populations 
showed that while R1 and R3 produced homogenous progeny, R2 consistently generated 
a mixed population of cells, i.e., FcɣRII/III+CD209a-  and FcɣRII/III+CD209a+ cells. 
Adoptively transferring R2 into B16-GM-treated recipients caused the differentiation of 
R2 cells into FcɣRII/III+CD209a-, FcɣRII/III+CD209a+ and FcɣRII/III-CD209a- cells. The 
FcɣRII/III+CD209a+ cells generated by R2 were approx. 10% of the progeny of the total 
transferred cells. This frequency was similar to the frequency within R2 that displayed 
dual mRNA expression of FcɣRII/III and CD209a by single-cell analysis (refer Chapter 
3, Figure 3-24). Thus I can conclude that by the use of Flt3 and CD11c to denote R2 at 
steady state, I can isolate the fraction of Ly6Chi monocytes that contain the precursors to 
mo-DCs.  
Thus, the findings in this chapter allow a clearer phenotypic description of the GM-CSF-




















5 The development of iNOS-producing inflammatory 
macrophages 
 
5.1 Introduction and objectives 
An effective defence against pathogens like viruses, bacteria and parasites requires the 
efficient activation of innate cells. Monocytes mount prompt responses to pathogenic 
invasion. Amongst their many defence mechanisms, production of inflammatory factors 
such as tumour necrosis factor a (TNF-), nitric oxide (NO) and hydrogen peroxide 
(H2O2) and are essential for the clearance of pathogens (Sprangers et al., 2016).  
5.1.1 iNOS-producing cells are important for pathogen control 
 
Nitrate biosynthesis was originally studied in the context of stomach cancer and the role 
of nitrosamines in causing it (Cuello et al., 1976). The carcinogenicity of N-nitroso 
compounds had been found to occur across 39 species and was being investigated in man 
(Bogovski and Bogovski, 1981).  Nitrates and nitrites, thought to be synthesized through 
metabolic breakdown by gut microbes, were thought to bind with exogenously acquired 
amines forming the carcinogenic nitrosamines. However, further investigation with germ-
free mice, showed that nitrate biosynthesis was initiated through a mammalian 
mechanism   (Green et al., 1981). Peritoneal macrophages were found to carry out nitrate 
metabolism of L-arginine when stimulated with LPS in vitro and in vivo, inhibiting the 
proliferation of fungi (Granger et al., 1990). Nos2-/- (iNOS-/-) mice are more susceptible 
to infections like that of Trypanosoma cruzi infections and sepsis (Cobb et al., 1999; 
Huang et al., 1999) as well as autoimmune conditions like EAE (Fenyk-Melody et al., 
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1998). NO thus plays a crucial role in clearance of bacterial pathogens and a pathogenic 
role in autoimmunity. 
The production of NO is crucial to the clearance of  several pathogens such as Listeria 
(Serbina et al., 2003) and Leishmania (Liew et al., 1990; De Trez et al., 2009; Xie et al., 
1993). As NO diffuses through the cell membrane of iNOS-producing cells, it acts in a 
tissue-wide manner (Olekhnovitch et al., 2014) playing a critical bactericidal role against 
intracellular bacteria (e.g. Listeria monocytogenes, Mycobacterium tuberculosis and 
Salmonella) and defence against parasites (e.g. Leishmania, Trypanosoma brucei). Other 
than the production of NO during infection, iNOS+ cells also carry out antigen transfer, 
harbouring of pathogens and priming of T cells to initiate an immune response depending 
on the infectious agent (Jiao et al., 2002). These functions are however, redundant with 
that of cDCs and macrophages in the inflamed tissue (Serbina et al., 2003) and occur in 
response to some infections and not others (De Trez et al., 2009) . Mice depleted of DCs, 
have a higher resistance to infections like Yersinia enterocolitica  (Autenrieth et al., 2012) 
and others like Listeria due to increased infiltration of phagocytes that perform enhanced 
levels of phagocytosis and bactericidal activity mainly through the increased production 
of ROS and TNF-a (Kang et al., 2008).  
The generation of TNF-α and reactive oxygen species by Ly6Chi cells in response to 
infection with Listeria is not only crucial in a primary immune defense against the 
pathogen, but is also required in secondary response for bactericidal activity. During a 
secondary infection,  these cells are activated in an antigen-independent manner by CCL3, 
which is secreted by memory CD8+ T cells (Narni-Mancinelli et al., 2007). Thus, 
understanding the exact precursors, the transcriptional regulation and a phenotypic 
description that distinguishes iNOS+ cells from other inflammatory and steady state 




5.1.2 The induction of iNOS+ cells is dependent on its microenvironment  
 
The production of iNOS has been attributed largely to macrophages in response to 
pathogens. Macrophages are generated in vitro from bone marrow progenitors in the 
presence of growth factors like M-CSF or GM-CSF. Each of these cultures generate 
macrophages with slightly different characteristics. As alluded to in previous chapters, 
GM-CSF cultures of BM progenitors results in a mixture of macrophage and DC-like 
cells (Inaba et al., 1992)- of which the macrophages upon exposure to LPS are able to 
produce NO resulting in the elimination of the pathogen (Xu et al., 2007). Flt3L 
supplemented BM cultures do not generate cells capable of NO production indicating that 
cDCs are not capable of producing the inflammatory mediator (Xu et al., 2007). It could 
be inferred, therefore, that GM-CSF induces the generation of macrophages that are 
required for the clearance of pathogens via the production of NO. However, Csf2rb-/-
Csf2rb2-/- (GM-CSF-R-/-) mice efficiently control infection with Listeria monocytogenes 
(L.m.) as there are no differences in the numbers of TNF- and iNOS-producing 
macrophages generated (Greter et al., 2012). Thus, the role of GM-CSF in the 
development of iNOS-producing cells may be redundant acting more to promote the 
expansion of these cells. In fact, Greter et al noted that Csf1r (M-CSF-R) was 
indispensable for the generation of iNOS+ cells instead.   
The functional and phenotypic characteristics of these cells is determined by the presence 
of a number of other inflammatory factors at the site of inflammation. For instance, 
regulatory factors such as IL-10 controls the production of iNOS and TNF-α from 
CD11c+CD11b+Ly6G- splenocytes in a Trypanosoma brucei infection (Guilliams et al., 
2009). The reduction in iNOS+ cells reduces the levels of inflammatory chemokines and 
cytokines like CXCL9, CXCL10 and CXCL11 released, thus reducing the numbers of 
other recruited inflammatory cells (Guilliams et al., 2009). TGF-β is also a potent inhibitor 
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of iNOS and its presence was found to be the reason for increased susceptibility to 
Leishmania major infection in Balb/c mice over the resistant C57Bl/6 strain in spite of 
no differences in inflammatory macrophage-inducing-IFN-ɣ at the site of infection 
(Stenger et al., 1994). CX3CR1-deficient mice have reduced numbers of recruited 
inflammatory Ly6Chi monocytes due to the reduction in Ly6Clo (CX3CR1) monocytes and 
thus a lack of iNOS-, TNFα- and ROS- producing inflammatory cells This leads to 
increased susceptibility to L.m. (Auffray et al., 2009).. iNOS+ cells thus form an important 
part of an inflammatory network of cells. 
5.1.3 Characterisation of the precursors to iNOS+ cells  
Studies addressing the source of key inflammatory mediators such as NO, H2O2 and TNF-
α show an inflammation-induced population of myeloid cells that play a key role in the 
destruction of pathogens. In particular, these cells have been described to be CD11cint-
highCD11b+Mac-3+ cells that express high levels of co-stimulatory molecules such as 
MHC-II, CD80 (B7-H1), CD86 (B7-H2) and are found in a variety of infectious settings 
(Guilliams et al., 2014; Serbina et al., 2003; De Trez et al., 2009). Unfortunately, this 
description defines a rather broad population of myeloid cells. Thus, Guilliams et al. set 
out to determine the population that is responsible for pathogen elimination in a parasitic 
model of infection. It was found that a sub-set of these CD11b+CD11c+Ly6C+Ly6G- cells 
produced TNF-α  (Guilliams et al., 2009) of which some also expressed iNOS - a function 
critical for pathogen control regardless of an effective T cell response to the pathogen 
(Serbina et al., 2003).  Due to the use of these widely expressed markers, iNOS+ cells are 
called macrophages in some studies while they are called DCs in others (Serbina et al., 
2003; De Trez et al., 2009). Thus there is a requirement to clearly define inflammatory 
cell populations from those resident at steady state.  
The expression of iNOS is a useful marker for myeloid cells that are inflammatory. 
However, using an inflammatory factor such as iNOS does not define all the cells that 
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are, in fact, capable of producing iNOS. This could be aided by the knowledge of their 
cellular lineage from progenitor cells. Studies addressing the cell lineage of iNOS+ cells 
have produced conflicting results. iNOS+ cells are often referred to as DCs since they are 
cDC-like in their co-stimulatory molecule expression and the ability to prime T cells in 
an allogeneic reaction in vitro (Serbina et al., 2003). However, most myeloid cells will 
upregulate co-stimulatory molecules and mice lacking iNOS+ cells are fully capable of 
priming CD4 and CD8 T cells in response to infection. Additionally, it is noted that iNOS+ 
cells are still present in Flt3l-/- mice (Greter et al., 2012),which lack a critical growth 
factor required for the development of cells in the cDC lineage. In contrast, iNOS-
producing cells were reported to be CCR2 dependent and Csf1r-dependent (Greter et al., 
2012; Serbina et al., 2003) indicating that they belong to the monocyte lineage. Despite 
their dependence on growth factors associated with monocyte development, these iNOS+ 
inflammatory cells continue to be called ‘dendritic cells’. 
I wished to decipher a clear distinction between iNOS producing cells and other 
populations at the site of inflammation. 
5.1.4 Objectives and aims 
The overall objectives of this chapter will be the following:  
 To characterize iNOS+ cells using distinct phenotypic marker expression to 
delineate these cells from different subsets of Ly6Chi monocytes. 
 To investigate lineage specific transcription factors to distinguish iNOS-
producing cells from tissue-resident macrophages and cDCs. 
 To determine the dependence of the transcription factor PU.1 on the expression 




5.2.1 iNOS production in vitro  
5.2.1.1 Titration of Listeria for the generation of iNOS+ cells in vitro 
In order to be able to study the production of iNOS by Ly6Chi monocytes, the precursors 
of iNOS+ cells and the result of their terminal differentiation, I set up an in vitro model 
of infection with Listeria monocytogenes (L.m.) and LPS. This was done by taking total 
Ly6Chi monocytes enriched by MACS sorting from WT C57BL/6 BM and culturing these 
cells overnight with varying concentrations of either virulent L.m. or LPS. Analysis of the 
cultures showed an increase in iNOS+ cells when exposed to L.m.at an MOI 0.01, 0.1 and 
LPS in comparison to isotype controls for anti-iNOS staining., At higher MOIs, there was 
no increase in iNOS producing cells as many of the MACS-sorted cells died of infection 




Figure 5-1: iNOS producing cells differentiate from bone marrow monocytes 
following microbial stimulation. 100,000 SIRPa+CD115+ MACS-enriched bone 
marrow monocytes were plated in complete medium with 1ug/ml LPS or Listeria 
monocytogenes at a multiplicity of infection (MOI) of 0.01, 0.1, 1 and 10. After an 
overnight incubation cells were stained with either isotype or anti-iNOS antibody and 
anti-MHCII. This was done with 3 technical replicates. 
 
5.2.1.2 Requirement for IFN-ɣ in the expression of MHC-II on iNOS+ cells 
In vivo generated iNOS+ cells are MHCII+ (Kang et al., 2008). In the previous experiment, 
I showed that iNOS+ cells were MHCII-. This could be expected as it has been previously 
reported that the presence of MHCII+iNOS+ cells among activated macrophages is 
dependent on IFN-ɣ generated by NK cells (Kang et al., 2008). Since our experimental 
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protocol was devoid of any IFNɣ, I do not expect to see expression of MHCII in the iNOS 
producing cells. In order to confirm that the lack of MHCII expression is due to the 
absence of IFN-ɣ, an in vitro culture of MACS-sorted BM monocytes was carried out 
with L.m., in the presence or absence of IFNɣ.  Cultures containing IFN-ɣ showed an 
increase in the MHCII+ expression on the iNOS+ cells (Figure 5-2). 
 
Figure 5-2: IFN-ɣ is required for the intermediate expression of MHCII on iNOS+ 
cells. Enriched BM monocytes cultured overnight in the presence or absence of IFN-ɣ. 
Cells were then analysed by flow cytometry by gating onto CD11b+ cells and assessing 
the expression of iNOS.  The number within each gate is indicative of the percentage of 
cells within total iNOS+ cells. Graphs shows the mean ± SEM of n=3; 
**p<0.005;Student’s t-test. 
 
5.2.1.3 R1 cells are the precursors to iNOS+ cells 
Previous reports have distinctly shown that iNOS+ cells arise from a Lin-
CD11b+MHCII+Ly6Chi population in vivo. However, iNOS+ cells whether identified by 
reporter labelling with CX3CR1 or antibody staining always appears to be only a small 
sub-population of Ly6Chi monocytes (Serbina et al., 2003; Zigmond et al., 2012). I thus 
wanted to test the ability of each of the Ly6Chi subsets of monocytes discussed in Chapter 
3, to give rise to these iNOS+ cells. This was done in comparison with the pre-cDC 
population R3.  
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FACS sorted R1, R2 and R3 cultured with L.m. showed that R1 was the most efficient at 
generating iNOS+ cells. These iNOS+ cells were MHCII- as was expected given that the 
culture did not have any IFN-ɣ present. Additionally, R3 generated cells that were iNOS- 
and MHCII+. R2 was able to generate MHCII+ progeny to a greater extent than R1 (Figure 
5-2).  
A similar experiment was performed with LPS overnight at a concentration of 1µg/ml. 
Here, the FACS sorted R1 were the only cells capable of producing iNOS. R2 and R3 
populations generated MHCII+ cells (Figure 5-3b). Thus, using 2 different types of 
microbial stimulation, I could conclude that R1 Ly6Chi monocytes have the strongest 




Figure 5-3: R1 generates iNOS+ cells in-vitro. R1, R2 and R3 were sorted by flow 
cytometry and cultured in complete RPMI supplemented with 3ng/ml GM-CSF, 100ng/ml 
Flt3L and 20ng/ml M-CSF.(a) Listeria was added at MOI 0.01 and cells cultured 
overnight. Representative FACS analysis of MHCII and either anti-iNOS or isotype 
control is shown. (b) Cells were cultured overnight with 1ug/ml LPS. Graphs reflect the 
mean of 2-3 independent cultures. 
 
5.2.2 In vivo production of iNOS+ cells in response to Listeria 
With the initial discovery of iNOS production by macrophages (Stenger et al., 1994), a 
novel mechanism for bactericidal action had been found. Furthermore it was found that 
there was a specific subset of myeloid cells that were CD11b+CD11c+ and MHCIIhi that 
were able to produce iNOS  in response to cytosolic bacteria such as Listeria (Serbina et 
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al., 2003,) and parasites such as Leishmania (Guilliams et al., 2009; De Trez et al., 2009); 
These cells were labelled as ‘monocyte-derived dendritic cells’ due to their reliance on 
CCR2 and subsequent high expression of MHCII (Serbina et al., 2003; De Trez et al., 
2009). However, in order to understand if these iNOS+ cells were in fact the same as those 
that arise in response to GM-CSF (that are also called monocyte-derived dendritic cells) 
as had been previously assumed (Naik et al., 2006; Zigmond et al., 2012), I wanted to 
phenotype iNOS+ cells for the same markers as studied in in vivo models of increased 
levels of GM-CSF. To do this I used an in vivo model system of L.m. infection and 
assessed the presence of iNOS+ cells in the spleen. 
5.2.2.1 Setup of Listeria monocytogenes infection model 
Experiments performed previously in the literature indicated 2-4 x 103 Listeria CFU/ 
mouse was sufficient to generate an immune response that peaked at approximately 2 
days after infection (Serbina et al., 2003). I thus used 2.5 x 103 CFU/mouse and tested for 
anti-iNOS antibody staining. I were able to discern a clear population of Lin-CD11b+ cells 
that were expressing iNOS. These iNOS+ cells were MHCII+ and Ly6Chi. This was in 
agreement with previous studies on iNOS+ cells (Kang et al., 2008; De Trez et al., 2009). 
I also noted an increase in granulocytes (CD11bhighLy6CintMHCII-) that can be expected 




Figure 5-4: L.m. induces the production of iNOS+ cells in vivo. WT mice were injected 
with 2500 CFU/mouse i.v. Mice were culled 2 days after infection and spleens assessed 
for iNOS+ cells among Lin-CD11b+ cells and analysed for Ly6C, CD11b and MHCII.   
 
5.2.2.2 Fate mapping of iNOS+ cells 
Next, I wished to address the fate of iNOS+ cells. A number of studies on iNOS+TNFα+ 
cells have noted that they are Ly6Chi. Jung and colleagues tracked adoptively transferred 
Cx3cr1gfp/+ cells in a model of colitis and noted at later time points, that CX3CR1
gfp/+ cells 
lose Ly6C expression to gain a more DC-like phenotype after an initial iNOS+ stage 
(Zigmond et al., 2012). To accurately determine the fate of iNOS+ cells I used an 
improved fate mapping mouse model; The Nos2CreTomato x ROSAlslTomato system undergoes 
stable recombination in cells that express iNOS resulting in permanent expression of the 
fluorescent molecule Tomato. 
Listeria infected mice were culled 2 days after infection. Splenocytes were stained with 
anti-iNOS antibody to assess the percentage of cells that were currently expressing iNOS 
(anti-iNOS+) and compare these to any cells that had previously done so (Tom+). I 
reported a slightly lower percentage of Tom+ cells than anti-iNOS+ cells indicating that 
the model might display a more conservative iNOS reporter expression than is actually 
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present (Figure 5-5a). Both anti-iNOS+ and Tom+ cells expressed high levels of Ly6C 
(Figure 5-5a). An overlay of iNOS-tomato labelled cells (Tom+) over anti-iNOS antibody 
stained cells (anti-iNOS+) showed that staining with anti-iNOS captured approximately 
65% of the total cells that had produced iNOS in response to the infection (Figure 5-5b). 
 
Figure 5-5: L.m. induced iNOS+ cells are Ly6Chi. Nos2creTomato x ROSAlslTomato and 
C57Bl/6 controls were infected with L.m. Spleens were harvested 2 days after infection. 
Cells were either permeabilized to intracellularly stain with anti-iNOS antibody (anti-
iNOS) or left non-permeabilized to ensure reporting of Tomato+ cells (iNOS-Tom). Graph 
shows mean ± SEM from 4 mice. Lower panel shows an overlay of iNOS-Tom+ cells over 
anti-iNOS stained splenocytes (red dots). 
 
The study of iNOS production in response to bacterial infection is often done with live 
bacteria. In the previous experiment done in vitro, I noted that infections with higher 
MOIs resulted in the death of the cells in culture. This is because as fully virulent bacteria, 
L.m. evades host immune responses by directing  the polymerization of actin filaments in 
order exit the host lysosome to then enter the cytosol which is its site of multiplication 
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(Poussin and Goldfine, 2010). A mutated strain of L.m. that has a deletion in the virulence 
factor ActA (ActA Listeria) is unable to direct actin polymerization. This results in 
lysosomal clearance of the pathogen by the infected cell. The induction of iNOS 
production in macrophages is equivalent in infection with the WT and the ActA strains 
of L.m.. Thus, using ActA L.m. infection allows the study of iNOS producing cells 
without overwhelming host cells with bacterial burden. 
The spleens of mice infected with ActA L.m were tested for Tomato expression as well 
as anti-iNOS antibody staining within the Lin-CD11b+ population. The peak in Tomato 
and anti-iNOS antibody staining appeared at day2. Most of the Tomato+ cells were stained 
with anti-iNOS antibody indicating most of the cells were actively expressing iNOS at 
the time. By day 4, the number of cells stained for iNOS either by tomato expression or 
anti-iNOS antibody staining had reduced dramatically albeit there was a small number of 
cells still expressing Tomato that were not stained by the antibody. This indicated that 
most of the cells that expressed iNOS in response to the infection, had died. Furthermore, 
whether at day 2 or day 4, the iNOS-tomato+ cells were always Ly6Chi even when they 
they were no longer expressing iNOS as indicated by the lack of anti-iNOS-antibody 
staining (Figure 5-6). I could thus conclude that iNOS+ cells are in fact terminally 
differentiated cells that arise in response to bacterial infection, express MHCII in vivo and 




       
Figure 5-6: iNOS+ cells are an end-stage population. Analysis of iNOS+ by 
intracellular anti-iNOS antibody staining and labelling with Tomato expression, in the 
spleens of NOS2creTomato x ROSAlstdlTomato mice at days 2 and 4 after L.m. infection. 
Percentage of Ly6Chi cells within each population is quantified as mean ± SEM of the 
percentage of iNOS-Tom+ or iNOS-Ab+ within total cells is shown in the graphs; n=3; 
**p<0.005, ***p<0.0005, ns=not significant; Student’s t-test. This experiment was 
performed in collaboration with Daisy Melandri. 
 
5.2.2.3 Phenotype of iNOS+ cells 
Given the ability of R1 cells to generated iNOS+ cells, I wondered if iNOS+ cells would 
have a similar phenotype to R1. Previous reports have found iNOS+ cells to be F4/80int 
MHCIIintCD11c+CD11b+Ly6Chi (Guilliams et al., 2009; Serbina et al., 2003). These 
markers are not distinctive among the myeloid lineage and are expressed on other cell 
types such as tissue-resident macrophages and cDCs as well. I therefore performed FACS 
analysis for the markers that I noted were differentially expressed among the 
Ly6Chimonocytes by mRNA expression in the BM and by surface expression in the blood 
(refer Chapter 3). I found that iNOS+ cells were Ly6ChiMHCIIint and distinctly separate 
from an iNOS-Ly6Clo MHCII+ population (Figure 5-7a). 
FACS analysis of the iNOS+ cells against specific isotype controls showed that they were 
FcɣRII/III+CD209-Flt3-CD115- (Figure 5-7b). Additionally, they were PDL2+ and PDL1-
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. This phenotype was similar to that of Inf-Macs generated by R1 monocytes when 
exposed to high levels of GM-CSF. 
 
Figure 5-7: iNOS+ cells have a similar phenotype to GM-induced inflammatory 
macrophages. (a) Representative FACS analysis of spleens from WT.  L.m. infected mice 
2 days after infection. (b) iNOS + cells were assayed for CD209a (DC-SIGN), FcɣRII/III 
(CD16/32), Flt3(CD135), CD115 (MCSF-R), PDL1 (CD274) and PDL2 (CD273) (black 
shaded) against isotype control (grey shaded). n=3 
I could thus conclude that iNOS+ cells had a phenotype similar to inflammatory 
macrophages and not inflammatory DCs. Additionally, iNOS+ cells had a phenotype that 
was distinct from the MHCIIhiLy6Clo population that resembled the inflammatory DC 
phenotype.   
 
5.2.2.4 Fate-mapping reveals iNOS+ cells do not belong to the cDC lineage 
Previous literature suggests the conversion of CX3CR1int cells that produce iNOS within 
the first 24-48 hrs that then begin to describe a more DC phenotype expressing DC-
specific markers such as Zbtb46 and Flt3 (Zigmond et al., 2012). Using a recent model 
for fate mapping of DC lineage cells with the Zbtb46CRE x ROSAlslYFP mice, I attempted 
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to assess whether the Ly6ChiCD11b+iNOS+ cells belonged to the DC lineage (Loschko et 
al., 2016a). Infection of Zbtb46CRE x ROSAlslYFP mice with L.m. resulted in the generation 
of iNOS+ cells that expressed minimum background levels of YFP while this was far 
higher in the positive control CD4+ cDCs (cDC2s) (20%) (Figure 5-8). Collectively, I 
found that iNOS+ cells did not arise from a cDC lineage. 
 
Figure 5-8: iNOS+ cells are Zbtb46-YFP negative. Representative flow cytometry 
analysis of L.m. infected or naïve Zbtb46CRE x ROSA lslYFP mice. iNOS+ cells, iNOS-
CD11b- and CD4+CD11b+ cells were analysed for their expression of YFP. 
 
 
5.2.3 Role of PU.1 in the generation of iNOS+ cells 
5.2.3.1 Listeria infection in Sfpi1+/- mice leads to elevated production of iNOS 
As described in Chapter 3, R1 has far lower levels of PU.1 than R2 monocytes or R3 pre-
DCs. I therefore wondered if PU.1 might play an inhibitory role on the functions of R1, 
i.e in the production of iNOS. Sfpi1+/- mice were injected alongside wild type controls 
with ΔActA L.m.. At day 2, splenocytes were harvested and assayed by FACS for their 
expression of iNOS. I found that Sfpi1+/- mice had increased numbers of 
CD11b+Ly6ChiiNOS+ cells than their wild type counterparts (Figure 5-9). However, it 
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should be noted that there was an increase in the number of total splenic Lin-
CD11b+Ly6Chicells. Within Lin-CD11b+Ly6Chicells, the percentage of iNOS+ cells was 
also increased. This data suggested that iNOS expression was negatively regulated by 
PU.1. 
 
Figure 5-9: Sfpi1+/- mice have increased levels of iNOS production than WT controls.  
Sfpi1+/- and Sfpi1+/+ mice were injected with WT Listeria and sacrificed 2 days later. 
Representative FACS plots show the expression of iNOS among Lin-CD11b+ splenocytes 
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in mice of each genotype as well as the corresponding MHCII levels of the iNOS+ cells. 
Graphs show mean ± SEM data from 1 of 2 experiments with similar results; n=3; 
*p<0.05, ***p<0.0005, ns=not significant; Student’s t-test. 
5.2.3.2 Sfpi+/- bone marrow derived macrophages exhibit higher levels of iNOS 
The role of PU.1 in the generation of macrophages and DCs was discussed previously. I 
have found that PU.1 plays a crucial role in the development of R2 monocytes and R3 
pre-DCs. Additionally, I found that hemizygosity rendered R1 cells an enhanced ability 
to produce iNOS (Figure 5-3). I therefore wondered whether this important transcriptional 
regulator may play a role in the further downstream functional development of iNOS+ 
production in comparison to MHCII+ upregulation within monocyte subsets, during 
infection.  
Culturing normalized numbers of bone marrow derived macrophages from Sfpi1+/- or 
Sfpi+/+ mice with L.m. at an MOI of 1 or 10 or with LPS resulted in far greater amounts 
of iNOS in Sfpi1+/- bone marrow derived macrophages as compared to their wild type 
counterparts. This was true in the percentage of iNOS+ cells as well as in the MFI of iNOS 
generated (Figure 5-10). Thus, PU.1 inhibits iNOS expression within macrophages. Given 
that Sfpi1+/- bone marrow is depleted of R2 monocytes, the cultures would contain a 
majority of macrophages derived from R1 monocytes. It could thus be suggested that 






Figure 5-10:Sfpi1+/- macrophages generate higher levels of iNOS. 10,000 bone 
marrow derived macrophages were cultured in fresh medium with 20ng/ml M-CSF and 
either L.m. (MOI 1 or 10 ) or LPS at 1ug/ml. Graphs show mean ± SEM data; n=3; 









5.2.3.3 Sfpi1+/- BM generates iNOS+ cells in vivo 
Having found an in vitro reliance on PU.1 to express iNOS by PU.1lo R1 monocytes, I 
wished to test this reliance in vivo through an adoptive transfer experiment where I 
injected whole BM from Sfpi1+/+ or Sfpi1+/- mice (CD45.2) into congenic CD45.1 WT 
recipients (Figure 5-11a). Six hours later the recipients were injected with ΔActA Listeria 
and sacrificed at day 1.5 post infection. By harvesting cells from the spleen, I were able 
to analyse the CD45.2+ cells and study their expression of iNOS in comparison to 
endogenous levels as an internal control for iNOS expression on CD45.1+ cells. Sfpi1+/- 
cells, being enriched in R1 monocytes, generated far more iNOS+ cells that were 
CD11b+Ly6Chi cells as compared to the Sfpi1+/+ cells (Figure 5-11b). Thus, by 
circumventing any developmental abnormalities that may have explained the increased 
expression of iNOS in the hemizygous mice, I could show conclusively that PU.1 plays 




Figure 5-11: Sfpi1+/- BM generates greater percentage of iNOS+ cells. a) Schematic 
diagram of experimental procedure. b) Representative FACS analysis of the spleens from 
L.m. infected WT recipients of Sfpi1+/+ or Sfpi1+/- BM. Graphs show mean ± SEM; n=3; 
***p,0.0005; Student’s t-test. 
 
5.2.3.4 PU.1 plays a cell-intrinsic role in the generation of iNOS in monocytes  
In order to study the reliance of R1 monocytes on PU.1 for the expression of iNOS, I next 
performed an adoptive transfer experiment where Sfpi1+/- or Sfpi1+/+ bone marrow 
monocytes were sorted with MACS beads and then injected into recipient WT ΔActA- 
L.m. infected mice (Figure 5-12a). Since Sfpi1+/- monocytes are devoid of both R2 
monocytes and R3 pre-DCs, this experimental system would allow the adoptive transfer 
of mostly R1 monocytes into recipient mice. Additionally, to test for the competitive 
advantage of PU.1 in the generation of iNOS in an infected mouse model, I injected both 
Sfpi1+/+ and Sfpi1+/- monocytes into the same infected recipient. I generated F1 mice from 
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a cross between CD45.2+ and CD45.1+ mice so that endogenous cells would be labelled 
with both markers. Sfpi1+/+ bone marrow was taken from CD45.1+ mice while the Sfpi1+/- 
mice were on a CD45.2 background. Thus, by injecting monocytes in a 1:1 proportion 
into the same recipient I were able to identify each genotype as well as the endogenous 
cells. 
Adoptively transferred Sfpi1+/- monocytes generated a much higher percentage of iNOS+ 
cells as compared to both the Sfpi1+/+ monocytes and the endogenous recipient monocytes 
(Figure 5-12b). This corroborated with the data obtained from the previous adoptive 
transfer experiment with whole BM from Sfpi1+/+ and Sfpi1+/- mice (Figure 5-11). 
Additionally, I could conclude that PU.1 was not only required for the development of 
R1 monocytes from its precursors at steady state but also played a central role in the 




Figure 5-12: Sfpi1+/- monocytes regulate iNOS production on cell intrinsic level a) 
Schematic diagram of experiment setup b) Representative FACS plots of a recipient 
CD45.1/.2+ spleen showing CD45.1+(Sfpi1+/+) Ly6Chimonocytes and CD45.2+(Sfpi1+-/) 
Ly6Chi monocytes gated on Lin-CD11b+cells. Graph shows mean ± SEM; n=4, 





5.3 Discussion and chapter overview 
Inflammatory stimuli such as IFN-ɣ and TNF- (Liew et al., 1990; Xie et al., 1993), TLR 
ligands (De Trez et al., 2009), co-stimulatory molecules and inflammatory cytokines (like 
IL-1, IL-17, IL-18) induce the production of NO by macrophages. This is because iNOS 
production requires the concomitant activation of the STAT and NF-kB pathways that are 
stimulated by TLR and cytokine receptor signalling (Farlik et al., 2010). By providing 
appropriate stimuli, iNOS+ cells are easily studied in vivo and in vitro. 
While iNOS is responsible for important bactericidal activity to fight a number of 
infections, these cells can also prove pathological due to sustained exposure of 
neighbouring tissue to nitric oxide. In the case of chronic infection with the parasite 
Trypanosoma brucei, , iNOS-producing cells accumulate in large numbers in the liver, 
spleen and lymph nodes causing destruction to these organs (Guilliams et al., 2009).  
By studying the induction of iNOS+ cells in vitro in response to L.m. or LPS, I was able 
to draw on the separation between iNOS+ cells and MHCIIhi cells. iNOS induction and 
the expression of MHCII on iNOS+ cells has been attributed to the action of IFNɣ 
produced by Th1 cells and NK cells in response to an infection (Kang et al., 2008; De 
Trez et al., 2009). In the case of our in vitro infection of flow cytometry assisted sorting 
of monocytes and pre-cDCs, I was able to decipher the precursor populations within 
Ly6Chi monocytes that were specialized to produce iNOS versus those that upregulated 
MHCII expression in response to L.m. infection or LPS – R1 (Flt3-CD11c-) cells had high 
mRNA expression levels of inflammation associated genes at steady state and were found 
to be the monocyte precursors with a predisposition to generate iNOS in response to 
infection with L.m. or LPS. R3 pre-cDCs did not produce iNOS and instead upregulated 
MHCII which was expected given their high expression of MHCII-associated genes. R2 
displayed an intermediate phenotype generating both iNOS+ cells (albeit at a lower 
percentage than R1) and upregulated MHCII. Thus, between the 2 Ly6Chi monocytes – 
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R1 and R2, R1 represents the precursors to inflammatory macrophages capable of 
generating iNOS+ cells. Our in vitro and in vivo results hereby suggest that the occurrence 
of a DC-like phenotype in response to inflammation as reported by Zigmond et al, could 
be explained by the presence of  R2 and R3 within the population gated as Lin-
CD11b+CD115+Ly6Chi cells. 
Additional experiments that could not be completed for this report include a thorough 
functional assessment of the resulting progeny of each of these precursor cells. Future 
work would include assessment of the ability of MHCIIhi cells to prime CD4+ T cells and 
a colony-forming-unit analysis of the cultures after overnight infections with L.m.. 
 An important finding was that PU.1 regulates the expression of iNOS. A culture of 
Sfpi1+/- bone marrow with M-CSF results in the enrichment of progeny from R1 
monocytes as R2 monocytes are dramatically reduced in these mice.  Upon infection with 
L.m. of normalized numbers of BMDMs., I noted that the Sfpi1+/- BMDMs produced 
higher levels and percentage of iNOS+ cells. Such an experimental setup accommodated 
for any developmental differences that may occur as a result of PU.1 hemizygosity.  I 
demonstrated that PU.1 directly influences the production of iNOS and the development 
of iNOS+ cell precursors- R1 monocytes. The cell intrinsic role of PU.1 in the induction 
of iNOS expression was further demonstrated by mixed adoptive transfer experiments of 
Sfpi1+/+ and Spi1+/- bone marrow into infected recipients. 
The inhibitory role of PU.1 on iNOS generation that I describe both in vivo and in vitro, 
could be explained through PU.1 target miRNAs, namely miR146 and miR155 that have 
been found to inhibit iNOS production (Perske et al., 2010). Further details of this 
mechanism are alluded to later in the final conclusion of this thesis. PU.1 thus helps 
regulate the inflammatory response through various target genes. 
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The PU.1hi R2 monocytes that I describe, therefore, are suitably able to generate 
FcɣRII/III+CD209a+ moDCs that are GM-CSF dependent while the PU.1lo R1 monocytes 
are pre-equipped to generate iNOS+ phagocytes. Further studies are required to elucidate 
the effector role played by each of these populations in different inflammatory contexts. 
Are these cells the same as GM-CSF -induced FcɣRII/III+CD209a+/- cells? 
L.m. infection is cleared efficiently in Csfr2r-/- Csf2rb2-/- mice but not in Ccr2-/- mice 
(Greter et al., 2012) or in Nos2-/- mice (Serbina et al., 2003). This indicates that the cells 
responsible for controlling the pathogen are the Ccr2-dependent iNOS producing cells 
that are independent of GM-CSF. Our data shows that these iNOS+ cells arise from the 
R1 Ly6Chimonocytes and resemble the phenotype of the GM-CSF induced inflammatory 
macrophages (FcɣRII/III+CD209a-Flt3-CD115+ cells) that also arise from R1 cells. This 
suggests that R1 cells are plastic and respond to different environmental cues to generate 




























6.1 Summary of findings 
The study presented here differentiates between the 2 well characterized populations of 
inflammatory myeloid cells, namely iNOS-producing cells and mo-DCs. With the use of 
intricate in vivo and in vitro models of inflammation I was able to delineate characteristics 
from each population in order to better identify their distinctive functions, phenotypes 
and ontogeny.  
Furthermore, I was able to decipher the precursor populations to iNOS+ cells (i.e., R1) 
and to MHCIIhi  cells that bear a more DC-like phenotype (i.e., R2). I was able to establish 
novel surface marker expression patterns by which to distinguish them from other tissue-
resident myeloid cells. Additionally, this study provided some clarity on the heterogeneity 
of the Ly6Chi monocytes that were previously considered to be homogenous and capable 
of becoming ‘inflammatory macrophages’. Our t-SNE analysis highlighted various sub-
populations within the conventional gating strategy of Ly6Chi monocytes that was 
encompassed within the novel R2 population. Bulk population analysis of this subset 
using cDC-associated markers like Flt3 and CD11c allowed the study of genetic and 
functional aspects of this novel R2 population. Single-cell analyses provided an in-depth 
view of the cells that truly express a unique transcriptional programme to other Ly6Chi 
monocytes and pre-cDCs. Highlighting the presence of pre-cDCs (R3) within 
conventional Ly6Chi monocyte gates also cautions against the inclusion of Flt3+CD11c+ 
cells in future studies. Table 6-1 provides a comparison of the surface markers expressed  
on these novel populations with precursor populations for monocytes and cDCs. 
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Table 6-1: Comparion of novel Ly6Chi sub-population surface markers 
 
*(Hettinger et al., 2013; Onai et al., 2007) 
 
Finally, I show that the transcriptional regulator, PU.1, is responsible for delineating, the 
differential capacity of the Ly6Chi monocyte subsets to generate either iNOS+ cells or mo-
DCs under various conditions of inflammation.  
The next section will discuss the significance and implications of these findings. 
6.1.1 Ly6Chi monocyte gating strategy 
This study has revealed the presence of Flt3+ cells within what was considered to be a 
homogenous population of bonafide Ly6Chi monocytes. These Flt3+Ly6Chi monocytes are 
capable of generating mo-DCs within appropriate inflammatory environments and are 
GM-CSF-induced. Identifying the FcɣRII/III+CD209+ cells within Flt3+CD11c-Ly6Chi 
monocytes in the blood at steady state proved particularly challenging. This was due to 
the small number of mo-DC precursor cells present and their relatively low expression of 
distinctive markers to identify them in the BM and blood by FACS analysis.  
Single-cell analysis of BM progenitors has proved extremely useful in delineating the 
dynamic transcriptional programmes of progenitor cells.  Although most work within the 
field of ontogeny is driven by an a priori definition of myeloid and lymphoid progenitors 
based on cell surface markers, single cell analyses have helped reveal the dynamic nature 
R1 R2 R3 Pre-DC 
P
cMop* CDP* MDP*
CX3CR1 lo lo lo  -  +  -  +
SIRPa  +  +  +  -  +  +  +
CD115  +  +  +  -  +  +  +
Ly6C  +  +  + lo  +  -  -
CD11b  +  +  +  -  -  -  -
FcgRII/III  +  +  -  -
CD209a  -  +  +   +/-
Flt3  -  +   +  +  -  +  + 
MHCII  -  +/-  +/-  +  -  -  -




















of these cells and the stage of transcriptional divergence between various cell lineages 
(Ishizuka et al., 2016; Jaitin et al., 2015). In this study, our single cell qPCR studies 
allowed for a focused analysis of relevant surface markers and transcription factors that 
helped characterize the heterogeneity not only within Ly6Chi monocytes but also within 
the R2 population. Index-sorting of single-cells of the total population of Ly6Chi 
monocytes followed by RNA-Seq or microarray analysis might have enabled 
identification of unique markers and a more in-depth transcriptional characterisation of 
R1 and R2 without a priori gating for Flt3 and CD11c expression.  
Additionally, this study was unable to identify a position in the developmental hierarchy 
for R2 among myeloid progenitors, precursors and differentiated cell populations, such 
as cMop, CDP and R1 Ly6Chi monocytes. R2 can be classified as a committed population 
of cells given that it does not express ckit.  However, the exact transcriptional programme 
of these cells would have helped delineate whether R2 represented a transitional 
population of cells that co-expresses Flt3 and CD115, and whether they are a population 
that could give rise to R1 monocytes.   
6.2 An improved definition of inflammatory myeloid cells 
6.2.1 Phenotypic definition of monocyte-derived dendritic cells 
Ly6Chi monocytes differentiate into cells of various phenotypes during inflammation. As 
these cells egress into the tissue, they have been documented to become macrophages, 
DCs or myeloid-derived suppressor cells (MDSCs). Their phenotypic characterisation has 
continually been based on a mixture of markers such as CD11c and MHCII that are 
commonly expressed on a number of cells along with macrophage markers like CD64 
(Tamoutounour et al., 2013), MertK, FcɛRI (Plantinga et al., 2013), CD206 (Cheong et 




Here, I focus on a combination of FcɣRII/III, which is expressed at high levels on 
monocytes and macrophages, and can be recognized by commercially available high 
affinity antibodies, along with CD209a, a marker that is expressed on in vitro derived 
GM-DCs as well as tissue DCs in humans. This report outlines a unique expression 
pattern to identify monocyte-derived macrophages and monocyte-derived dendritic cells 
as distinct cell types. While both are positive for a number of common markers that have 
previously been used to characterize inflammatory DCs and macrophages (such as 
CD206, CD115, FcɛR1 and CD64), our study has shown that these inflammatory cells 
can be better characterized as FcɣRII/III+CD209a- inflammatory macrophages and 
FcɣRII/III+CD209a+ mo-DCs.   
Other than the expression of CD209a, our study did not highlight any other surface 
markers that distinctly differentiated between FcɣRII/III+CD209a- and 
FcɣRII/III+CD209a+ cells. Performing microarrays on these populations could flag new 
markers that would help identify mo-DCs and inflammatory macrophages and provide a 
more functional understanding of the populations.  
An important comparative study that would complement this approach would be with 
tissue-resident macrophages using markers such as CD169 and SIGN-R1 to outline the 
metallophilic and marginal zone macrophages, respectively. FcɣRII/III+CD209a- and 
FcɣRII/III+CD209a+ cells are CCR2-dependent and recruited to the spleen in response to 
GM-CSF indicating that they do not arise from local proliferating macrophages. Ensuring 
that FcɣRII/III+CD209a- and FcɣRII/III+CD209a+ cells have markers to distinguish them 





6.2.2 Ontogenic perspective of mo-DCs and inflammatory macrophages. 
The origins of mo-DCs and inflammatory macrophages has been highly debated. Using 
relative expression levels of markers such as CD11b, CD11c, CX3CR1 and MHCII, 
previous reports have indicated the absence of inflammatory myeloid cells in Ccr2-/- mice 
during inflammation. Inflammatory myeloid cells are thus suggested to originate from a 
Ccr2-dependent population. CCR2 is expressed on a number of cells including NK cells, 
T cells and pre-cDCs (Schlitzer et al., 2015). However, the reliance on the receptor for 
egress from the bone marrow lies mainly with Ly6Chi monocytes (Geissmann et al., 2003; 
Kurihara et al., 1997). Inflammatory macrophages and mo-DCs thus arise from Ly6Chi 
monocytes.  
In order to answer the questions regarding the relationship of mo-DCs and iNOS+ cells 
with the cDC lineage, I used the most accurate mouse models available to track the 
expression of the cDC-lineage specific transcription factor- Zbtb46, within mo-DCs. The 
models included the reporter Zbtb46gfp/+ mice and the fate mapping Zbtb46CRE x 
ROSAlslYFPmice. While both mouse models showed that neither population expressed 
ZBTB46 to a significant degree, FcɣRII/III+CD209a+ mo-DCs express slightly higher 
levels of ZBTB46-GFP than their CD209a- counterparts in Zbtb46gfp/+ mice. The origin 
of these cells cannot be attributed to the cDC lineage however, as fate mapping analysis 
in the Zbtb46CRE x ROSAlslYFP mice showed that they had close to background levels of 
Zbtb46-YFP expression.  Furthermore, Zbtb46gfp/+reporter mice showed that GFP 
expression was not as high as in CD4+ cDCs in the spleen.  
By addressing the heterogeneity in the Ly6Chi monocyte population capable of generating 
FcɣRII/III+CD209a+ mo-DCs, I was able to identify a Flt3+CD11c- population that was 
able to give rise to the FcɣRII/III+CD209a+ mo-DCs. This population was negative for 
reporter expression of the DC-specific Zbtb46 (Zbtb46-GFP- and Zbtb46-YFP-) and in 
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spite of being Flt3+, they were independent of Flt3L for their development. Thus, I 
conclude that the Flt3+CD11c- Ly6Chi monocytes are not part of the cDC population and 
represent a distinct monocyte population. 
These experiments would have been complemented by studies that addressed the 
progenitor populations that were responsible for giving rise to Flt3+CD11c- R2 cells. 
While I noted that R2 are not cKit+, colony formation experiments with CDP, cMop and 
MDP to test the origin of R2 cells would have better established the precise position 
within the monocyte lineage hierarchy to which R2 cells belong. I cannot confirm whether 
R2 is a divergent precursor population deriving from the MDP or whether the cMop 
diverges into Nr4a1-dependent Ly6Clo monocytes, PU.1lo Ly6Chi monocytes and PU.1hi 
Ly6Chi monocytes. This may need to be addressed in future studies. Among the various 
techniques used to fate map cells I attempted the use of reporter mice, fate-mapping via 
the use of the cre/loxp system and adoptive transfer experiments of congenically marked 
progenitor cells. Another technique that may be used is cellular barcoding which would 





Figure 6-1: Fate mapping strategies. Reproduced from (Poltorak and Schraml, 2015). 
A number of techniques are used to more accurately define cDC populations. These 
include:  A. Adoptive transfer experiments with pre-labelled cells that track transferred 
cells by the use of congenic markers, for example. B. and D. Tracking a lineage via 
fluorescent molecules encoded downstream of lineage-specific transcription factor 
promoters (eg. Zbtb46) (B) or via the cre - loxp system that ensures constitutive 
expression of the reporter gene via the action of cre recombinase (D). Bar-coding in C 
relies on in vitro viral transduction of progenitor populations with semi-random DNA 
sequences (barcodes). These progenitors are adoptively transferred into irradiated 
recipients and the differentiated progeny of each transduced cell can then be traced by 
RNA-Seq or microarray. This method does not rely on prior knowledge of lineage-




6.3 The functional role of mo–DCs and inflammatory macrophages 
An aspect that remained outside the scope of this report is the functional description of 
the characterized mo-DCs and inflammatory macrophages. While the expression of 
MHCII in the R2 cells and their inflammatory progeny FcɣRII/III+CD209+ mo-DCs might 
indicate the propensity of these cells to present antigen to T cells, I did not formally 
address this. Additionally, while FcɣRII/III+CD209a- cells were found to produce iNOS 
in response to an L.m. infection, I might have also tested the bactericidal capacity of these 
cells by checking for the number of colony forming units that survived the effector 
functions of the inflammatory macrophages or mo-DCs in culture. I might infer from our 
adoptive transfer experiments with Sfpi1+/- and Sfpi1+/+ monocytes into L.m.-infected 
recipients, that PU.1lo R1 monocytes would perform greater levels of bactericidal activity 
due to a cell-intrinsic iNOS-producing advantage.  Additional analyses might also include 
the production of chemokines and cytokines by these cells as mo-DCs have been reported 
to produce large amounts of CCL2, CCL6, CCL9, CCL24 in the lung in response to house 
dust-mite allergen (Plantinga et al., 2013).  
 
6.3.1 The M1/M2 paradigm 
For the past 2 decades, alternatively-activated macrophages or M2 macrophages have 
been found to be important in the development of a tissue repair response. Several signals 
have been implicated in the development of an alternatively activated immune state 
namely signalling through the IL-4R, FcR and TLRs (Wynn et al., 2013). Currently 
defined by activation through IL4-Ra signalling via IL-4 and IL-13, M2 macrophages are 
often associated with the expression of proteins like arginase1, chitinase-like proteins (eg. 
YM1, Ym2), and RELMa. These proteins have been found to directly influence tissue 
repair (RELMa via a negative feedback loop to control fibrosis) or through the alternative 
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activation of macrophages, fibroblast formation and matrix deposition (Chi3l1) (Zhou et 
al., 2015).  
The origin of M2 cells is thought to be either from resident macrophages or circulating 
monocytes (Gundra et al., 2014). This origin influences the functional outcome of the 
monocytes in a way that supersedes the action of cytokine exposure. Peritoneal 
macrophages from naïve mice injected with IL-4 generate far fewer M2 macrophages that 
those in mice injected with IL-4 and thioglycollate- a model known to induce the 
recruitment of circulating monocytes. Monocyte-derived alternatively activated 
macrophages (AAMs) exclusively express high levels of RALDH2, PDL2 and CD206. 
Thus, monocyte-derived macrophages responding to IL-4 exhibit an M2 phenotype 
(Gundra et al., 2014).  
Our study presents 2 types of monocyte-derived inflammatory cells that express PDL2 
and CD206 among other surface markers. Whilst fitting the phenotype of monocyte-
recruited M2 macrophages, it remains to be ascertained if one or both populations of GM-
CSF-induced FcɣRII/III+ cells express M2-specific markers such as Raldh2, Chi3l3, 
arignase1 or is sensitive to IL-4 and IL-13 signalling.  
6.3.2 Mo-DCs and inflammatory macrophages express PDL2 
PDL1 has been known to be expressed at steady state on a number of non-immune and 
immune cells including cDCs and this is enhanced under inflammation. In contrast, PDL2 
is induced under inflammatory conditions on macrophages and cDCs both in vitro and in 
vivo (Yamazaki et al., 2002). Their common receptor Programmed Death receptor -1 PD-
1 (Latchman et al., 2001) is expressed on activated T and NKT cells. PD-1 has an 
immune-receptor tyrosine switch motif (ITSM) site indicating that it could illicit both 
stimulatory and inhibitory signals. Pdcd1-/- (PD-1-/-) mice develop spontaneous 
autoimmune diseases emphasizing the role of PD-1 in the induction of immune tolerance 
(Nishimura et al., 1999). PD-1 interactions with its ligands namely PDL1 and PDL2 have 
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been documented in several conditions including airway hyper-reactivity (AHR), 
transplantation, tumour immunology and infectious disease (Singh et al., 2011). PD-1 
acts as a ‘rheostat’ in modulating the levels of T cell activation in these conditions 
(Nguyen and Ohashi, 2015).  
PDL1 and PDL2 have very short cytoplasmic tails with no obvious signalling sequence 
indicating that they may not signal back into the APC expressing the ligand. PD1/PD-L1  
interactions have been documented to illicit Treg responses and have been implicated in 
immune-evasion mechanisms used by cancerous cells and cells infected with murine 
cytomegalovirus (mCMV)  (Benedict et al., 2008; Konishi et al., 2004). Engleman and 
colleagues noticed that blockade of PDL2 leads to a loss in polarization of in vitro anti-
CD3 stimulated  T cells (Davidson et al., 2013). Additionally, in the case of airway 
hypersensitivity reactions (AHR), PDL2 deficient mice have been found to have 
exacerbated AHR which was due to an increased production of IL-4 on iNKT cells 
(Akbari et al., 2010). PDL1 deficiency resulted in reduced AHR and increased levels of 
IFNg. This indicates the role of PDL2 in the blocking of Th2 responses while PDL1 
mediates their induction (Akbari et al., 2010). Agarwal and colleagues also noticed that 
Flt3L administration induced the upregulation of PDL2 on CD11bloCD11chi cDCs from 
OVA-sensitized mice, that in turn display regulatory properties (Shao et al., 2009). PD1 
has been found to be highly expressed on synovial fluid T cells in patients with 
rheumatoid arthritis indicating that PD-1 may exert tolerogenic effects in inflammatory 
tissue (Hatachi et al., 2003).  Thus, PDL2 and PDL1 exhibit immune regulatory functions 
and influence the polarization of T cells by APCs. 
In this study, I noted an almost perfect divide in the expression of PDL2 and PDL1. 
FcɣRII/III+CD209+ and FcɣRII/III+CD209-  cells expressed high levels of PDL2 while 
CD4+ cDCs and FcɣRII/III- CD11b+MHCII+ cells expressed high levels of PDL1. The 
divergent expression of each ligand on the FcɣRII/III+ cells and the cDCs in response to 
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GM-CSF could indicate a differential ability to polarize T cells towards a Th1 versus Th2 
phenotype. Further work is required to test the requirement for the disparate expression 
of PD-1 ligands on mo-DCs, inflammatory macrophages and tissue-resident cDCs. 
6.4 The role of PU.1 in the development of FcɣRII/III+CD209a+ mo-DCs 
PU.1 is an example of a master transcriptional regulator in hematopoietic development, 
especially in the myeloid compartment. Lineage commitment is directed by master 
transcriptional regulators like PU.1, that are capable of creating ‘poised’ regions/ 
enhancers in the genome where the chromatin is unwound (Garber et al., 2012). Various 
stimuli drive the activation of specific transcription factors that bind to these poised 
enhancer regions (Garber et al., 2012). This occurs in a cell-type specific manner and 
induces a unique phenotype and function. Poised enhancers can be indicative of past 
lineage commitment or can arise at the stage of cell fate choice. PU.1 is constitutively 
expressed in macrophages (Ghisletti et al., 2010) and interacts with multiple transcription 
factors (such as C/EBPa, IRF4, IRF8 etc.) depending on cell fate decisions, which in turn 
may be regulated by environmental stimuli. Lavin et al. showed that differentiated 
peritoneal macrophages could acquire the transcriptional phenotype of lung macrophages 
when transplanted into the lung (Lavin et al., 2014).  
The data in this thesis suggests that the role of PU.1 is considerably important with 
regards to the differentiation of inflammatory macrophages and mo-DCs from progenitor 
cells. Considering that relative levels of the master transcription factor shows clear 
differences between R1 and R2, it might be inferred that the elevated levels of PU.1 in 
R2 might be a unique cell fate choice that is made within the BM and becomes more 
pronounced in the blood and tissue. Indeed, the levels of PU.1 could not be distinctly 
discriminated within the bone marrow. PU.1 might act in a cell-specific way in R2, 
binding to regions in the chromatin to enhance the expression of genes such as Ciita, 
CD209a, and FcɣRII/III. An important point of discussion would be to understand how 
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PU.1 is regulated and the mechanism by which it exerts its effects on inflammatory 
macrophages and mo-DCs. 
6.4.1 The regulation of PU.1 
A number of studies investigating the role of PU.1 has been performed on fetal liver 
progenitors as removal of the gene is embryonically or post-natally lethal (McKercher et 
al., 1996; Scott et al., 1994). Overexpression of PU1 in hematopoietic fetal liver cells 
results in an exaggerated production of Mac-1+ cells (DeKoter and Singh, 2000). 
However, extrapolating embryonic hematopoietic studies to our understanding of adult 
hematopoiesis can be misleading as removal of transcription factors such as AML-1 have 
shown different results in adult hemaotpoietic progenitors versus fetal liver progenitors 
(Ichikawa et al., 2004).  
PU.1 is present in similar amounts in HSCs, myeloid and lymphoid progenitors as 
evidenced in Pu.1gfp mice (Back et al., 2004; Carotta et al., 2010; Nutt et al., 2005). 
Overexpression of the transcription factor plays a myeloid lineage instructive role, not at 
the point of myeloid commitment, but further downstream in myeloid differentiation 
(Dakic et al., 2005), through both positive selection for the myeloid lineage as well as 
negative regulation of other lineages, for example, by inhibiting GATA1-dependent 
erythroid cell development (Arinobu et al., 2007; Stopka et al., 2005). Inducible ablation 
of PU.1 in the MxCre dependent Sfpi1 deleting mice have an expansion of aberrantly 
developed granulocytes in the spleen (Dakic et al., 2005). PU.1 thus influences myeloid 
development toward a monocytic lineage (which includes the propensity to generate 
cDCs) while dampening the selection of granulocytes.  
PU.1 is able to regulate the transcription of about 3000 genes including those that code 
for cytokines (GM-CSF, G-CSF, M-CSF), their receptors (GM-CSFR, M-CSFR, Flt3) 
(Dakic et al., 2007) as well as cell-surface integrins used as markers of differentiation 
(CD11b, CD68, etc.) between various immune cells. Intriguingly, the protein-protein 
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complexes generated with PU.1 and its co-factors/co-regulators, can dramatically alter 
the transcriptional outcome of PU.1-regulated genes (Burda et al., 2010). Mo-DCs and 
inflammatory macrophages and their precursors that I describe rely on a number of these 
receptors for their development and are phenotypically characterised using a number of 
the markers that are regulated by PU.1. It is therefore crucial to understand how PU.1 
regulates cell fate choice in these myeloid populations. 
Within the myeloid lineage, PU.1 has been found to play a role in the development of 
DCs- cultured Sfpi1-/- embryonic thymocytes (Guerriero et al., 2000) and mice inducibly 
knocked-out for PU.1 (Carotta et al., 2010) are unable to give rise to CD11c+ cells. This 
is possibly due to the direct transcriptional regulation of the Flt3 gene by PU.1 (Carotta 
et al., 2010). The role of PU.1 in the development of myeloid cells under inflammation, 
however has not been previously analysed.  
Here I show that PU1 has a positive effect on the development of GM-DCs (Chapter 4) 
and a negative effect on iNOS+ phagocytes (Chapter 5). In spite of the known ability of 
PU.1 to regulate the transcription of growth factor receptor, GM-CSFR (Hohaus et al., 
1995), Sfpi1-/- thymocyte cultures are supported by GM-CSF (Guerriero et al., 2000) and 
CMPs from MxCrexSfpi1fl/fl mice (Dakic et al., 2005) are still able to able to respond to 
GM-CSF. Thus, in our study, the loss of GM-CSF responsive FcɣRII/III+CD209a+ cells 
in Sfpi1+/- mice is possibly due to the reliance of their precursor population on PU.1 rather 
than a loss in expression of GM-CSFR.  
The inhibitory role of PU.1 on iNOS generation that I describe both in vivo and in vitro, 
could be explained through PU.1 target miRNAs, namely miR146 and miR155 that have 
been found to inhibit iNOS production (Perske et al., 2010). MiR146 and miR155 target 
the transcription of molecules downstream of the TLR signalling pathway such as 
IRAK1, TRAF6 and IFN response signalling (which play a crucial role in the induction 
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of Nos2) whilst being dependent on NF-B thus generating a negative feedback loop to 
regulate the strength of the immune responses (Ivashkiv and Donlin, 2013; Taganov et 
al., 2006). Additionally, ectopic expression of miR146  in HSCs directs the development 
of functional macrophages (Ghani et al., 2011). Thus, PU.1 may exert its influence on the 
generation of iNOS in macrophages via miRNAs. PU.1 itself is regulated post-
transcriptionally by miR-155 that binds with the 3’ untranslated region of PU.1. miR155 
is encoded by the BIC gene and binds over 400 mRNAs thus regulating a number of 
functions in the hematopoiesis of B cells, T cells, macrophages and granulocytes (Burda 
et al., 2010). A third mechanism by which PU.1 regulates cell fate decisions is by its 
concentration within a cell. It has been shown that high PU.1 concentration leads to a 
more monocyte/DC lineage commitment while lower concentrations are required for B 
cell development (Burda et al., 2010). This may also be the mechanism by which PU.1 
regulates the development of R2 monocytes over R1 monocytes given its higher 
expression of transcriptional regulator. 
The PU.1hi R2 monocytes that I describe in this study are suitably able to generate 
FcɣRII/III+CD209a+ moDCs while the PU.1lo R1 monocytes are pre-equipped to generate 
iNOS+ phagocytes. Studying the co-factors that interact with PU.1 that may be expressed 
more highly in one or the other population would provide a deeper mechanistic 
understanding of how the levels of PU.1 affect these populations. Further studies are 
required to decipher the effector role played by R1 and R2 in different inflammatory 
contexts and whether PU.1 continues to direct their function. 
6.5 The role of GM-CSF in inflammation and cancer 
GM-CSF is known to promote the development of myeloid precursors, as well as promote 
the differentiation of monocytes into macrophages and iNOS-producing cells during 
inflammation. Steady state influence of GM-CSF has been studied in great detail with the 
use of Csf2r-/- and Csf2rb2-/- mice (Greter et al., 2012). The quantity, timing and context 
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of the provision of GM-CSF influences the impact that the growth factor has on various 
cells and inflammatory outcomes. For example,  GM-CSF is known to have an inhibitory 
effect on the differentiation of pDCs from murine hematopoietic cells (Gilliet et al., 
2002). However, administration of GM-CSF to IFNα-producing cells results in their 
terminal differentiation (Ghirelli et al., 2010). Such studies emphasize the importance of 
the timing of GM-CSF. 
Studies on the role of GM-CSF during inflammation have highlighted the pro-
inflammatory influence of the growth factor in disease models such as EAE (Croxford et 
al., 2015) and airway hypersensitivity (Zhou et al., 2014). KrasG12D and p48CRE x 
KrasLSLG12D mutant mice develop pancreatic epithelial cell neoplastic lesions and have 
elevated levels of GM-CSF within the pancreas. This was noticed in pancreatic lesions 
from patients as well (Pylayeva-Gupta et al., 2012). GM-CSF orchestrates the recruitment 
of myeloid cells into the tumour via the CD8+ T cells. Allogeneic cancer cells that are 
genetically engineered to overexpress GM-CSF (GVAX) are being used in a number of 
cancer immunotherapies in combination with  T-cell checkpoint inhibitors such as anti-
PD1/PD-L1 blockade and anti-CTLA4 in PhaseI and II clinical trials (Soares et al., 2015). 
This has had moderately good results in cancers such as melanoma and pancreatic ductal 
adenocarcinoma as it promotes strong effector T cell responses within the tumour 
(Pylayeva-Gupta et al., 2012; Soares et al., 2015).  
In spite of the improved success of these therapies, the exact mechanisms of action and 
the cells involved in the response to excess levels of GM-CSF is not known. Given the 
strong response of the FcɣRII/III+CD209+ and FcɣRII/III+CD209- cells to GM-CSF, it 
would be interesting to study if these cells appear in the tumour and if so, what their 




By exploring the heterogeneity within the Ly6Chi monocyte population, this study has 
presented the existence of a unique precursor population of cells that has the ability to 
generate mo-DCs. Additionally, this study establishes characteristics for inflammatory 
macrophages and mo-DCs that not only distinguish these populations from each other 
with phenotypic and ontogenic perspectives but also helps distinguish them from cDCs 
in the tissue during inflammation (Figure 6-2). Myeloid populations have been confused 
for one another due to the use of promiscuous myeloid markers and loose nomenclature. 
In combination with a number of previous studies on myeloid cells in inflammation, this 
thesis delineates macrophages, classical dendritic cells, inflammatory-DCs and iNOS-
producing macrophages in infections with intracellular bacteria and inflammatory 
settings of increased levels of GM-CSF (such as pre-clinical models of MS, pancreatic 
cancer, head and neck cancer etc.) (Bayne et al., 2012; Croxford et al., 2015; Hong, 2016; 
Van De Laar et al., 2012) . 
By using single-cell analysis and a multi-dimensional reduction approach to study the 
Ly6Chi monocytes at steady state, my collaborators and I were also able to outline a 
unique transcriptional programme for the precursors to mo-DCs. Furthermore, I find that 
PU.1 is the master transcriptional regulator that is responsible for the cell fate choice 
between R1 and R2. Understanding this ontogenic and transcriptional diversity in the 
development of iNOS+ macrophages and mo-DCs firstly provides a basis for 
understanding the conflicting data of previous reports and also part of the groundwork 
needed to improve the targeting of the most appropriate monocytic cells in future studies 
and immune therapies. Thus, these results can have potentially far-reaching consequences 




Figure 6-2:Graphical summary. R1 and R2 are Ly6Chi monocytes that egress from the 
bone marrow to the blood via CCR2. They differ in their expression of PU.1- R1 
expresses lower levels while R2 expresses higher levels of the transcriptional regulator. 
R1 exhibits plasticity in responding to infection and elevated levels of GM-CSF by 
generating inflammatory macrophages and upregulating FcɣRII/III and in the case of 
infection, iNOS. R2 on the other hand responds to GM-CSF by upregulating both 
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